Page last updated: 2024-12-05

emodin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Emodin is a natural anthraquinone compound found in various plants, including rhubarb, aloe, and senna. It has been shown to exhibit a range of biological activities, including antioxidant, anti-inflammatory, and anticancer properties. Its synthesis has been explored through various methods, including chemical synthesis and microbial fermentation. Emodin's effects are attributed to its ability to modulate cellular signaling pathways, such as the NF-κB pathway, which plays a role in inflammation and cancer. Its importance stems from its potential therapeutic applications, particularly in the treatment of inflammatory diseases, cancer, and skin conditions. Ongoing research aims to further investigate its mechanisms of action, optimize its delivery, and develop novel therapeutic agents based on its structure.'

Emodin: Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as a laxative, but is now used mainly as a tool in toxicity studies. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

emodin : A trihydroxyanthraquinone that is 9,10-anthraquinone which is substituted by hydroxy groups at positions 1, 3, and 8 and by a methyl group at position 6. It is present in the roots and barks of numerous plants (particularly rhubarb and buckthorn), moulds, and lichens. It is an active ingredient of various Chinese herbs. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
RhamnusgenusA plant genus of the family RHAMNACEAE. This genus is often called buckthorn but should not be confused with HIPPOPHAE or KARWINSKIA. Some RHAMNUS species have been reclassified into this genus. F. purshiana bark is cascara sagrada. Members contain frangulanin, frangulin, and anthraquinones such as EMODIN.[MeSH]RhamnaceaeThe buckthorn plant family, of the order Rhamnales, includes some species with edible fruits and some that are medicinal.[MeSH]

Cross-References

ID SourceID
PubMed CID3220
CHEMBL ID289277
CHEBI ID42223
SCHEMBL ID177689
MeSH IDM0007302

Synonyms (165)

Synonym
MLS001066370
smr000326798
AC-1004
BRD-K58685305-001-03-0
nsc-622947
KBIO1_001372
DIVK1C_006428
NCIMECH_000049
NCI60_003906
1,3,8-trihydroxy-6-methylanthra-9,10-quinone
1,3,8-trihydroxy-6-methyl-9,10-anthraquinone
frangulic acid
nsc 622947
nsc 408120
9,10-anthracenedione, 1,3,8-trihydroxy-6-methyl-
rheum emodium
anthraquinone, 6-methyl-1,3,8-trihydroxy-
brn 1888141
archin
hsdb 7093
einecs 208-258-8
anthraquinone, 1,3,8-trihydroxy-6-methyl-
ccris 3528
1,3,8-trihydroxy-6-methylanthraquinone
1,3,8-trihydroxy-6-methyl-9,10-anthracenedione
ai3-38286
4,5,7-trihydroxy-2-methylanthraquinone
EU-0100552
emodin, from frangula bark, >=90% (hplc)
SPECTRUM_001954
SPECTRUM4_001757
emodin; 6-methyl-1,3,8-trihydroxyanthraquinone
K00056
tnp00318
NCGC00015420-02
lopac-e-7881
NCGC00015420-01
emodin, frangula
emodin, rheum
SPECTRUM5_000614
MEGXP0_000460
SMP2_000211
LOPAC0_000552
ACON1_001939
MLS000563068
1,3,8-trihydroxy-6-methyl-anthracene-9,10-dione
6-methyl-1,3,8-trihydroxy-9,10-anthracenedione
nsc622947
1,8-trihydroxy-6-methylanthraquinone
anthraquinone,3,8-trihydroxy-6-methyl-
rheum emodin
1,8-trihydroxy-6-methyl-9,10-anthraquinone
nsc-408120
frangula emodin
schuttgelb
NSC408120 ,
4,7-trihydroxy-2-methylanthraquinone
3-methyl-1,8-trihydroxyanthraquinone
9, 1,3,8-trihydroxy-6-methyl-
persian berry lake
emodol
c.i. 75440
c.i. natural yellow 14
emo ,
NCGC00091540-01
emodin
518-82-1
3-methyl-1,6,8-trihydroxyanthraquinone
CHEBI:42223 ,
bdbm11318
1,3,8-trihydroxy-6-methyl-9,10-dihydroanthracene-9,10-dione
chembl289277 ,
1F0Q
BSPBIO_002324
NCGC00091540-05
6-methyl-1,3,8-trihydroxyanthraquinone
KBIOSS_002508
KBIO3_001544
KBIO2_007636
KBIO2_005068
KBIO2_002500
KBIOGR_002234
SPECTRUM2_000895
SPECPLUS_000332
SPBIO_000710
SPECTRUM3_000742
NCGC00091540-02
NCGC00091540-03
NCGC00091540-04
LMPK13040008
NCGC00015420-04
E 7881
NCGC00015420-08
DB07715
AKOS003348641
FT-0667846
E0500
1,3,8-trihydroxy-6-methylanthracene-9,10-dione
HMS3261P05
tox21_303218
dtxsid5025231 ,
cas-518-82-1
NCGC00257090-01
dtxcid205231
tox21_202999
NCGC00260544-01
1,3,8-trihydroxy-6-methyl-anthracene-9,10-dione;3-methyl-1,6,8-trihydroxyanthraquinone
A828825
MLS004257392
1,3,8-trihydroxy-6-methyl-anthraquinone
HMS2230K22
CCG-35263
NCGC00015420-07
NCGC00015420-03
NCGC00015420-05
NCGC00015420-06
CS-1412
ka46rni6hn ,
unii-ka46rni6hn
FT-0606539
NCGC00015420-09
LP00552
3BQC
S2295
HMS3373B16
emodin [mi]
emodin [inci]
emodin [usp-rs]
emodin [hsdb]
HY-14393
MLS006011712
SCHEMBL177689
3ED0
KS-5189
emdoin
NCGC00261237-01
tox21_500552
Q-100581
1,3,8-trihydroxy-6-methylanthra-9,10-quinone #
mfcd00001207
alatinone
emodin, analytical standard
emodin, united states pharmacopeia (usp) reference standard
HMS3655H22
EN300-179559
1,3, 8-trihydroxy-6-methyl-9,10-anthraquinone
1,3,8-trihydroxy-6-methyl-9,10-anthracenedione, 9ci
rheum-emodin
frangulinic acid
9,10-anthracenedione, 1,3,8-trihydroxy-6-methyl- (9ci)
sr-01000075615
SR-01000075615-6
SR-01000075615-1
SW219906-1
BCP18372
Q4348178
emodin - cas 518-82-1
emodin,(s)
SDCCGSBI-0050535.P004
NCGC00015420-22
EX-A6778
STL581876
3-methyl-1,6,8-trihydroxy-antraquinone
emodin (usp-rs)
SY050737

Research Excerpts

Overview

Emodin is an anthraquinone derivative found in the roots and bark of a variety of plants, molds, and lichens. Emodin (EMO) is an active ingredient of Chinese traditional medicine with the potential to reportedly treat ulcerative colitis (UC)

ExcerptReferenceRelevance
"Emodin is a natural product, which can alleviate the symptoms of AP."( Emodin inhibits the progression of acute pancreatitis via regulation of lncRNA TUG1 and exosomal lncRNA TUG1.
Chen, Z; He, B; Tang, X; Wang, B; Wen, X, 2021
)
2.79
"Emodin is a Chinese herb-derived compound extracted from the roots of Rheum officinale that exhibits numerous pharmacological characteristics."( Emodin induces apoptosis and suppresses non-small-cell lung cancer growth via downregulation of sPLA2-IIa.
Fan, XX; Guan, XX; Leung, EL; Li, JX; Li, RZ; Liang, TL; Liu, L; Meng, WY; Pan, HD; Wang, XR; Wu, QB; Xu, C; Yao, XJ; Zhang, FY, 2022
)
2.89
"Emodin (EMD) is a major ingredient of "( Cysteine-Based Protein Covalent Binding and Hepatotoxicity Induced by Emodin.
Ding, Z; Ma, K; Peng, Y; Sun, C; Wang, X; You, Y; Zhang, S; Zheng, J; Zheng, X, 2022
)
2.4
"Emodin (EMO) is an active ingredient of Chinese traditional medicine with the potential to reportedly treat ulcerative colitis (UC). "( Dual-targeted colon-based integrated micelle drug delivery system for treatment of ulcerative colitis.
Gu, M; Lu, L; Miao, Z; Ning, L; Xu, Y; Yan, J, 2022
)
2.16
"Emodin is an anthraquinone derivative found in the roots and bark of a variety of plants, molds, and lichens. "( Exploring the journey of emodin as a potential neuroprotective agent: Novel therapeutic insights with molecular mechanism of action.
Alhumaydhi, FA; Anjum, J; Bin Emran, T; Das, R; Hemeg, HA; Islam, F; Mitra, S; Muni, M; Rauf, A; Semwal, P; Wilairatana, P, 2022
)
2.47
"Emodin is a typical anthraquinone derivative from various plants that exhibits a wide spectrum of biological activities, such as anticancer, antibacterial, hepatoprotective and anti-inflammatory activities."( The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers.
Chen, WW; Li, MY; Peng, W; Qian, D; Sun, X; Tang, DD; Wang, LY; Wu, CJ; Zhang, LL; Zhang, Q, 2022
)
1.8
"Emodin is a natural anthraquinone derivative in many plants with promising bioactivities."( Emodin Ameliorates Intestinal Dysfunction by Maintaining Intestinal Barrier Integrity and Modulating the Microbiota in Septic Mice.
Bai, Y; Guo, Y; He, S; Lian, B; Lin, Y; Liu, Q; Wang, N; Wang, X; Xu, X; Zhang, M; Zhang, R; Zhao, J, 2022
)
2.89
"Emodin is an active ingredient of traditional Chinese medicine Rheum palmatum L. "( Emodin targeting the colonic metabolism via PPARγ alleviates UC by inhibiting facultative anaerobe.
Chen, Y; Guo, S; He, J; Huang, B; Huang, S; Li, Y; Luo, S; Luo, X; Su, Y; Wang, X; Yang, G; Zhou, L, 2022
)
3.61
"Emodin is a natural anthraquinone, which displays numerous pharmacological activities, including anti-tumor, anti-inflammation and immunosuppression. "( Comprehensive investigation on the metabolism of emodin both in vivo and in vitro.
Fu, Z; Han, C; Han, L; Hu, X; Niu, X; Pan, G; Yu, H; Zhou, L, 2023
)
2.61
"Emodin is an anthraquinone compound extracted from rhubarb that can alleviate the damage to pancreatic ductal epithelial cells induced by adenosine triphosphate, but whether it has a similar protective effect on sodium taurocholate (STC)-stimulated pancreatic ductal cells and the underlying mechanism has not yet been reported."( Emodin Alleviates Sodium Taurocholate-Induced Pancreatic Ductal Cell Damage by Inhibiting the S100A9/VNN1 Signaling Pathway.
Chen, M; Guo, F; Wu, Y; Xiang, H; Zhao, L; Zhou, Q, 2022
)
2.89
"Emodin is a natural anthraquinone compound, which is the main component found in the traditional Chinese herb Polygonum cuspidatum. "( Emodin inhibiting epithelial-mesenchymal transition in pulmonary fibrosis through the c-MYC/miR-182-5p/ZEB2 axis.
Fan, L; Jiang, G; Ni, K; Tong, W; Yang, J, 2023
)
3.8
"Emodin is a natural bioactive ingredient mainly extracted from traditional Chinese herbs. "( Recent findings regarding the synergistic effects of emodin and its analogs with other bioactive compounds: Insights into new mechanisms.
Hu, Y; Lai, Y; Yang, L, 2023
)
2.6
"Aloe-emodin (Ae) is an active ingredient of Chinese herbs with antiviral, anticancer, and anti-inflammatory effects."( Aloe-emodin inhibits African swine fever virus replication by promoting apoptosis via regulating NF-κB signaling pathway.
Feng, Y; Gao, Q; Gong, T; Luo, Y; Wang, H; Wang, W; Wu, D; Yang, Y; Zhang, G; Zheng, X, 2023
)
1.88
"Emodin is a bioactive compound with strong anti-inflammatory and antioxidant properties. "( Effect of ultrasound on binding interaction between emodin and micellar casein and its microencapsulation at various temperatures.
Ashokkumar, M; Han, N; Qin, J; Wang, Y; Wei, Y; Yang, M, 2020
)
2.25
"Emodin is an anthraquinone that has been implicated in cardiac protection."( Emodin and emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity and cardiac myocyte hypertrophy.
Angermann, JE; Bender, A; Burnett, L; Evans, LW; Ferguson, BS; Godoy, L; Shen, Y; Staten, D; Zhou, T, 2020
)
2.72
"Emodin is a promising anti-cancer reagent. "( Emodin succinyl ester inhibits malignant proliferation and migration of hepatocellular carcinoma by suppressing the interaction of AR and EZH2.
Bai, Y; Feng, H; Feng, J; Jia, W; Jiang, Y; Khan, H; Song, H; Yang, B; Yu, Z; Zaib, T, 2020
)
3.44
"Emodin is an effective component in rhubarb to cure intestinal dysfunction, but the specific mechanism remains unknown. "( Effects of emodin on intestinal mucosal barrier by the upregulation of miR-218a-5p expression in rats with acute necrotizing pancreatitis.
Liu, MW; Qian, CY; Tan, Y; Wu, HY; Xia, J; Zhang, HB; Zhang, W,
)
1.96
"Emodin is a naturally‑occurring medicinal herbal ingredient that possesses numerous pharmacological properties, including anti‑inflammatory and antioxidant effects. "( Neuroprotective effect of emodin against Alzheimer's disease via Nrf2 signaling in U251 cells and APP/PS1 mice.
Bi, H; Fei, X; Jiang, H; Li, Z; Meng, Q; Song, J; Zhang, Y, 2021
)
2.36
"Emodin is a natural anthraquinone derivative that exhibits variety of pharmacologic effects including lowering lipids and regulating glucose utilization."( Emodin Improves Glucose and Lipid Metabolism Disorders in Obese Mice
Cheng, L; Dong, S; He, R; Huang, Z; Ning, Y; Shang, F; Sun, J; Zhang, S, 2021
)
2.79
"Emodin (EMO) is a major bioactive constituent of CMD that has apparent therapeutic efficacy against obesity and fatty liver."( Emodin palliates high-fat diet-induced nonalcoholic fatty liver disease in mice via activating the farnesoid X receptor pathway.
Cai, J; Deng, Z; Guo, J; Huang, Q; Lan, S; Liu, H; Liu, M; Liu, Z; Pan, Z; Shen, C; Si, Y; Tu, H; Wu, H; Wu, S; Xian, S; Xin, X; Yu, Y; Zhang, J; Zheng, M; Zhong, C; Zhong, Y; Zhu, Z, 2021
)
2.79
"Emodin is an active compound found in rhubarb."( Protective effects of Da-cheng-qi decoction in rats with intracerebral hemorrhage.
Lin, L; Ning, LN; Shi, Y; Su, HF; Tian, Q; Wang, XM; Yang, SS; Zeng, P; Zhang, T, 2021
)
1.34
"Emodin is a natural bioactive compound from traditional Chinese herbs that exerts anti-inflammatory, antioxidant, anticancer, hepatoprotective, and neuroprotective effects. "( Emodin Attenuates Acetaminophen-Induced Hepatotoxicity via the cGAS-STING Pathway.
Chen, G; Cheng, Z; Han, L; Liu, Q; Shen, P, 2022
)
3.61
"Emodin is a natural anthraquinone derivative isolated from the Rheum palmatum. "( Emodin suppresses the nasopharyngeal carcinoma cells by targeting the chloride channels.
Chen, L; Liu, M; Ma, L; Wang, L; Yang, H; Yang, Y; Yin, Z; Zhu, L, 2017
)
3.34
"Emodin is an anthraquinone obtained from Rheum palmatum rootstocks. "( Growth arrest and morphological changes triggered by emodin on Trypanosoma cruzi epimastigotes cultivated in axenic medium.
Bretaña, A; Bubis, J; Contreras, VT; De Lima, AR; Navarro, MC; Noris-Suárez, K; Pérez-Ybarra, L, 2017
)
2.15
"Emodin is an active constituent found in the roots and rhizomes of numerous Chinese medicinal herbs. "( Emodin promotes the arrest of human lymphoma Raji cell proliferation through the UHRF1‑DNMT3A‑∆Np73 pathways.
Cai, P; Chen, W; Lin, Y; Wang, Z, 2017
)
3.34
"Emodin is an anthraquinone derivative originally isolated from Chinese rhubarb, possesses anticancer properties."( Emodin Inhibits ATP-Induced Proliferation and Migration by Suppressing P2Y Receptors in Human Lung Adenocarcinoma Cells.
Guan, R; Li, L; Shen, L; Song, N; Wang, X; Zhu, D, 2017
)
2.62
"Emodin is a natural active component extracted from Chinese herbs. "( Emodin ameliorates renal fibrosis in rats via TGF-β1/Smad signaling pathway and function study of Smurf 2.
Chen, K; Deng, G; Jiang, K; Jiang, P; Li, H; Ma, L; Xiong, X; Zhang, S, 2018
)
3.37
"Emodin is a major ingredient of rhubarb and has been proven to protect against lung disruptions."( Emodin Attenuates Bleomycin-Induced Pulmonary Fibrosis via Anti-Inflammatory and Anti-Oxidative Activities in Rats.
Liu, XL; Tian, SL; Xu, QB; Yang, Y, 2018
)
2.64
"Emodin is an anthraquinone-active substance that has the ability to affect tumor progression."( Emodin Inhibits Colon Cancer Cell Invasion and Migration by Suppressing Epithelial-Mesenchymal Transition via the Wnt/β-Catenin Pathway.
Cui, CF; Gu, J; Jiang, XH; Wang, L; Yang, L, 2019
)
2.68
"Emodin is a natural anthraquinone isolated from several traditional Chinese medicines including Rhubarb and Polygonum cuspidatum."( Emodin inhibits TGF-β2 by activating the FOXD3/miR‑199a axis in ovarian cancer cells in vitro.
Chen, Y; Diao, Y; Lv, T; Song, K; Wang, Y; Yao, Q, 2018
)
2.64
"Emodin is an anthraquinone compound derived from Rheum officinale Baill. "( Emodin ameliorates ulcerative colitis by the flagellin-TLR5 dependent pathway in mice.
Deng, X; Liu, Q; Luo, S; Luo, X; Pan, Z; Zhao, Z; Zhou, L, 2018
)
3.37
"Emodin is an anthraquinone derived from Polygonum multiflorum Thunb, possessing anti-cancer activity."( Anti-Cancer Effects of Emodin on HepG2 Cells as Revealed by
Chen, C; Chen, JF; Hong, W; Li, MH; Ruan, LY; Tao, L; Wang, JS; Xing, YX; Xu, H; Zhao, WL, 2018
)
1.51
"Emodin is an active anthraquinone derivative isolated from Rheum palmatum, with anticancer properties that have been reported to inhibit lung metastasis in a nude mouse xenograft model."( Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes.
Liu, S; Qin, Y; Song, X; Sun, Z; Wang, Y; Yang, J; Yu, K; Zhang, S; Zhou, X, 2018
)
2.64
"Emodin is a natural anthraquinone derivative that is present in various herbal preparations. "( NMR-based Metabolomic Techniques Identify the Toxicity of Emodin in HepG2 Cells.
Chen, C; Gao, J; Gu, LW; Guo, C; Li, ZF; Liu, A; Mao, CY; Wang, TS; Yan, YJ; Yang, Y, 2018
)
2.17
"Emodin is an important constituent of Rheum emodi, an important medicinal herb. "( Antitumor effects of emodin in CACO-2 human colon carcinoma cells are mediated via apoptosis, cell cycle arrest and downregulation of PI3K/AKT signalling pathway.
Ding, Y; Li, Y; Ma, Q; Wu, Z,
)
1.89
"Emodin is a main anthraquinone compound which exists in Chinese traditional medicines including Polygonum multiflorum and Rhubarb. "( Gender Differences in the Hepatotoxicity and Toxicokinetics of Emodin: The Potential Mechanisms Mediated by UGT2B7 and MRP2.
Chen, Y; Han, C; Han, W; Liu, H; Liu, J; Liu, S; Tang, L; Wu, L; Zhang, T; Zhang, Z; Zhong, S, 2018
)
2.16
"Emodin is an anthraquinone with potent anti-cancer activities."( Integration of bioinformatics and experiments to identify TP53 as a potential target in Emodin inhibiting diffuse large B cell lymphoma.
Cao, Y; Chen, Y; Gan, D; Hu, J; Lin, M; Mei, X; Wu, Z; Yang, T; Zhang, N, 2018
)
1.42
"Emodin is an active component of Chinese herbs, and is effective against leukemia, lung cancer, colon cancer, pancreatic cancer, and HCC; however, the sensitizing effect of emodin on sorafenib-based HCC therapy has not been evaluated."( Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism.
Kan, SY; Kang, H; Kim, BM; Kim, GH; Kim, JH; Kim, YS; Lee, YM; Lim, JH; Oh, TI; Shin, DH; Yim, WJ, 2018
)
2.64
"Emodin is an active ingredient in many herbal medicines and has a broad spectrum of pharmacological activities. "( Paradoxical Effects of Emodin on ANIT-Induced Intrahepatic Cholestasis and Herb-Induced Hepatotoxicity in Mice.
Bi, Y; Fan, G; Gao, X; Han, L; Li, C; Wang, X; Zhang, Y, 2019
)
2.27
"Emodin is a natural product extracted from Rheum palmatum. "( Emodin Attenuates Lipopolysaccharide-Induced Injury via Down-Regulation of miR-223 in H9c2 Cells.
Jiang, Z; Yang, Y; Zhuge, D, 2019
)
3.4
"Emodin is a Chinese herbal anthraquinone used in several diseases."( Emodin protects H9c2 cells from hypoxia-induced injury by up-regulating miR-138 expression.
Cai, S; Dai, H; Guan, J; Qin, Q; Zhang, X; Zhou, C, 2019
)
2.68
"Emodin is a natural anthraquinone derivative with numerous beneficial effects, including antioxidant properties, anti-tumor activities, and protecting the nerves. "( Emodin inhibits zinc-induced neurotoxicity in neuroblastoma SH-SY5Y cells.
Fan, Z; Gao, F; Li, M; Liu, W; Luo, W; Miao, F; Ou, L; Wei, P; Zhou, X, 2019
)
3.4
"Emodin is a natural anthraquinone derivative that occurs in many widely used Chinese medicinal herbs."( Emodin ameliorates rheumatoid arthritis by promoting neutrophil apoptosis and inhibiting neutrophil extracellular trap formation.
Huang, G; Li, X; Lu, Q; Luo, G; Wang, H; Wang, T; Xu, A; Yuan, K; Zhang, S; Zhao, L; Zhu, M; Zhu, Q, 2019
)
2.68
"Emodin is a Chinese herb-derived compound that exhibits a variety of pharmacological benefits. "( Anticancer activity of emodin is associated with downregulation of CD155.
Fan, D; Fang, L; Iwanowycz, S; Wang, J; Wang, Y; Yin, S; Zhao, F, 2019
)
2.27
"Emodin is an anthraquinone derivative from the Chinese herb Radix et Rhizoma Rhei. "( Emodin ameliorates lipopolysaccharide-induced mastitis in mice by inhibiting activation of NF-κB and MAPKs signal pathways.
Cao, Y; Fu, Y; Guo, M; Li, D; Li, F; Liang, D; Liu, B; Liu, Z; Su, G; Sun, Y; Yang, Z; Zhang, N; Zhang, W; Zhang, X, 2013
)
3.28
"Emodin is a major ingredient of Rheum Palmatum, a Chinese herb that is widely used in China for treatment of endotoxemia-related diseases."( Emodin improves lipopolysaccharide-induced microcirculatory disturbance in rat mesentery.
Deng, JN; Dong, L; Duan, ML; Fan, JY; Han, JY; Li, A; Liu, YY; Sun, K; Wang, BE; Wang, MX, 2013
)
2.55
"Emodin is an active anthraquinone that has been reported to have diverse biological effects."( Emodin induces cytotoxic effect in human breast carcinoma MCF-7 cell through modulating the expression of apoptosis-related genes.
Chan, RY; Chan, SW; Li, WY; Yu, PH, 2013
)
2.55
"Emodin is an active component isolated from the root and rhizome of Rheum palmatum that has been widely used in traditional Chinese medicine for the treatment of various diseases."( Synergistic effects of curcumin with emodin against the proliferation and invasion of breast cancer cells through upregulation of miR-34a.
Gao, J; Guo, J; Kong, Y; Li, L; Li, W; Liu, P; Shi, H; Tang, H; Wei, W; Wu, M; Xie, X; Yang, L, 2013
)
1.38
"Emodin is a traditional Chinese medicine that has been found to inhibit proliferation and induce apoptosis in ovarian cancer cells."( The combined effect of survivin-targeted shRNA and emodin on the proliferation and invasion of ovarian cancer cells.
Cai, X; Chen, Y; Guo, K; He, A; Xue, H; Zhao, L; Zheng, X, 2013
)
1.36
"Emodin is a pleiotropic molecule capable of interacting with several major molecular targets including NF-κB, casein kinase II, HER2/neu, HIF-1α, AKT/mTOR, STAT3, CXCR4, topoisomerase II, p53, p21, and androgen receptors which are involved in inflammation and cancer."( Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer.
Ahn, KS; Kumar, AP; Sethi, G; Shanmugam, MK; Shrimali, D; Tan, BK; Zhang, J, 2013
)
1.35
"Emodin is a natural anthraquinone derivative extracted from Chinese herbs, which have been used to treat bone diseases for thousands of years."( Emodin enhances osteogenesis and inhibits adipogenesis.
Hao, YQ; Lu, ZM; Yang, F; Yuan, PW, 2014
)
2.57
"Emodin is an effective active ingredient extracted from Chinese herbal medicine, which has the function of antimicrobial, anti-inflammatory, antioxidant and scavenging oxygen free radicals, inhibiting platelet aggregation, improving microcirculation, protecting various organs and tissues as well as a wide range of anti-tumor effect. "( [Research progress of emodin anti-gallbladder carcinoma].
Dong, SB; Liu, C; Liu, YP; Wang, RT; Yin, H; Yuan, W, 2014
)
2.16
"Emodin is a major component of the Chinese herb rhubarb, which has been widely used in the treatment of numerous diseases, including inflammation and cancer."( Emodin has a protective effect in cases of severe acute pancreatitis via inhibition of nuclear factor‑κB activation resulting in antioxidation.
Qian, AH; Qiao, MM; Yang, SL; Yao, WY; Yuan, YZ; Zhai, ZK; Zhang, YP; Zhou, YF, 2015
)
2.58
"Emodin is a natural anthraquinone in rhubarb used for treatment of diabetes, but its mechanism of action is not fully understood."( Protection of vascular endothelial cells from high glucose-induced cytotoxicity by emodin.
Bee, YM; Gao, Y; Huang, L; Li, G; Liang, S; Song, M; Tan, M; Wu, Q; Xu, H; Yi, Y; Zhang, J, 2015
)
1.36
"Emodin is a major component of the widely used Chinese herb, rhubarb, which has been used to treat inflammation in several types of disease."( Inhibition of mechanical stress-induced hypertrophic scar inflammation by emodin.
Liu, C, 2015
)
1.37
"Emodin is a bioactive anthraquinone that has diverse biological effects. "( Dual activities of emodin--DNA protectivity vs mutagenicity.
Bodnarova, K; Galova, E; Imreova, P; Loderer, D; Miadokova, E; Sevcovicova, A, 2014
)
2.17
"Emodin (EMD) is an anthraquinone derivative extracted from the root and rhizome of Rheum palmatum L. "( The anthraquinone derivative Emodin inhibits angiogenesis and metastasis through downregulating Runx2 activity in breast cancer.
Chen, B; Fu, J; Ke, X; Liu, T; Liu, Z; Lu, H; Ma, J; Wang, S, 2015
)
2.15
"Emodin is a traditional Chinese medicine, which has been demonstrated to inhibit the growth of pancreatic cancer cells. "( Emodin inhibits angiogenesis in pancreatic cancer by regulating the transforming growth factor-β/drosophila mothers against decapentaplegic pathway and angiogenesis-associated microRNAs.
Chen, H; Chen, L; Chen, MY; Guo, JQ; Hu, P; Ji, X; Lin, SZ; Lu, D; Tong, HF; Wang, ZH; Xu, HT; Xu, JB, 2015
)
3.3
"Emodin is a natural compound isolated from certain plant roots."( Emodin inhibits coxsackievirus B3 replication via multiple signalling cascades leading to suppression of translation.
Hanson, P; Qiu, Y; Shen, H; Wang, F; Yang, D; Ye, X; Zhang, HM, 2016
)
2.6
"Emodin is an active anthraquinone derivative from Rheum palmatum and some other Chinese herbs and it is traditionally used for treating a variety of diseases. "( Hypocholesterolemic effect of emodin by simultaneous determination of in vitro and in vivo bile salts binding.
Guo, C; He, X; Ji, J; Li, F; Song, Z; Wang, C; Wang, J; Yuan, C; Zhang, C; Zhang, W, 2016
)
2.17
"Emodin is a Chinese herb-derived compound and has shown potential to inhibit inflammation in various settings."( Emodin Bidirectionally Modulates Macrophage Polarization and Epigenetically Regulates Macrophage Memory.
Altomare, D; Fan, D; Hui, Y; Iwanowycz, S; Wang, J, 2016
)
2.6
"Emodin is a natural anthraquinone derivative that occurs in many widely used Chinese medicinal herbs, such as Rheum palmatum, Polygonum cuspidatum and Polygonum multiflorum. "( Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics.
Cao, S; Dong, X; Fu, J; Li, X; Lin, L; Ni, J; Yin, X, 2016
)
3.32
"Emodin is an active ingredient derived from root and rhizome of Rheum palmatum L and many studies have reported that it exhibits anticancer effects in a number of human tumors. "( Emodin induces hepatocellular carcinoma cell apoptosis through MAPK and PI3K/AKT signaling pathways in vitro and in vivo.
Cao, Q; Chen, Y; Lin, W; Ling, C; Wang, C; Yin, H; Zhong, M, 2016
)
3.32
"Emodin is an anthraquinone derived from Chinese herb that exerts anti-inflammation effects. "( Emodin alleviates jejunum injury in rats with sepsis by inhibiting inflammation response.
Chen, YK; Fan, X; Fu, HY; Liu, DD; Wan, B; Xu, YK; Yin, JT; Zhang, H, 2016
)
3.32
"Emodin (EM) is a major constituent of the herb and has been reported to be hepatotoxic."( Chemical Reactivity of Emodin and Its Oxidative Metabolites to Thiols.
Chen, J; Huang, W; Peng, Y; Qin, B; Xu, Y; Zheng, J, 2016
)
1.47
"Emodin is a component of Chinese herb that has been reported to be medicament on pancreatic fibrosis and liver fibrosis."( Emodin suppresses TGF-β1-induced epithelial-mesenchymal transition in alveolar epithelial cells through Notch signaling pathway.
Cao, Y; Chen, R; Gao, R; Song, K; Wang, Y; Yang, J; Zhang, Y, 2017
)
2.62
"Emodin is a component in a Chinese herb, "( Poloxamer-Based Thermoreversible Gel for Topical Delivery of Emodin: Influence of P407 and P188 on Solubility of Emodin and Its Application in Cellular Activity Screening.
Ban, E; Jeong, S; Jung, K; Kim, A; Kim, EH; Kwon, T; Park, M, 2017
)
2.14
"Emodin is a phytochemical with potent anticancer activities against various human malignant cancer types, including lung cancer; however, the molecular mechanisms underlying the effects of emodin remain unclear. "( Emodin induces apoptosis of lung cancer cells through ER stress and the TRIB3/NF-κB pathway.
Cai, H; Liu, Z; Qu, J; Su, J; Xue, X; Yan, Y, 2017
)
3.34
"Emodin is a natural anthraquinone in rhubarb. "( Emodin augments calcium activated chloride channel in colonic smooth muscle cells by Gi/Go protein.
Chen, Y; Lv, N; Xu, L; Yang, J; Zhu, X, 2009
)
3.24
"Emodin is a principle ingredient isolated from rhubarb rhizome, which is commonly used for constipation or pain-related diseases in traditional Chinese medicine (TCM) practice. "( Emodin down-regulates expression of TRPV1 mRNA and its function in DRG neurons in vitro.
Du, XL; Guo, JY; Guo, SY; Huo, HR; Jiang, TL; Li, LF; Liu, HB; Sui, F; Yang, N; Zhang, CB; Zhao, BS, 2010
)
3.25
"Emodin is a potent and selective 11beta-HSD1 inhibitor with the IC(50) of 186 and 86 nM for human and mouse 11beta-HSD1, respectively. "( Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice.
Chen, JH; Dou, W; Feng, Y; Huang, SL; Leng, Y; Shen, JH; Shen, Y; Zhang, S, 2010
)
3.25
"Emodin is a natural anthraquinone in rhubarb."( Effect of emodin on neuropathic pain transmission mediated by P2X2/3 receptor of primary sensory neurons.
Deng, L; Gao, Y; Kong, F; Li, G; Liang, S; Liu, H; Liu, J; Liu, S; Wu, R; Xie, J; Xu, C; Zhu, G, 2011
)
1.49
"Emodin is an active component of Chinese medicinal herbs and can inhibit the activation of Akt and NF-κB."( Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibition of Akt activation.
Chen, H; Fan, L; Guo, HC; Lin, SZ; Liu, A; Liu, DL; Liu, HB; Ni, ZL; Qiu, MX; Tong, HF; Wang, ZH; Wei, WT, 2011
)
1.35
"Emodin is a component from traditional Chinese herbal medicines. "( Effects of an anthraquinone derivative from Rheum officinale Baill, emodin, on airway responses in a murine model of asthma.
Cao, Q; Chu, X; Deng, X; Guan, M; Wang, D; Wei, M; Xie, X; Yang, X, 2012
)
2.06
"Emodin is a multifunctional Chinese traditional medicine with poor water solubility. "( Formulation, antileukemia mechanism, pharmacokinetics, and biodistribution of a novel liposomal emodin.
Lu, Y; Shan, W; Wang, T; Xiong, S; Yin, X, 2012
)
2.04
"Emodin is an active herbal component traditionally used in China for treating a variety of diseases. "( Emodin protects against high-fat diet-induced obesity via regulation of AMP-activated protein kinase pathways in white adipose tissue.
Chang, CJ; Liou, SS; Liu, IM; Lu, HJ; Tzeng, TF, 2012
)
3.26
"Emodin is an important component of traditional Chinese herb rhubarb, and has well-documented anti-inflammatory effect."( Emodin, a naturally occurring anthraquinone, ameliorates experimental autoimmune myocarditis in rats.
Bai, JH; Hu, J; Li, Z; Song, ZC; Wang, ZS, 2012
)
2.44
"Emodin is a poorly bioavailable but promising plant-derived anticancer drug candidate. "( Coupling of UDP-glucuronosyltransferases and multidrug resistance-associated proteins is responsible for the intestinal disposition and poor bioavailability of emodin.
Feng, Q; Hu, M; Li, Y; Liu, W; Liu, Z; Ye, L, 2012
)
2.02
"Aloe-emodin (AE) is a plant-derived hydroxyanthraquinone with potential anticancer activity. "( Aloe-emodin prevents cytokine-induced tumor cell death: the inhibition of auto-toxic nitric oxide release as a potential mechanism.
Harhaji, L; Maksimovic-Ivanic, D; Mijatovic, S; Miljkovic, D; Momcilovic, M; Popadic, D; Radovic, J; Trajkovic, V, 2004
)
1.35
"Emodin is a natural anthraquinone derivative that exhibits anti-proliferative effects in various cancer cell lines by efficient induction of apoptosis."( Emodin negatively affects the phosphoinositide 3-kinase/AKT signalling pathway: a study on its mechanism of action.
Bjørling-Poulsen, M; Guerra, B; Olsen, BB, 2007
)
2.5
"Aloe-emodin is a novel active compound found in the root and rhizome of Rheum palmatum. "( Growth inhibitory effects of gastric cancer cells with an increase in S phase and alkaline phosphatase activity repression by aloe-emodin.
Guo, J; Liao, Y; Liu, D; Sun, Q; Xiao, B; Zhang, S, 2007
)
1.06
"Emodin is an active component of a traditional Chinese and Japanese medicine isolated from the root and rhizomes of Rheum palmatum L. "( Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor.
Asakura, K; Hori, M; Ikeda, Y; Kaneda, T; Kizaki, M; Maekawa, T; Muto, A; Nakazato, T; Saitoh, A; Sasaki, Y; Uchida, T; Yasuda, I; Yoshida, T, 2007
)
3.23
"Emodin is a naturally occurring anthraquinone present in the roots and bark of numerous plants of the genus Rhamnus. "( Emodin accelerates osteoblast differentiation through phosphatidylinositol 3-kinase activation and bone morphogenetic protein-2 gene expression.
Kim, SH; Lee, SU; Min, YK; Shin, HK, 2008
)
3.23
"Emodin is a commonly used traditional herbal treatment in China, including use for pancreatic malignancy. "( Feasibility evaluation of emodin (rhubarb extract) as an inhibitor of pancreatic cancer cell proliferation in vitro.
Babcock, TA; Cai, J; Espat, NJ; Helton, S; Hering, J; Razzak, A; Saed, A,
)
1.87
"Emodin is an active principle of Rheum palmatum. "( [Study on effect of emodin on the isolated intestinal smooth muscle of guinea-pigs].
Jin, ZH; Lin, XZ; Ma, DL, 1994
)
2.05
"Emodin is a naturally occurring anthraquinone which is widely used as a laxative and has other versatile biological activities."( Generation of free radicals by emodic acid and its [D-Lys6]GnRH-conjugate.
Barbosa, F; Bilkis, I; Fridkin, M; Gescheidt, G; Koch, Y; Mazur, Y; Péron, V; Rahimipour, S; Weiner, L, 2001
)
1.03

Effects

Emodin has a broad therapeutic window, and in addition to its antineoplastic activity, it displays anti-ulcer, anti-inflammatory, hepatoprotective, neuroprotective, antimicrobial, muscle relaxant, immunosuppressive and antifibrotic activities. It has a direct inhibitory effect on the growth and metastasis of a variety of malignant tumor cells.

Emodin has an effect on hepatic fibrosis in rats. Emodin also has the effects of liver protection, anti-liver fibrosis, and so on. Aloeemodin has emerged as a potent hypotensive agent.

ExcerptReferenceRelevance
"Emodin has a protective effect on asthma. "( Emodin inhibits NF-κB signaling pathway to protect obese asthmatic rats from pathological damage via Visfatin.
Cai, W; He, X; Hu, J; Miao, J, 2022
)
3.61
"Emodin has a broad therapeutic window, and in addition to its antineoplastic activity, it displays anti-ulcer, anti-inflammatory, hepatoprotective, neuroprotective, antimicrobial, muscle relaxant, immunosuppressive and antifibrotic activities, in both in vitro and in vivo models."( Emodin - A natural anthraquinone derivative with diverse pharmacological activities.
Combrinck, S; Semwal, DK; Semwal, RB; Viljoen, A, 2021
)
2.79
"Emodin has a strong antibacterial activity, including methicillin-resistant Staphylococcus aureus (MRSA). "( Comparative analysis of methicillin-sensitive and resistant Staphylococcus aureus exposed to emodin based on proteomic profiling.
Ge, X; Ji, X; Liu, X; Peng, Y; Xu, H; Zhan, R, 2017
)
2.12
"Emodin has a direct inhibitory effect on the growth and metastasis of a variety of malignant tumor cells. "( Emodin inhibits pancreatic cancer EMT and invasion by up‑regulating microRNA‑1271.
Li, N; Wang, C; You, S; Zhang, P, 2018
)
3.37
"Emodin has a protective effect on hepatocytes and a restoring activity on cholestatic hepatitis. "( [Effect of emodin on P-gp expression in intrahepatic cholestatic rats].
Xu, H; Zhou, F, 2010
)
2.19
"Emodin has a direct excitatory effect on circular smooth muscle cells in rat colon mediated via Ca(2+)/CaM dependent pathways. "( Contractile effects and intracellular Ca2+ signalling induced by emodin in circular smooth muscle cells of rat colon.
Dong, ZL; Ma, T; Qi, QH; Xu, J; Yang, WX, 2003
)
2
"Emodin has a direct contractile effect on colonic smooth muscle cell. "( Signal pathways involved in emodin-induced contraction of smooth muscle cells from rat colon.
Dong, ZL; Ma, T; Qi, QH; Xu, J; Yang, WX, 2004
)
2.06
"Emodin has a different absorption spectrum in different solvents."( Evaluation of MTT assay for measurement of emodin-induced cytotoxicity.
Ge, J; Qian, J; Wang, K; Wang, X; Zou, Y, 2006
)
1.32
"Emodin has an anti-fibrotic effect on pancreatic fibrosis in rats. "( Effect of emodin on pancreatic fibrosis in rats.
Cai, JT; Du, Q; Gao, ZQ; Qian, KD; Wang, CH; Xie, CG; Ye, B, 2007
)
2.18
"Emodin has an effect on hepatic fibrosis in rats. "( [Effects of emodin on hepatic fibrosis in rats].
Huang, X; Li, D; Lu, H; Wang, Z; Wei, H; Xu, Q; Zhan, Y, 2001
)
2.13
"Emodin has been reported to alleviate I/R injury in the heart, brain, and small intestine in rats and mice through its anti-inflammatory effects."( Emodin prevents renal ischemia-reperfusion injury via suppression of CAMKII/DRP1-mediated mitochondrial fission.
Bae, ON; Cai, J; Huyan, T; Li, X; Liu, Q; Shi, Y; Su, J; Tie, L; Wang, D; Wang, H; Wang, Q; Wang, Y; Wu, P; Zhang, F, 2022
)
2.89
"Emodin has been confirmed to have anti-inflammatory effects."( Emodin Promotes Autophagy and Prevents Apoptosis in Sepsis-Associated Encephalopathy through Activating BDNF/TrkB Signaling.
Gao, LL; Liu, ZL; Mu, YH; Pang, L; Wang, ZH, 2022
)
2.89
"Emodin has a protective effect on asthma. "( Emodin inhibits NF-κB signaling pathway to protect obese asthmatic rats from pathological damage via Visfatin.
Cai, W; He, X; Hu, J; Miao, J, 2022
)
3.61
"Emodin has been used as a traditional medication for more than 2000 years and is still common in numerous herbal drugs."( Exploring the journey of emodin as a potential neuroprotective agent: Novel therapeutic insights with molecular mechanism of action.
Alhumaydhi, FA; Anjum, J; Bin Emran, T; Das, R; Hemeg, HA; Islam, F; Mitra, S; Muni, M; Rauf, A; Semwal, P; Wilairatana, P, 2022
)
1.75
"Emodin has been reported to fulfill an important function in suppressing the vicious outcome of liver cancer. "( Emodin regulates the autophagy via the miR-371a-5p/PTEN axis to inhibit hepatic malignancy.
Huang, Y; Li, C; Liu, Y; Lu, P; Wu, W; Zhu, Z, 2022
)
3.61
"Emodin has been reported to alleviate lung injuries caused by various pathological processes and attenuate ischemia-reperfusion (I/R) injuries in diverse tissues."( Emodin alleviates lung ischemia-reperfusion injury by suppressing gasdermin D-mediated pyroptosis in rats.
Ai, F; Chen, Z; Jin, T; Kong, L; Lu, R; Wang, D; Xiong, Z; Zhang, M; Zhou, J, 2023
)
3.07
"Aloe-emodin (AE) has been shown to inhibit the proliferation of several cancer cell lines, including human nasopharyngeal carcinoma (NPC) cell lines. "( Aloe-emodin targets multiple signaling pathways by blocking ubiquitin-mediated degradation of DUSP1 in nasopharyngeal carcinoma cells.
Chen, S; Fan, H; Guan, X; He, M; Hu, J; Li, C; Li, Q; Liu, C; Tang, J; Xiao, S; Xie, L; Yang, M; Zhang, X, 2023
)
1.94
"Emodin (Emo) has received much attention for its notable anti-inflammatory and antibacterial properties."( Emodin protects against intestinal dysfunction and enhances survival in rat model of septic peritonitis through anti-inflammatory actions.
Chen, W; Hua, Z; Li, W; Shen, J; Wang, Y, 2023
)
3.07
"Emodin has been reported to block the entry of the SARS-CoV-2 virus into human cells and might also inhibit cytokine production, resulting in the reduction of pulmonary injury induced by SARS-CoV-2."( Hybrid molecules based on an emodin scaffold. Synthesis and activity against SARS-CoV-2 and
Benoit-Vical, F; de Lamballerie, X; Laurent, M; Li, Y; Liu, Y; Meunier, B; Nguyen, M; Robert, A; Touret, F, 2023
)
1.92
"Emodin has the potential to attenuate DIC by directly binding to GSDMD to inhibit pyroptosis. "( Emodin attenuates cardiomyocyte pyroptosis in doxorubicin-induced cardiotoxicity by directly binding to GSDMD.
Chen, Y; Dai, S; Fan, X; Han, J; Huang, W; Huang, Z; Lin, J; Liu, Q; Su, L; Ye, B; Zhang, Y; Zhong, L, 2023
)
3.8
"Emodin has analgesic effect but the detailed mechanism is not clear at the present time."( Integration of microbiota and metabolomics reveals the analgesic mechanisms of emodin against neuropathic pain.
Ali Khan, A; Chen, L; Chen, P; Hu, Y; Huang, S; Lu, D; Song, C; Wang, C; Wu, L; Zhou, R, 2023
)
1.86
"Emodin has the effects of anti-inflammatory and regulating immune function, but the mechanism is not very clear."( Effect of Emodin on Coxsackievirus B3m-Mediated Encephalitis in Hand, Foot, and Mouth Disease by Inhibiting Toll-Like Receptor 3 Pathway In Vitro and In Vivo.
Cheng, LB; Ding, Y; Huang, YQ; Ji, JY; Li, H; Li, Y; Wang, YQ; Xu, J; Zhang, JH; Zhao, L, 2020
)
1.68
"Emodin has neuroprotective effects against ischemia/reperfusion injury both in vitro and in vivo, which may be through activating the ERK-1/2 signaling pathway."( Neuroprotective Effects of Emodin against Ischemia/Reperfusion Injury through Activating ERK-1/2 Signaling Pathway.
Chang, CF; Chen, KY; Chen, YH; Chiang, YH; Kang, SJ; Lai, JH; Leung, SW; Tsai, YR; Wu, JC, 2020
)
1.58
"Emodin has been considered to play a protective role for acute lung edema in cecal ligation and puncture (CLP)-induced sepsis model."( Emodin attenuates acute lung injury in Cecal-ligation and puncture rats.
Guo, R; Han, M; Li, Y; Liu, J; Sun, Y, 2020
)
2.72
"Emodin has been shown of the effects of antioxidant, anti-inflammatory and antiviral."( Emodin resists to Cyprinid herpesvirus 3 replication via the pathways of Nrf2/Keap1-ARE and NF-κB in the ornamental koi carp (Cyprinus carpio haematopterus).
Guo, S; Liang, J; Liu, Y; Wang, H; Wang, Q; Wang, Z; Yuan, H; Zhang, R; Zheng, N; Zhou, J; Zu, X, 2021
)
2.79
"Emodin has shown pharmacological effects in the treatment of infection with severe acute respiratory syndrome coronavirus-2, which leads to coronavirus disease 2019 (COVID-19). "( Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology.
Chen, J; Du, HX; Wan, HT; Yang, JH; Zhou, HF; Zhu, JQ, 2021
)
2.3
"Emodin has been shown to exert strong anti-inflammatory property via acting on macrophages in a range of disease models."( Emodin inhibits lipid accumulation and inflammation in adipose tissue of high-fat diet-fed mice by inducing M2 polarization of adipose tissue macrophages.
Peng, J; Wang, F; Wang, X; Xu, X; Yu, F; Yu, N; Zhang, L; Zhao, Y; Zhou, J, 2021
)
2.79
"Emodin has a broad therapeutic window, and in addition to its antineoplastic activity, it displays anti-ulcer, anti-inflammatory, hepatoprotective, neuroprotective, antimicrobial, muscle relaxant, immunosuppressive and antifibrotic activities, in both in vitro and in vivo models."( Emodin - A natural anthraquinone derivative with diverse pharmacological activities.
Combrinck, S; Semwal, DK; Semwal, RB; Viljoen, A, 2021
)
2.79
"Emodin has previously been reported to inhibit mechanical stress-induced HS inflammation."( Emodin alleviates hypertrophic scar formation by suppressing macrophage polarization and inhibiting the Notch and TGF-β pathways in macrophages.
Cheng, Y; Deng, C; Hu, H; Li, W; Liu, C; Liu, Y; Qian, J; Qin, S; Wang, J; Xia, Z; Yang, S, 2021
)
2.79
"Emodin has demonstrated potent anticancer activity in human hepatocarcinoma cells and animal models, however, the cellular targets of emodin have not been fully defined. "( Emodin targets mitochondrial cyclophilin D to induce apoptosis in HepG2 cells.
He, D; Li, J; Li, K; Liu, H; Wang, B; Zhang, L; Zheng, L, 2017
)
3.34
"Emodin has a strong antibacterial activity, including methicillin-resistant Staphylococcus aureus (MRSA). "( Comparative analysis of methicillin-sensitive and resistant Staphylococcus aureus exposed to emodin based on proteomic profiling.
Ge, X; Ji, X; Liu, X; Peng, Y; Xu, H; Zhan, R, 2017
)
2.12
"Emodin has been reported to exhibit significant pharmacological potential."( Antitumor effects of emodin in CACO-2 human colon carcinoma cells are mediated via apoptosis, cell cycle arrest and downregulation of PI3K/AKT signalling pathway.
Ding, Y; Li, Y; Ma, Q; Wu, Z,
)
1.17
"Emodin has a direct inhibitory effect on the growth and metastasis of a variety of malignant tumor cells. "( Emodin inhibits pancreatic cancer EMT and invasion by up‑regulating microRNA‑1271.
Li, N; Wang, C; You, S; Zhang, P, 2018
)
3.37
"Emodin has been recognized to be an anti‑cancer agent against a number of types of human cancer. "( Emodin suppresses angiogenesis and metastasis in anaplastic thyroid cancer by affecting TRAF6‑mediated pathways in vivo and in vitro.
Shi, GH; Zhou, L, 2018
)
3.37
"Emodin has little effect on the concentrations of bile acids (BAs) in livers of ANIT-treated mice."( Paradoxical Effects of Emodin on ANIT-Induced Intrahepatic Cholestasis and Herb-Induced Hepatotoxicity in Mice.
Bi, Y; Fan, G; Gao, X; Han, L; Li, C; Wang, X; Zhang, Y, 2019
)
1.55
"Emodin has recently been reported to have a powerful antiinflammatory effect, protecting the myocardium against ischemia/reperfusion (I/R) injury. "( Emodin alleviates myocardial ischemia/reperfusion injury by inhibiting gasdermin D-mediated pyroptosis in cardiomyocytes.
Cai, X; Chen, X; Dai, S; Han, J; Huang, W; Huang, Z; Liang, X; Lin, S; Ye, B, 2019
)
3.4
"Emodin has been reported to possess anti-inflammatory and anti-oxidant activities. "( Emodin ameliorated lipopolysaccharide-induced fulminant hepatic failure by blockade of TLR4/MD2 complex expression in D-galactosamine-sensitized mice.
Gong, X; Jiang, R; Kuang, G; Wan, J; Wang, B; Xu, G; Yin, X; Zhang, L, 2014
)
3.29
"Emodin (Emo) has been reported to exhibit protective effects against diabetic nephropathy."( Emodin protects against diabetic cardiomyopathy by regulating the AKT/GSK-3β signaling pathway in the rat model.
Chen, Q; Deng, W; Ke, D; Li, G; Wu, Z, 2014
)
2.57
"Emodin has been found to exert anti-tumor effects through promoting cell cycle arrest and apoptosis, and inhibiting angiogenesis, but its effects on tumor-associated macrophages during cancer metastasis have not been investigated."( Emodin suppresses pulmonary metastasis of breast cancer accompanied with decreased macrophage recruitment and M2 polarization in the lungs.
Fan, D; Hu, J; Iwanowycz, S; Jia, X; Saaoud, F; Wang, J; Wang, Q; Wang, Y; Yu, F, 2014
)
2.57
"Emodin has antioxidative activities. "( Emodin Attenuates Cigarette Smoke Induced Lung Injury in a Mouse Model via Suppression of Reactive Oxygen Species Production.
Liang, SH; Liu, KF; Shi, XQ; Xue, WH; Zhao, J; Zhou, L, 2015
)
3.3
"Aloe-emodin (AE) has been found to be an anti-tumor agent in many studies, and has also been demonstrated as a photosensitizer, in the recent years."( Exploring a Novel Target Treatment on Breast Cancer: Aloe-emodin Mediated Photodynamic Therapy Induced Cell Apoptosis and Inhibited Cell Metastasis.
Bai, DQ; Chen, Q; Li, KT; Tian, S; Yu, LH; Yu, TH; Zhu, J, 2016
)
1.13
"Emodin (EMO) has multi-targets and multi-way antitumor effect, which was limited by the instability and poor solubility of EMO. "( A Promising Emodin-Loaded Poly (Lactic-Co-Glycolic Acid)-d-α-Tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles for Liver Cancer Therapy.
Deng, S; Gao, M; Guan, X; Liu, H; Lv, L; Tian, Y; Xu, H; Zhang, C, 2016
)
2.26
"Emodin (EMO) has been shown to possess pleiotropic anticancer capabilities in many types of cancer, including epithelial ovarian cancer (EOC). "( Emodin inhibits epithelial to mesenchymal transition in epithelial ovarian cancer cells by regulation of GSK-3β/β-catenin/ZEB1 signaling pathway.
Dong, T; Hu, C; Li, R; Liu, P; Lu, J; Wei, X, 2016
)
3.32
"Emodin has been used as a traditional Chinese medicine for over 2000 years and is still present in various herbal preparations."( Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics.
Cao, S; Dong, X; Fu, J; Li, X; Lin, L; Ni, J; Yin, X, 2016
)
2.6
"Emodin has anti-neoplastic activities on multiple tumors. "( Emodin Increases Expression of Insulin-Like Growth Factor Binding Protein 1 through Activation of MEK/ERK/AMPKα and Interaction of PPARγ and Sp1 in Lung Cancer.
Chen, Y; Hann, SS; Tang, Q; Wu, J; Zheng, F, 2017
)
3.34
"Emodin has the effect of reduce the hepatocellular apoptosis following OLT in rats and the effect can stronger by CsA."( [Effect of emodin on hepatocellular apoptosis following orthotopic liver transplantation in rats].
Jing, H; Lin, SZ; Xu, XC; Yang, X, 2008
)
2.18
"Emodin has been reported to sensitize human tumor cells to chemotherapeutic agents."( Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxel-induced apoptosis in vitro.
Li, J; Liu, P; Mao, H; Wanga, A; Zhang, X, 2009
)
2.52
"Emodin has a protective effect on hepatocytes and a restoring activity on cholestatic hepatitis. "( [Effect of emodin on P-gp expression in intrahepatic cholestatic rats].
Xu, H; Zhou, F, 2010
)
2.19
"Emodin has been demonstrated to inhibit the fibrotic process in chronic renal disease, but its mechanisms have yet to be fully elucidated. "( Emodin inhibits extracellular matrix synthesis by suppressing p38 and ERK1/2 pathways in TGF-β1-stimulated NRK-49F cells.
Cheng, XX; Huang, CZ; Lin, Y; Lu, Y; Wang, YJ; Zhu, B; Zhu, CF; Zhu, XL,
)
3.02
"Emodin has been used as an anti-inflammatory agent and inflammation is a crucial feature of atherosclerosis. "( Sonodynamic effect of an anti-inflammatory agent--emodin on macrophages.
Cao, W; Cheng, J; Gao, Q; Guo, S; Jin, Y; Li, B; Li, J; Shi, S; Tian, Y; Wang, F; Wang, H; Zhang, Z; Zhu, B, 2011
)
2.07
"Emodin has therapeutic potential against cancers."( Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis.
Bu, HQ; Chen, H; Guo, HC; Li, HH; Li, W; Lin, SZ; Liu, DL; Luo, J; Tong, HF; Wang, ZH; Wei, WT; Wu, HY; Zuo, MM, 2012
)
2.54
"Emodin has such pharmacological effects as ant-inflammatory, anti-tumor, immunoregulation. "( [Research progress of the anti-proliferation effect of emodin on VSMCs].
Chen, Y; Lu, C; Zeng, Z, 2012
)
2.07
"Emodin has been showed to induce apoptosis of pancreatic cancer cells and inhibit tumor growth in our previous studies. "( Antitumor activity of emodin against pancreatic cancer depends on its dual role: promotion of apoptosis and suppression of angiogenesis.
Chen, H; Chen, KJ; Guo, HC; Lin, SZ; Liu, DL; Liu, HB; Ni, ZL; Tong, HF; Wang, ZH; Wei, WT, 2012
)
2.14
"Aloe-emodin has been shown to exit anticancer activity."( Aloe-emodin inhibited N-acetylation and DNA adduct of 2-aminofluorene and arylamine N-acetyltransferase gene expression in mouse leukemia L 1210 cells.
Chang, WC; Cheng, KC; Chung, JG; Lee, YM; Li, YC; Lin, JP, 2003
)
1.29
"Emodin has a direct excitatory effect on circular smooth muscle cells in rat colon mediated via Ca(2+)/CaM dependent pathways. "( Contractile effects and intracellular Ca2+ signalling induced by emodin in circular smooth muscle cells of rat colon.
Dong, ZL; Ma, T; Qi, QH; Xu, J; Yang, WX, 2003
)
2
"Emodin has two-way regulation on [Ca2+]i and ICa-L of cardiomyocytes in guinea pig."( [Effects of emodin on the intracellular calcium concentration ([Ca2+]i) and L-type calcium current of the single ventricular mytocytes from guinea pig].
He, SZ; Liu, Y; Shan, HL; Sun, HL; Yang, BF, 2004
)
2.15
"Emodin has a direct contractile effect on colonic smooth muscle cell. "( Signal pathways involved in emodin-induced contraction of smooth muscle cells from rat colon.
Dong, ZL; Ma, T; Qi, QH; Xu, J; Yang, WX, 2004
)
2.06
"Emodin has the effect of promoting liver regeneration and improving liver function in rats after reduced size transplantation."( Effects of emodin and double blood supplies on liver regeneration of reduced size graft liver in rat model.
Lv, Y; Meng, KW; Pan, CE; Wu, SL; Yu, L, 2005
)
1.44
"Emodin has been reported to induce apoptosis in many human cancer cell lines, although its effects on leukocyte functions in vitro have not been demonstrated Therefore, the purpose of this study was to assess the effect of emodin on the phagocytosis of macrophages, the activity of natural killer cells and the expression of cytokines in leukocytes from Sprague-Dawley rats. "( The effects of emodin on the expression of cytokines and functions of leukocytes from Sprague-Dawley rats.
Chan, JK; Chang, YH; Chung, JG; Kuo, HM; Lin, JP; Tang, NY; Yu, CS; Yu, FS,
)
1.93
"Emodin has a different absorption spectrum in different solvents."( Evaluation of MTT assay for measurement of emodin-induced cytotoxicity.
Ge, J; Qian, J; Wang, K; Wang, X; Zou, Y, 2006
)
1.32
"Aloe-emodin has shown anti-neoplastic activity against some human cancer cell lines. "( Aloe-emodin affects the levels of cytokines and functions of leukocytes from Sprague-Dawley rats.
Chan, JK; Chang, YH; Chen, SC; Chung, JG; Hsia, TC; Li, TM; Lin, SS; Yu, CS; Yu, FS,
)
1.16
"Emodin has an anti-fibrotic effect on pancreatic fibrosis in rats. "( Effect of emodin on pancreatic fibrosis in rats.
Cai, JT; Du, Q; Gao, ZQ; Qian, KD; Wang, CH; Xie, CG; Ye, B, 2007
)
2.18
"Emodin has numerous biochemical and pharmacological activities, though information about its intestinal absorption and first-pass metabolism is scarce. "( Quantitation assay for absorption and first-pass metabolism of emodin in isolated rat small intestine using liquid chromatography-tandem mass spectrometry.
Cao, DY; Liu, RW; Liu, XY; Mei, QB; Teng, ZH; Yang, JY; Yang, RT; Yang, X; Zhang, BL; Zhou, SY, 2007
)
2.02
"Emodin has been shown to exhibit an anti-cancer effect."( Effects of emodin on gene expression profile in small cell lung cancer NCI-H446 cells.
Fu, ZY; Han, JX; Huang, HY, 2007
)
1.45
"Emodin also has the effects of liver protection, anti-liver fibrosis, and so on, the mechanisms for those effects still need more studies."( [Experimental advance of applying emodin for prevention and treatment of liver diseases].
Lin, SZ; Xu, XC, 2008
)
1.35
"Emodin has an effect on hepatic fibrosis in rats. "( [Effects of emodin on hepatic fibrosis in rats].
Huang, X; Li, D; Lu, H; Wang, Z; Wei, H; Xu, Q; Zhan, Y, 2001
)
2.13
"Aloeemodin has emerged as a potent hypotensive agent in current pharmacological investigations and caused 26 %, 52 %, and 79 % falls in mean arterial blood pressure at the corresponding doses of 0.5, 1, and 3 mg/kg in rats."( Hypotensive effect of chemical constituents from Aloe barbadensis.
Ahmad, SI; Ahmed, M; Akhtar, S; Dar, A; Faizi, S; Hasnain, SN; Hussain, SA; Qazi, A; Qazi, MH; Saleem, R; Siddiqui, BS, 2001
)
0.79
"Emodin has effect on hepatic fibrosis in rats. "( Emodin on hepatic fibrosis in rats.
Huang, X; Li, D; Lu, H; Wang, Z; Wei, H; Xu, Q; Zhan, Y, 2000
)
3.19
"Emodin has therapeutic effect on the development of hepatic fibrosis in rats. "( [Effect of emodin on development of hepatic fibrosis in rats].
Li, D; Wei, H; Zhan, Y, 2000
)
2.14
"Aloe emodin has been reported to be nontoxic for normal cells but to possess specific toxicity for neuroectodermal tumor cells."( The effect of aloe emodin on the proliferation of a new merkel carcinoma cell line.
Avigad, S; Beery, E; Fenig, E; Nordenberg, J; Wasserman, L, 2002
)
1.1

Actions

Emodin can inhibit the acute rejection of liver transplantation in rats. It may play the role with reduction of TNF-alpha and upregulation of IL-10. Emodin might inhibit TEMT by down-regulation the expression of ILK.

ExcerptReferenceRelevance
"Emodin can enhance the sensitivity of HepG2 HCC cells to cisplatin by inhibiting epithelial-mesenchymal transition, and thus, play a role in preventing recurrence and metastasis in HCC."( Effect of emodin combined with cisplatin on the invasion and migration of HepG2 hepatoma cells.
Chen, X; Deng, H; Lai, Q; Leng, Y; Wang, H; Xiong, Z; Yang, M, 2023
)
2.03
"Emodin could inhibit the proliferation ability of pancreatic cancer cells and increased miR‑1271 expression level."( Emodin inhibits pancreatic cancer EMT and invasion by up‑regulating microRNA‑1271.
Li, N; Wang, C; You, S; Zhang, P, 2018
)
2.64
"Emodin can inhibit the growth of HCC cells in"( Anticancer Effects of Emodin on HepG2 Cell: Evidence from Bioinformatic Analysis.
Liu, JW; Sun, QF; Tang, Y; Wang, XW; Ye, ZJ; Zhou, DH; Zhou, RS, 2019
)
1.55
"Emodin could inhibit HMG-CoA reductase and DGAT1, which were key enzymes in the synthesis of TC and TG."( In vitro effects of active components of Polygonum Multiflorum Radix on enzymes involved in the lipid metabolism.
Gu, W; He, Y; Li, Y; Lin, P; Sun, R; Wang, W; Yu, J; Zhao, R, 2014
)
1.12
"Emodin may inhibit inflammation by blocking HIF-1α/NF-ΚB-COX-2 signaling pathways."( [Hypoxia/reoxygenation and lipopolysaccharide induced nuclear factor-ΚB and hypoxia-inducible factor-1α signaling pathways in intestinal epithelial cell injury and the interventional effect of emodin].
Fu, Q; Qi, L; Yuan, B, 2014
)
1.31
"Emodin could inhibit E2-induced MCF-7 cell proliferation and anti-apoptosis effects, and arrest the cell cycle in G0/G1 phase, further blocking the effect of E2 on expression and transcriptional activity of ERα. "( Emodin inhibits breast cancer cell proliferation through the ERα-MAPK/Akt-cyclin D1/Bcl-2 signaling pathway.
Sui, JQ; Xie, KP; Xie, MJ; Zou, W, 2014
)
3.29
"Emodin-MgSiO3 can inhibit the expression of both VEGF gene and protein effectively."( Emodin-loaded magnesium silicate hollow nanocarriers for anti-angiogenesis treatment through inhibiting VEGF.
Li, Z; Ren, H; Song, E; Yang, W; Zhu, C, 2014
)
2.57
"Emodin did not increase the p-PKB (Ser473) to PKB ratio when the rapamycin-insensitive companion of mTOR was depleted, further supporting the involvement of mammalian target of rapamycin complex 2 in PKB phosphorylation."( 11β-HSD1 modulates LPS-induced innate immune responses in adipocytes by altering expression of PTEN.
Brown, J; Chu, K; Deng, J; Hong, G; Lai, W; Tian, X; Wei, Y; Xiang, Q; Zhang, S, 2015
)
1.14
"Emodin might suppress the growth of cervical cancer in mice by reducing tumor neovascularization, decreasing MIF expression and promoting tumor cell apoptosis."( [Inhibitory effect of emodin on the growth of cervical cancer in tumor-transplanted mice and underlying mechanism].
Chen, Z; Hu, Z; Zhang, J, 2015
)
2.17
"Emodin can inhibit human hepatoma cell line SMMC-7721."( Inhibitory effect of emodin on human hepatoma cell line SMMC-7721 and its mechanism.
Chen, Y; Zhang, T; Zhang, X; Zhang, Y, 2015
)
2.18
"Emodin can inhibit the proliferation of Tca8113 cells and affect their cell cycle distribution possibly by inhibiting the signaling pathways of cell cycle regulation."( [Effect of emodin on proliferation and cell cycle of human oral squamous carcinoma Tca8113 cells in vitro].
Jiao, K; Li, J; Wu, F; Yu, Z; Zhang, K; Zhu, Y, 2015
)
2.25
"Emodin could inhibit HBSS-induced LC3 II protein expression and the activation of autophagy in NRK-52E cells, and the effect of blocking autophagy may be mediated through mTOR signaling pathway."( [Molecular mechanism of emodin on inhibiting autophagy induced by HBSS in renal tubular cells].
Gu, LB; Hu, H; Liu, H; Sun, W; Tu, Y, 2015
)
2.17
"Emodin might inhibit TEMT by a down-regulation the expression of ILK."( [Interventional effect of emodin on the expression of intergern linked kinase in tubular epithelial-myofibroblast transdifferentiation].
Chen, M; Chen, TF; Qin, JH; Wang, MY, 2008
)
1.37
"Emodin might inhibit all of those changes induced by IL-1beta (P<0.05)."( [Interventional effects of emodin on transforming growth factor-beta1/integrin-linked kinase signal way in interleukin-1beta-induced transdifferentiation of rat tubular epithelial-myofibroblasts].
Chen, M; Chen, TF; Qin, JH; Wang, MY, 2009
)
1.37
"Emodin can inhibit the acute rejection of liver transplantation in rats model effectively and it may play the role with reduction of TNF-alpha and upregulation of IL-10."( [Effect of emodin on rejection of liver transplantation in rats].
Jing, H; Lin, S; Yang, X, 2009
)
2.19
"Emodin could cause the regression of tumor."( Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo.
Bei-Zhong, L; Chong, W; Chun-Guang, W; Dan, Z; Dan-Ting, J; Jun-Qing, Y; Liang, Z; Yan, W, 2010
)
1.39
"Emodin can inhibit the expressions of IL-6 and IL-8 mRNA induced by LPS in corneal fibroblasts, which maybe via inhibiting the degeneration of I kappaB-alpha and suppressing the activation of nuclear factor-kappaB."( [Effects of emodin on expression of cytokines induced by lipopolysaccharide in corneal fibroblasts].
Chen, GL; Liu, YL; Liu, ZY; Sun, HY; Wei, LW; Zhang, H, 2009
)
2.17
"Emodin can inhibit the apoptosis of intestinal mucosa cells and up-regulate the serum leptin content to protect the intestina1 barrier function and prevent the translocation of bacteria and endotoxin."( [Effects of emodin on cell apoptosis of intestinal mucosa and serum leptin in rats with severe acute pancreatitis].
Ji, F; Luo, DD; Ning, JW; Wang, LJ; Yang, CY, 2009
)
2.17
"Emodin can inhibit the activation of NF-kappaB and the expression of ICAM-1 induced by LPS in corneas, protect against acute corneal injury, and improve symptoms in rats."( Protective effect of emodin against lipopolysaccharides-induced corneal injury in rats.
Chen, GL; Gao, X; Liu, YL; Liu, ZY; Wang, J; Wei, LW, 2009
)
2.11
"Emodin can inhibit the genetic transcription and the translation of AQP2 gene in NRK cells, which demonstrates that the change of AQP2 expression regulated by emodin may be correlated with the diuresis effect of rhubarb, and it is likely that the regulation is going through PKA signal pathway."( [Effect and mechanism of emodin for regulating aquaporin-2 expression in cultured NRK cells].
Li, F; Liu, Q; Ren, QY, 2010
)
2.11
"Emodin was found to inhibit the replication of HSV-1 and HSV-2 in cell culture at the concentration of 50 μg/ml with antiviral index of 2.07 and 3.53, respectively. "( The effect of emodin, an anthraquinone derivative extracted from the roots of Rheum tanguticum, against herpes simplex virus in vitro and in vivo.
Hou, W; Luo, J; Xiao, H; Xiong, HR; Yang, ZQ, 2011
)
2.17
"Emodin could increase intestinal transit, suppress the activity of NF-kappaB in intestine, decrease the content of intestinal TNF-alpha and IL-1beta, and attenuate the pathological damage of intestine."( [Protective effects of emodin on intestinal lesion in rat model with acute necrotizing pancreatitis].
He, FQ; Huang, ZW; Li, YH; Xia, Q; Xue, P, 2010
)
2.11
"Emodin might activate AMPK by an indirect mechanism similar to berberine."( Promotion of adiponectin multimerization by emodin: a novel AMPK activator with PPARγ-agonist activity.
Chen, Z; Li, Z; Yang, Z; Yi, J; Zhang, L; Zhang, Z, 2012
)
1.36
"The emodin -induced increase in [Ca(2+)]i was unaffected by nifedipine, a voltage-gated Ca(2+)-channel antagonist, and the sustained phase of the rising of [Ca(2+)]i was attenuated by extracellular Ca(2+) removal with EGTA solution."( Contractile effects and intracellular Ca2+ signalling induced by emodin in circular smooth muscle cells of rat colon.
Dong, ZL; Ma, T; Qi, QH; Xu, J; Yang, WX, 2003
)
1.04
"Emodin could inhibit the growth of HepG2 cells significantly with IC(50) of 36+/-2.6 microg/ml; and could inhibit the colony formation of the cells in soft agar. "( [Apoptosis of human hepatoma HepG2 cells induced by emodin in vitro].
Gao, XG; Li, KZ; Lian, T; Liu, JB; Zhao, AZ, 2003
)
2.01
"Emodin may inhibit the growth and proliferation of HepG2 cells through the way of apoptosis introduction."( [Apoptosis of human hepatoma HepG2 cells induced by emodin in vitro].
Gao, XG; Li, KZ; Lian, T; Liu, JB; Zhao, AZ, 2003
)
2.01
"Emodin was shown to inhibit the proliferation of primary cultured bovine aortic endothelial cells in the absence or presence of basic-fibroblast growth factor (bFGF) or the presence of vascular endothelial growth factor (VEGF) in a dose-dependent manner."( Inhibitory effects of emodin on angiogenesis.
Wang, XH; Wu, SY; Zhen, YS, 2004
)
1.36
"Emodin can enhance the function of small intestinal peristalsis of mice by mechanisms of promoting secretion of motilin, lowering the content of somatostatin and inhibiting Na+-K+-ATPase activity of small intestinal mucosa."( Effect of emodin on small intestinal peristalsis of mice and relevant mechanism.
Wu, YQ; Zhang, HQ; Zhou, CH, 2005
)
2.17
"Emodin could suppress the proliferation of Anip 973 cell, and its mechanism of anticancer effect may be through activating Caspase-3, to induce apoptosis and block cell cycle."( [Effects of emodin on proliferation cycle and apoptotic gene of human lung adenocarcinoma cell line Anip 973].
Li, JN; Lv, FZ; Xiao, JL, 2006
)
2.16
"Emodin caused an increase in caspase 3-like activities and a caspase 3 inhibitor, Ac-DEVD-CHO, attenuated the apoptosis."( Emodin induces apoptosis through caspase 3-dependent pathway in HK-2 cells.
Chen, M; Duan, W; Sun, L; Wang, C; Wu, X; Yan, M; Zhang, L, 2007
)
2.5
"Emodin plays an anti-inflammatory role in several inflammatory diseases."( Emodin-mediated protection from acute myocardial infarction via inhibition of inflammation and apoptosis in local ischemic myocardium.
Chen, G; Cheng, Z; Fu, J; Huang, H; Lin, G; Liu, DX; Liu, M; Liu, Q; Tu, X; Wan, J; Wu, Y; Xia, H; Zhang, H, 2007
)
2.5
"Emodin can inhibit the growth of liver tumor cells in vitro and in vivo, inducing cell apoptosis is one of its mechanisms."( [Experimental advance of applying emodin for prevention and treatment of liver diseases].
Lin, SZ; Xu, XC, 2008
)
1.35
"Emodin could inhibit the proliferation of fibroblasts, and promote the programmed cell death through upregulate c-myc gene expression in human renal fibroblasts."( [Effect of emodin on fibroblasts in lupus nephritis].
Liu, G; Tan, Z; Ye, R, 2000
)
2.14
"Emodin can inhibit proliferation and promote apoptosis of fibroblasts, which may be important in ameliorate interstitial fibrosis, thus improving prognosis of LN."( [Effect of emodin on fibroblasts in lupus nephritis].
Liu, G; Tan, Z; Ye, R, 2000
)
2.14

Treatment

Emodin treatment evoked the expression alteration of 402 proteins (153 up-regulated and 249 down-regulated) in the CCI models. The proteins were primarily involved in PI3K/AKT signaling pathway, gamma-aminobutyric acid (GABA) receptor signaling, complement and coagulation cascades. Emodin also restored PC12 cell viability and reduced reactive oxygen species (ROS) production.

ExcerptReferenceRelevance
"Emodin treatment statistically elevated mechanical pain sensitivity, suppressed spontaneous pain, recovered motor coordination, decreased spinal inflammation score and IL-1β expression, increased spinal Nrf2 expression and SOD activity."( Emodin alleviates arthritis pain through reducing spinal inflammation and oxidative stress.
Chen, CX; Cheng, DW; Cheng, ML; Hu, YD; Li, D; Liu, L; Tang, Q; Xie, M; Yue, YF; Zhu, HL, 2022
)
2.89
"Emodin treatment evoked the expression alteration of 402 proteins (153 up-regulated and 249 down-regulated) in the CCI models, which were primarily involved in PI3K/AKT signaling pathway, gamma-aminobutyric acid (GABA) receptor signaling, complement and coagulation cascades, cGMP/PKG signaling pathway, MAPK signaling pathway, and calcium signaling pathway."( Proteomic and metabolomic approaches elucidate the molecular mechanism of emodin against neuropathic pain through modulating the gamma-aminobutyric acid (GABA)-ergic pathway and PI3K/AKT/NF-κB pathway.
Chen, P; Gong, Q; Huang, NY; Liu, C; Luo, RX; Pang, B; Wang, C; Wang, L; Ye, ZJ, 2023
)
1.86
"Emodin treatment attenuated testicular IRI and inhibited pyroptosis."( Emodin alleviates testicular ischemia-reperfusion injury through the inhibition of NLRP3-mediated pyroptosis.
Cheng, F; He, KX; Li, W; Ning, JZ, 2023
)
3.07
"Emodin treatment significantly reduced lipid peroxidation and NO levels while restoring the GST, GSH and catalase."( Emodin alleviates chronic constriction injury-induced neuropathic pain and inflammation via modulating PPAR-gamma pathway.
Ali, F; Alvi, AM; Badshah, I; Bungau, S; Hassan, SSU; Imran, M; Kandeel, M; Minhas, AM; Qazi, NG, 2023
)
3.07
"Emodin treatment restored PC12 cell viability and reduced reactive oxygen species (ROS) production and glutamate release under conditions of ischemia/hypoxia."( Neuroprotective Effects of Emodin against Ischemia/Reperfusion Injury through Activating ERK-1/2 Signaling Pathway.
Chang, CF; Chen, KY; Chen, YH; Chiang, YH; Kang, SJ; Lai, JH; Leung, SW; Tsai, YR; Wu, JC, 2020
)
1.58
"Emodin treatment increased the antioxidant activity and decreased the lipid peroxidation level of the koi."( Emodin resists to Cyprinid herpesvirus 3 replication via the pathways of Nrf2/Keap1-ARE and NF-κB in the ornamental koi carp (Cyprinus carpio haematopterus).
Guo, S; Liang, J; Liu, Y; Wang, H; Wang, Q; Wang, Z; Yuan, H; Zhang, R; Zheng, N; Zhou, J; Zu, X, 2021
)
2.79
"Emodin pretreatment significantly reduced the levels of ALT, AST, and ALP; increased the levels of ALB; alleviated hepatocellular damage and apoptosis; attenuated the exhaustion of GSH and SOD and the accumulation of MDA; and increased the expression of antioxidative enzymes, including nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase 1 (HO-1), and NAD(P)H quinone dehydrogenase 1 (NQO1)."( Emodin Attenuates Acetaminophen-Induced Hepatotoxicity via the cGAS-STING Pathway.
Chen, G; Cheng, Z; Han, L; Liu, Q; Shen, P, 2022
)
2.89
"Emodin treatment recovered PPAR-γ activity and phosphorylation, eNOS phosphorylation, and HSP90/eNOS coupling in HAECS in a concentration-dependent manner, which was reversed by the PPAR-γ inhibitor GW9662, and the eNOS inhibitor, L-NAME."( Emodin, A Chinese Herbal Medicine, Inhibits Reoxygenation-Induced Injury in Cultured Human Aortic Endothelial Cells by Regulating the Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) and Endothelial Nitric Oxide Synthase (eNOS) Signaling Pathway.
Liu, X; Ren, A; Shou, X; Wang, B; Wang, L; Wang, Y; Zhou, J; Zhou, R; Zhu, L, 2018
)
2.64
"Emodin treatment also increased HO-1 and NQO1 expression in a concentration- and time-dependent manner and caused antioxidant response element (ARE) transcription activity and nuclear Nrf2 accumulation."( Nrf2-mediated neuroprotection against oxygen-glucose deprivation/reperfusion injury by emodin via AMPK-dependent inhibition of GSK-3β.
Choi, YW; Park, G; Park, SY, 2018
)
1.43
"Emodin treatment protected against OGD/R-lead to neurotoxicity by potentiating Nrf2/ARE-regulated neuroprotection through the AMPK/GSK3β pathway, indicating that emodin may be useful for treating neurodegenerative disorders."( Nrf2-mediated neuroprotection against oxygen-glucose deprivation/reperfusion injury by emodin via AMPK-dependent inhibition of GSK-3β.
Choi, YW; Park, G; Park, SY, 2018
)
2.15
"Emodin treatment also resulted in generation of reactive oxygen species (ROS), which abrogated mitochondrial membrane potential (MMP)."( Emodin induces apoptosis in human hepatocellular carcinoma HepaRG cells via the mitochondrial caspase‑dependent pathway.
Dong, X; Fu, J; Leng, X; Liang, X; Ni, B; Ni, J; Yin, X; You, L, 2018
)
2.64
"Emodin treatment resulted in the ameliorated hypercoagulation and lung carcinogenesis accompanied by the decreased N2 neutrophils (CD66b"( Emodin regulates neutrophil phenotypes to prevent hypercoagulation and lung carcinogenesis.
Du, G; Duan, Y; Li, Z; Lin, H; Lin, Y; Tong, Q; Wang, M; Wang, Y; Yan, G; Zhang, M; Zhang, S; Zhou, L, 2019
)
2.68
"Emodin (72 h) treatment could up-regulate the gene expression of FASL (p < 0.05) and down-regulate the gene expression of C-MYC (p < 0.01), but induce no significant changes in the gene expressions of MCL1, GAPDH, BAX and CCND1."( Emodin elicits cytotoxicity in human lung adenocarcinoma A549 cells through inducing apoptosis.
Chan, SW; Guo, DJ; Guo, ZD; Kwan, YW; Lee, SM; Leung, GP; Li, WY; Ng, YF; Yu, PH; Zhang, H, 2014
)
2.57
"Emodin treatment did not induce specific cell cycle arrest, but it altered epigenetic modifications."( Emodin modulates epigenetic modifications and suppresses bladder carcinoma cell growth.
Cha, TL; Chang, SY; Chen, TT; Chuang, MJ; Ho, JY; Huang, SM; Liu, SY; Sun, GH; Sun, KH; Tang, SH; Wu, ST; Yu, CP; Yu, DS, 2015
)
2.58
"Emodin treatment also concentration-dependently induced LXRα, ABCA1 and ABCG1 expression."( Emodin enhances cholesterol efflux by activating peroxisome proliferator-activated receptor-γ in oxidized low density lipoprotein-loaded THP1 macrophages.
Fu, X; Guo, L; Xu, AG; Yao, MY; Zhao, LS, 2014
)
2.57
"Emodin treatment resulted in marked increases in phosphorylation of Akt a direct downstream signaling molecule of phosphatidylinositol 3-kinase (PI3K), but upstream of glycogen synthase kinase-3β (GSK-3β) and cAMP response element-binding protein (CREB)."( Emodin induces neurite outgrowth through PI3K/Akt/GSK-3β-mediated signaling pathways in Neuro2a cells.
An, HK; Choi, YW; Jin, ML; Kim, CM; Kim, KS; Ko, MJ; Lee, YC; Park, SJ, 2015
)
2.58
"Emodin treatment attenuated interleukin (IL)-1β secretion via the inhibition of NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome activation induced by ATP, nigericin, and silica crystals."( Anti-inflammatory effect of emodin via attenuation of NLRP3 inflammasome activation.
Han, JW; Heo, KH; Jeong, JH; Kang, TB; Kwak, SB; Lee, KH; Shim, DW; Shin, WY; Sim, EJ, 2015
)
1.43
"Emodin treatment abated the DEP-induced increase in airway resistance, and prevented the influx of neutrophils in bronchoalveolar lavage fluid."( Emodin mitigates diesel exhaust particles-induced increase in airway resistance, inflammation and oxidative stress in mice.
Al-Salam, S; Ali, BH; Beegam, S; Nemmar, A; Yuvaraju, P, 2015
)
2.58
"Emodin treatment (10 and 20 mg/kg per day, p.o.) attenuated all these biochemical indices, as well as histopathological alterations induced by BLM."( Inhibitory effect of emodin on bleomycin-induced pulmonary fibrosis in mice.
Chen, XH; Guan, WD; Hu, JM; Jin, GY; Mo, ZY; Sun, RS; Yang, ZF; Zhong, NS, 2009
)
1.39
"Emodin treatment can reduce the levels of TB, DB and ALT in ANIT induced-cholestatic hepatitis. "( [Effect and mechanism of emodin on cholestatic hepatitis].
DING, Y; GAO, Y; HUANG, ZH; KANG, SX; MEI, H; PENG, HM; ZHAO, L, 2009
)
2.1
"Upon emodin treatment, p53 is phosphorylated at Ser(15), which is accompanied by the ATM phosphorylation at Ser(1981)."( Emodin induces a reactive oxygen species-dependent and ATM-p53-Bax mediated cytotoxicity in lung cancer cells.
Chang, JT; Hsu, SL; Lai, JM; Wen, CL, 2009
)
2.25
"In emodin- and MMC-cotreated cells, ERK1/2 phosphorylation was enhanced by constitutively active MKK1/2 (MKK1/2-CA), thus increasing Rad51 protein levels and protein stability."( Role of Rad51 down-regulation and extracellular signal-regulated kinases 1 and 2 inactivation in emodin and mitomycin C-induced synergistic cytotoxicity in human non-small-cell lung cancer cells.
Cheng, CM; Chiu, YF; Kuo, YH; Lin, ST; Lin, YW; Su, YJ; Tsai, MS, 2010
)
1.09
"3. Emodin treatment prolonged liver allograft survival time from 10.9 days in Group B to 25.6 days in Group C."( Emodin attenuates acute rejection of liver allografts by inhibiting hepatocellular apoptosis and modulating the Th1/Th2 balance in rats.
Chen, KJ; Jing, H; Li, H; Lin, SZ; Tong, HF; Zheng, SS, 2010
)
2.32
"The emodin treatment increased the survival rate of HSV-infected mice, prolonged survival time and showed higher efficacy of HSV elimination from brain, heart, liver and ganglion, compared to the viral controls."( The effect of emodin, an anthraquinone derivative extracted from the roots of Rheum tanguticum, against herpes simplex virus in vitro and in vivo.
Hou, W; Luo, J; Xiao, H; Xiong, HR; Yang, ZQ, 2011
)
1.21
"Emodin treatment markedly and significantly mitigated all these effects."( Abrogation of cisplatin-induced nephrotoxicity by emodin in rats.
Al Husseini, IS; Al-Lawati, I; Al-Salam, S; Ali, BH; Fahim, M; Nemmar, A; Waly, M; Yasin, J, 2013
)
1.36
"Emodin-treated HFD/HF rats were protected from hepatosteatosis and metabolic derangements usually observed in HFD/HF animals."( Emodin prevents intrahepatic fat accumulation, inflammation and redox status imbalance during diet-induced hepatosteatosis in rats.
Alisi, A; Bruscalupi, G; Ceccarelli, S; Gnani, D; Massimi, M; Nobili, V; Panera, N; Pastore, A; Piemonte, F; Tozzi, G, 2012
)
2.54
"Emodin treatment also resulted in a dose-dependent accumulation of intracellular reactive oxygen species."( Emodin regulates apoptotic pathway in human liver cancer cells.
Bao, W; Lei, JC; Yu, JQ, 2013
)
2.55
"Emodin treatment significantly improved left ventricular (LV) function and reduced the severity of myocarditis, as reflected by echocardiographic and histopathological examination."( Emodin, a naturally occurring anthraquinone, ameliorates experimental autoimmune myocarditis in rats.
Bai, JH; Hu, J; Li, Z; Song, ZC; Wang, ZS, 2012
)
2.44
"Emodin treatment resulted in repressing androgen-dependent transactivation of AR by inhibiting AR nuclear translocation."( Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth.
Cha, TL; Chen, CT; Hung, MC; Qiu, L; Wen, Y, 2005
)
2.49
"Aloe emodin treatment of t-HSC/Cl-6 cells caused activation of caspase-3 and caspase-9, detected with a caspase activity assay, although no change was observed in caspase-8 activity."( Aloe emodin-induced apoptosis in t-HSC/Cl-6 cells involves a mitochondria-mediated pathway.
Lian, LH; Park, EJ; Piao, HS; Sohn, DH; Zhao, YZ, 2005
)
1.3
"The emodin-treated rats were fed with different doses of emodin (20, 40, and 80 mg/kg body weight), while the normal and model control groups received 0.9% sodium chloride solution instead."( [Effect of emodin on pancreatic fibrosis: experiment with rats].
Cai, JT; Du, Q; Gao, ZQ; Qian, KD; Wang, CH; Xie, CG; Ye, B, 2006
)
1.2
"Emodin-treated rats were fed with different doses of emodin (20, 40 and 80 mg/kg body weight) for 28 d, while normal group and control group received 0.9% sodium chloride solution."( Effect of emodin on pancreatic fibrosis in rats.
Cai, JT; Du, Q; Gao, ZQ; Qian, KD; Wang, CH; Xie, CG; Ye, B, 2007
)
1.46
"In emodin-treated rats, the serum levels of HA and LN were decreased significantly (HA, 62.2 +/- 19.3 microg/L vs 112.7 +/- 26.5 microg/L, P < 0.05; LN 44.3 +/- 10.4 microg/L vs 86.2 +/- 16.5 microg/L, P < 0.05); the degree of fibrosis was ameliorated observably; the expression of collagen in pancreatic tissue was reduced especially in high-dose emodin-treated group (36% +/- 5% vs 42% +/- 6%, P < 0.05); with the increased doses of emodin, the expression of TGF-beta(1) was declined, compared with those in control group."( Effect of emodin on pancreatic fibrosis in rats.
Cai, JT; Du, Q; Gao, ZQ; Qian, KD; Wang, CH; Xie, CG; Ye, B, 2007
)
1.36
"Emodin treatments had markedly more hydroxyproline content in day 7 wounds and tensile strength in day 14 wounds than that of vehicle control."( Emodin, an anthraquinone derivative from Rheum officinale Baill, enhances cutaneous wound healing in rats.
Shan, G; Tang, T; Yang, J; Yin, L, 2007
)
2.5
"Emodin treatment resulted in the release of cytochrome c into cytosol and a loss of mitochondrial membrane potential (DeltaPsi(m)), as well as a decrease in the expression of an anti-apoptotic protein (Bcl-2) and an increase in the expression of an a pro-apoptotic protein (Bax)."( Emodin inhibits TNF-alpha-induced human aortic smooth-muscle cell proliferation via caspase- and mitochondrial-dependent apoptosis.
Heo, SK; Park, SD; Park, WH; Yun, HJ, 2008
)
2.51
"Emodin treatment resulted in a marked decrease in the transduction efficiency of HER-2/neu-overexpressing cells but not in the parental cells."( Enhanced adenoviral transduction efficiency in HER-2/neu-overexpressing human breast cancer cells not induced by an integrin pathway.
Im, SA; Jeon, HM; Kim, JS; Lee, SN,
)
0.85
"The emodin treatment induced P450s 1A1 and 1B1 mRNA in human lung carcinoma NCI-H322 and breast cancer MCF-7 cells."( Induction of cytochromes P450 1A1 and 1B1 by emodin in human lung adenocarcinoma cell line CL5.
Chen, TL; Ueng, TH; Wang, HW; Yang, PC, 2001
)
1.05
"Aloe-emodin-treated CH27 cells had an increased relative abundance of cytochrome c in the cytosolic fraction."( Effects and mechanisms of aloe-emodin on cell death in human lung squamous cell carcinoma.
Hsu, SL; Lee, HZ; Liu, MC; Wu, CH, 2001
)
1.05
"The emodin-treated rats were treated with low-dose, mediate-dose and high-dose emodin (20, 40 and 80 mg/kg body weight, once a day for 42 days) dissolved in 0.5% sodium carboxymethylcellulose (CMC), except receiving CCl4."( Emodin on hepatic fibrosis in rats.
Huang, X; Li, D; Lu, H; Wang, Z; Wei, H; Xu, Q; Zhan, Y, 2000
)
2.23
"Pretreatment with emodin ameliorated renal injury in mice following I/R injury."( Emodin prevents renal ischemia-reperfusion injury via suppression of CAMKII/DRP1-mediated mitochondrial fission.
Bae, ON; Cai, J; Huyan, T; Li, X; Liu, Q; Shi, Y; Su, J; Tie, L; Wang, D; Wang, H; Wang, Q; Wang, Y; Wu, P; Zhang, F, 2022
)
2.49
"For treatment of Emodin, intraperitoneal injection of 20 mg/kg Emodin was performed before the surgery."( Emodin Promotes Autophagy and Prevents Apoptosis in Sepsis-Associated Encephalopathy through Activating BDNF/TrkB Signaling.
Gao, LL; Liu, ZL; Mu, YH; Pang, L; Wang, ZH, 2022
)
2.49
"Treatment of emodin significantly increased the proportion of M2-polarized macrophages and the expression level of TGF-β, a typical ECM formation-related cytokine secreted by the M2 macrophages in the co-cultured supernatant."( Emodin accelerates diabetic wound healing by promoting anti-inflammatory macrophage polarization.
Chen, C; Guan, S; Hu, Q; Hu, T; Jin, X; Lin, Z; Liu, W; Quan, S; Shen, J; Wang, J; Wu, X; Zhuang, X, 2022
)
2.52
"Cotreatment with emodin and STF-083010 led to the downregulation of BiP and upregulation of CHOP, the Bax/Bcl-2 ratio, and cleaved caspase-3 compared with single treatment with emodin."( Emodin, an Emerging Mycotoxin, Induces Endoplasmic Reticulum Stress-Related Hepatotoxicity through IRE1α-XBP1 Axis in HepG2 Cells.
Cho, GH; Chun, HS; Park, SB; Park, YE, 2023
)
2.68
"Treatment of Emodin in DKD models could significantly attenuated these changes and reduced renal injury."( Emodin attenuates diabetic kidney disease by inhibiting ferroptosis via upregulating Nrf2 expression.
Cao, M; Cui, M; Ji, J; Tao, P; Wang, Q; Xu, Y, 2023
)
2.71
"Pretreatment with emodin significantly recovered these alterations caused by NaF."( Emodin protected against synaptic impairment and oxidative stress induced by fluoride in SH-SY5Y cells by modulating ERK1/2/Nrf2/HO-1 pathway.
Chen, Q; Ding, Y; Lai, C; Liu, H; Tang, Z, 2020
)
2.32
"Co-treatment of Emodin and Cisplatin increased chemosensitivity by inhibiting the expression of drugresistant genes through reducing the ROS levels in endometrial cancer cells."( Emodin Enhances the Chemosensitivity of Endometrial Cancer by Inhibiting ROS-Mediated Cisplatin-resistance.
Ding, N; Ding, Y; Liu, P; Su, S; Tang, Y; Wang, Q; Yu, X; Zhang, H, 2018
)
2.26
"Treatment with emodin obviously ameliorated pancreatic injury and decreased the release of amylase and inflammatory cytokines."( Effect of emodin on endoplasmic reticulum stress in rats with severe acute pancreatitis.
Cai, B; Cai, H; Li, H; Liu, X; Wu, L; Zheng, S, 2013
)
1.13
"Treatment with emodin at concentrations of 10-20 μM led to a direct increase in the reactive oxygen species (ROS) content in IMR-32 cells, along with significant elevation of cytoplasmic free calcium and nitric oxide (NO) levels, loss of mitochondrial membrane potential (MMP), activation of caspases-9 and -3, and cell death."( Characterization of apoptosis induced by emodin and related regulatory mechanisms in human neuroblastoma cells.
Chan, WH; Hsuuw, YD; Huang, FJ, 2013
)
1
"Treatment with emodin significantly turns down the accelerated cell cycle and proliferation of MCs cultured in high glucose (HG) via inhibiting cFLIP."( Emodin suppresses hyperglycemia-induced proliferation and fibronectin expression in mesangial cells via inhibiting cFLIP.
Cao, S; Gao, J; Guo, C; Su, Z; Wang, F; Wang, W, 2014
)
2.18
"Treatment with emodin normalized the change of plasma corticosterone level, which demonstrated that emodin could partially restore CUMS-induced HPA axis impairments."( Emodin opposes chronic unpredictable mild stress induced depressive-like behavior in mice by upregulating the levels of hippocampal glucocorticoid receptor and brain-derived neurotrophic factor.
Fu, Q; Li, M; Li, S; Li, Y; Ma, S; Xue, J, 2014
)
2.18
"Treatment with emodin led to significant decreases in the levels of IL-4, IL-5, IL-13 and eotaxin in BALF and total IgE level in serum."( Protective effect of emodin against airway inflammation in the ovalbumin-induced mouse model.
Gao, YS; Jia, X; Li, YH; Liu, M; Wang, T; Wu, RH; Zhang, SJ; Zhong, XG, 2015
)
1.08
"Cotreatment with emodin and cDDP inhibited the tumor growth in vivo by increasing tumor cell apoptosis."( Emodin augments cisplatin cytotoxicity in platinum-resistant ovarian cancer cells via ROS-dependent MRP1 downregulation.
Dong, Y; Lin, X; Ma, J; Wang, C; Wang, Y; Yang, J; Zhang, N, 2014
)
2.17
"Treatment with emodin significantly attenuated HS inflammation, as determined by histopathological assessment of the scar elevation index, collagen structure and inflammation (P<0.05)."( Inhibition of mechanical stress-induced hypertrophic scar inflammation by emodin.
Liu, C, 2015
)
0.99
"Pretreatment with emodin significantly protected the animals from T cell-mediated hepatitis, as shown by the decreased elevations of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as well as reduced hepatic necrosis. "( Emodin protects against concanavalin A-induced hepatitis in mice through inhibiting activation of the p38 MAPK-NF-κB signaling pathway.
Chen, F; Chen, Z; He, J; Liu, Y; Wang, J; Wu, S; Xue, J; Zheng, M; Zhu, H, 2015
)
2.19
"Treatment with emodin, baicalin, schizandrin and berberine significantly decreased the MICs of amoxicillin and tetracycline against some strains, decreased by 1 to 2 times, but did not significantly change the MICs of clarithromycin, levofloxacin, and metronidazole against MDR strains."( Inhibitory effects of emodin, baicalin, schizandrin and berberine on hefA gene: treatment of Helicobacter pylori-induced multidrug resistance.
Chen, BP; Huang, GR; Huang, XF; Huang, YQ; Huang, ZS; Mo, XQ; Su, JW; Tang, HY; Wei, HY; Wei, LD; Wu, MH; Yu, WQ; Zhao, LJ; Zhou, XH, 2015
)
1.07
"Pretreatment with emodin resulted in significantly reduced glutamate-induced apoptotic cell death in HT22 cells. "( Emodin from Polygonum multiflorum ameliorates oxidative toxicity in HT22 cells and deficits in photothrombotic ischemia.
Ahn, SM; Choi, BT; Choi, YW; Kim, CM; Kim, HN; Kim, YR; Shin, HK, 2016
)
2.21
"Pretreatment with emodin significantly suppressed the TGF-β-induced EMT and cell migration in BT20 cells."( Stromal Fibroblasts from the Interface Zone of Triple Negative Breast Carcinomas Induced Epithelial-Mesenchymal Transition and its Inhibition by Emodin.
Ho, CT; Hsu, HC; Hung, CM; Lin, YC; Liu, LC; Wang, HY; Way, TD, 2017
)
0.98
"Treatment of emodin (20, 30 and 40 mg/kg, po) significantly lessened the toxicity by protecting acetaminophen-induced alterations in various blood and tissue biochemical variables after 24h of its administration."( Dose-dependent hepatoprotective effect of emodin against acetaminophen-induced acute damage in rats.
Bhadauria, M, 2010
)
0.98
"Co-treatment with emodin additively inhibited survivin expression in a ROS-dependent manner."( Emodin potentiates the anticancer effect of cisplatin on gallbladder cancer cells through the generation of reactive oxygen species and the inhibition of survivin expression.
Chen, Y; Li, H; Li, X; Sun, Y; Tian, Y; Wang, J; Wang, W; Yi, J, 2011
)
2.14
"Treatment with emodin, rhein, or aloin failed to reduce H(2)O(2) injury."( Anthraquinone-2-sulfonic acid (AQ2S) is a novel neurotherapeutic agent.
Jackson, TC; Kochanek, PM; Verrier, JD, 2013
)
0.73
"Treatment with emodin inhibited myocardial cell apoptosis by inhibiting caspase-3 activation."( Emodin-mediated protection from acute myocardial infarction via inhibition of inflammation and apoptosis in local ischemic myocardium.
Chen, G; Cheng, Z; Fu, J; Huang, H; Lin, G; Liu, DX; Liu, M; Liu, Q; Tu, X; Wan, J; Wu, Y; Xia, H; Zhang, H, 2007
)
2.12
"Treatment with emodin reduced VEGFR phosphorylation, as evidenced by Western blot analysis."( The effect of emodin on VEGF receptors in human colon cancer cells.
Lu, Y; Qian, J; Zhang, J, 2008
)
1.05
"Treatment with emodin resulted in a decrease in intracellular protein-tyrosine phosphorylation."( Selective inhibition of the growth of ras-transformed human bronchial epithelial cells by emodin, a protein-tyrosine kinase inhibitor.
Chan, TC; Chang, CJ; Geahlen, RL; Koonchanok, NM, 1993
)
0.85

Toxicity

Emodin is the main toxic component in Chinese medicinal herbs such as rhubarb. The mechanism of emodin's adverse effects is complicated and currently not well understood.

ExcerptReferenceRelevance
" The rat maternal lowest observed adverse effect level (LOAEL) was 1700 ppm; the no observed adverse effect level (NOAEL) was 850 ppm."( Developmental toxicity evaluation of emodin in rats and mice.
George, JD; Jahnke, GD; Marr, MC; Myers, CB; Price, CJ, 2004
)
0.6
" Taken together, these results suggest an innovative and safe chemotherapeutic strategy that uses natural anthraquinone derivatives as ROS generators to increase the susceptibility of tumor cells to cytotoxic therapeutic agents."( Anthraquinones sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo via reactive oxygen species-mediated dual regulation of apoptosis.
Chen, YY; Guo, QS; Hu, QS; Kang, XL; Li, H; Lu, Y; Shi, GY; Tang, XM; Wang, XJ; Yang, J; Yi, J, 2004
)
0.32
" Data on natural toxic chemicals could be used for extrapolation methods such as read-across."( The comparative toxicity to soil invertebrates of natural chemicals and their synthetic analogues.
Chaplow, JS; Harman, M; Hopkin, S; Potter, E; Scott, WA; Sims, I; Sorokin, N; Whitaker, J, 2009
)
0.35
" However, liver adverse reactions caused by RPM or RPMP were frequently reported all around the world recent years."( Hepatoxicity of major constituents and extractions of Radix Polygoni Multiflori and Radix Polygoni Multiflori Praeparata.
Li, N; Mao, XJ; Wang, J; Wang, MJ; Xie, J; Yu, J; Zhao, RH; Zhaori, GT, 2011
)
0.37
" Water extractions of RPM and RPMP were less toxic than any other solvent in most of the assays."( Hepatoxicity of major constituents and extractions of Radix Polygoni Multiflori and Radix Polygoni Multiflori Praeparata.
Li, N; Mao, XJ; Wang, J; Wang, MJ; Xie, J; Yu, J; Zhao, RH; Zhaori, GT, 2011
)
0.37
" These adverse effects of high glucose could be prevented to a large extent by co-culture with 3 μM of emodin which per se did not affect HUVECs viability."( Protection of vascular endothelial cells from high glucose-induced cytotoxicity by emodin.
Bee, YM; Gao, Y; Huang, L; Li, G; Liang, S; Song, M; Tan, M; Wu, Q; Xu, H; Yi, Y; Zhang, J, 2015
)
0.86
" Adverse changes were associated with long-term AQ administration, and these focussed on the liver, lung and kidney, but after 15-day convalescence, most had reverted to normal."( Toxicity of anthraquinones: differential effects of rumex seed extracts on rat organ weights and biochemical and haematological parameters.
Abay, S; Abdugheny, A; Ali, Y; Islam, R; Ismayil, I; Kadir, M; Mamat, Y; Niyaz, M; Rapkat, H; Yan, M, 2015
)
0.42
" It was interesting to find that physcion was rather toxic to neuronal cells while albiflorin, aloeemodin and neohesperidin reduced the toxicity and ROS induced by both monomeric and oligomeric Aβ species."( Inhibition of β-amyloid Aggregation By Albiflorin, Aloeemodin And Neohesperidin And Their Neuroprotective Effect On Primary Hippocampal Cells Against β-amyloid Induced Toxicity.
Bian, Z; Ho, SL; Kwong, DW; Li, HW; Lin, C; Poon, CY; Wong, MS; Yan, T; Yung, KK, 2015
)
0.88
"Radix Wikstroemia indica (RWI), named "Liao Ge Wang" in Chinese, is a kind of toxic Chinese herbal medicine (CHM) commonly used in Miao nationality of South China."( Exploring the Q-marker of "sweat soaking method" processed radix Wikstroemia indica: Based on the "effect-toxicity-chemicals" study.
Chen, YL; Feng, G; Hai, Y; He, X; Li, LL; Li, W; Liu, CX; Wu, ZG; Wu, ZJ; Zhang, SC; Zheng, CQ, 2018
)
0.48
" The mechanism of emodin's adverse effects is complicated and currently not well understood."( NMR-based Metabolomic Techniques Identify the Toxicity of Emodin in HepG2 Cells.
Chen, C; Gao, J; Gu, LW; Guo, C; Li, ZF; Liu, A; Mao, CY; Wang, TS; Yan, YJ; Yang, Y, 2018
)
1.06
"Emodin is the main toxic component in Chinese medicinal herbs such as rhubarb."( Metabolism and Toxicity of Emodin: Genome-Wide Association Studies Reveal Hepatocyte Nuclear Factor 4α Regulates UGT2B7 and Emodin Glucuronidation.
Cai, Z; Cao, W; Cao, Y; Chen, W; Chen, Y; Dai, F; Huang, Y; Liu, S; Mao, Z; Tang, L; Wu, L; Zhan, Z; Zhang, T, 2020
)
2.3
" The results suggested that the emodin-type monoterpene and rhein might be the potential hepatotoxic components, while the metabolites of emodin-8-O-β-D-glucoside and emodin methyl ether showed more toxic risks."( [Study on potential hepatotoxicity of main monomers of Polygonum multiflorum based on liver micro-tissue].
Guo, HX; Ma, SC; Wang, Q; Wen, HR; Zhang, LS; Zhang, QH, 2020
)
0.84
" The primary purpose of this study was to uncover any potential toxic properties of emodin in mice at doses that have been shown to have efficacy in our cancer studies."( Safety of natural anthraquinone emodin: an assessment in mice.
Chatzistamou, I; Cotham, W; Enos, RT; Fan, D; Kelly, B; McDonald, S; Murphy, EA; Nagarkatti, M; Sougiannis, AT; VanderVeen, BN; Velazquez, KT, 2021
)
1.13
"In summary, our studies establish that 1) emodin is safe for use in both male and female mice when given at 20, 40, and 80 mg/kg doses for 12 weeks and 2) sex differences should be considered when establishing dosing intervals for emodin treatment."( Safety of natural anthraquinone emodin: an assessment in mice.
Chatzistamou, I; Cotham, W; Enos, RT; Fan, D; Kelly, B; McDonald, S; Murphy, EA; Nagarkatti, M; Sougiannis, AT; VanderVeen, BN; Velazquez, KT, 2021
)
1.17
" multiflorum vary, and the toxic components are even more controversial."( Polygonum multiflorum Thunb. Induces hepatotoxicity in SD rats and hepatocyte spheroids by Disrupting the metabolism of bilirubin and bile acid.
Ma, S; Wang, Q; Wen, H; Zhang, Y, 2022
)
0.72
" Recent results showed that emodin is the potential toxic components of PMT, but the molecular mechanisms of emodin on liver toxicity remain to be elucidated."( Emodin-induced hepatotoxicity is enhanced by 3-methylcholanthrene through activating aryl hydrocarbon receptor and inducing CYP1A1 in vitro and in vivo.
Gao, Y; Ruan, P; Wang, M; Wang, Y; Xiao, C; Zhang, G; Zhang, Z, 2022
)
2.46

Pharmacokinetics

Emodin has poor oral bioavailability in rats because of its extensive glucuronidation. Levels of aloe-emodin, rhein, emodin and chrysophanol in rat serum were quantified using a liquid chromatography tandem mass spectrometry (LC-MS/MS) method.

ExcerptReferenceRelevance
"A validated high-performance liquid chromatography (HPLC) method was developed for simultaneous determination and pharmacokinetic study of aloe emodin and chrysophanol in rats."( Simultaneous determination and pharmacokinetic studies of aloe emodin and chrysophanol in rats after oral administration of Da-Cheng-Qi decoction by high-performance liquid chromatography.
Chen, GY; Huang, X; Liang, MZ; Qin, F; Tang, WF; Wan, MH; Wang, YG; Yu, Q, 2007
)
0.78
"In this research, pharmacokinetic comparisons of icariin, emodin and psoralen from the extracts of herba Epimedii, Nepal dock root and Ficus hirta yahl, and GKG were conducted."( In vivo pharmacokinetics comparisons of icariin, emodin and psoralen from gan-kang granules and extracts of herba Epimedii, Nepal dock root, Ficus hirta yahl.
Chen, Y; Duan, J; Guo, T; Li, B; Li, Y; Xie, W; Yan, S; Zhou, Y, 2009
)
0.85
"5, 2, 4, 6, 8, 12 and 24 h) after administration, the concentrations of icariin, emodin and psoralen in rat plasma were determined by HPLC-UV, and main pharmacokinetic parameters were estimated."( In vivo pharmacokinetics comparisons of icariin, emodin and psoralen from gan-kang granules and extracts of herba Epimedii, Nepal dock root, Ficus hirta yahl.
Chen, Y; Duan, J; Guo, T; Li, B; Li, Y; Xie, W; Yan, S; Zhou, Y, 2009
)
0.83
"The pharmacokinetic parameters of icariin, emodin and psoralen in GKG were elevated comparing with those of herb extracts."( In vivo pharmacokinetics comparisons of icariin, emodin and psoralen from gan-kang granules and extracts of herba Epimedii, Nepal dock root, Ficus hirta yahl.
Chen, Y; Duan, J; Guo, T; Li, B; Li, Y; Xie, W; Yan, S; Zhou, Y, 2009
)
0.87
" However, the half-life and area under the concentration-time curve for emodin differed significantly between male and female rats."( Effects of food and gender on the pharmacokinetics of rhein and emodin in rats after oral dosing with Da-Cheng-Qi decoction.
Gong, H; Huang, X; Tang, W; Wang, H; Xia, Q, 2011
)
0.84
" The method was then successfully applied in a pharmacokinetic study of four bioactive components after a single oral administration of DHXD extract to rats."( A novel UPLC-MS/MS method for simultaneous quantification of rhein, emodin, berberine and baicalin in rat plasma and its application in a pharmacokinetic study.
Gao, JW; Huang, P; Lu, YS; Shi, Z; Yao, MC; Yuan, YM; Zou, JL, 2012
)
0.61
" The levels of aloe-emodin, rhein, emodin, chrysophanol, honokiol, magnolol, hesperidin, and naringin in rat serum were quantified using a liquid chromatography tandem mass spectrometry (LC-MS/MS) method for pharmacokinetic study."( Effect of formula compatibility on the pharmacokinetics of components from Dachengqi Decoction [See Text] in rats.
Chen, GY; Gong, HL; Huang, X; Tang, WF; Wang, J, 2012
)
0.7
"The area under the curve (AUC), mean retention time (MRT), the peak concentration (C(max)) of aloe-emodin, rhein, emodin, and chrysophanol in the DCQD group were significantly different compared with the Dahuang group (P <0."( Effect of formula compatibility on the pharmacokinetics of components from Dachengqi Decoction [See Text] in rats.
Chen, GY; Gong, HL; Huang, X; Tang, WF; Wang, J, 2012
)
0.6
"The compatibility in Chinese medicine could affect the drug's pharmacokinetics in DCQD, which proves that the prescription compatibility principle of Chinese medicine formulations has its own pharmacokinetic basis."( Effect of formula compatibility on the pharmacokinetics of components from Dachengqi Decoction [See Text] in rats.
Chen, GY; Gong, HL; Huang, X; Tang, WF; Wang, J, 2012
)
0.38
" Cmax and AUC of gallic acid were increased (P<0."( Influence of processing on pharmacokinetic of typical constituents in radix polygoni multiflori after oral administration by LC-ESI-MS/MS.
Chang, YX; Gao, XM; He, J; Li, J; Ma, WF; Zhang, BL; Zhang, L; Zhang, P; Zheng, F, 2013
)
0.39
" The LC-MS/MS method could be used to evaluate the effect of processing on pharmacokinetic of typical constituents in radix polygoni multiflori after oral administration."( Influence of processing on pharmacokinetic of typical constituents in radix polygoni multiflori after oral administration by LC-ESI-MS/MS.
Chang, YX; Gao, XM; He, J; Li, J; Ma, WF; Zhang, BL; Zhang, L; Zhang, P; Zheng, F, 2013
)
0.39
" The rapid and sensitive method was fully validated and successfully applied to the pharmacokinetic study of formononetin, cryptotanshinone, tanshinone IIA and emodin in rats following oral administration of Bu Shen Huo Xue formula."( A rapid UFLC-MS/MS method for simultaneous determination of formononetin, cryptotanshinone, tanshinone IIA and emodin in rat plasma and its application to a pharmacokinetic study of Bu Shen Huo Xue formula.
Huang, K; Pan, Y; Ren, Y; Wang, X; Xiang, Z; Xu, Y; Yan, P, 2013
)
0.8
" Finally, we demonstrated the application of a validated method in a comparative pharmacokinetic study of rats receiving an oral dose of Dahuang Fuzi Decoction or Radix et Rhei Rhizoma, the monarch drug in the prescription."( Simultaneous quantification of chrysophanol and physcion in rat plasma by ultra fast liquid chromatography-tandem mass spectrometry and application of the technique to comparative pharmacokinetic studies of Radix et Rhei Rhizoma extract alone and Dahuang
Cai, BC; Cai, H; Li, H; Liu, X; Poh, Y; Wu, L; Xing, J, 2015
)
0.42
" The peak concentration and area under curve of all three components were much higher in the AP group than those in the normal group with MLHP in external application for 48 h (P<0."( Effect of acute pancreatitis on the pharmacokinetics of Chinese herbal micron Liuhe Pill ointment in rats.
Chen, GY; Chen, WW; Li, J; Liu, YL; Tang, WF; Wan, MH; Zhao, XL, 2015
)
0.42
" The pharmacokinetic profiles of emodin after oral administration of emodin (20mg/kg) alone and in combination with piperine (20mg/kg) to rats were investigated via a validated LC/MS/MS method."( Effect of piperine on the bioavailability and pharmacokinetics of emodin in rats.
Di, X; Liu, Y; Wang, X, 2015
)
0.94
" This study was designed to confirm the expected synergistic effects of RGHP at pharmacodynamic and pharmacokinetic levels."( Synergistic effects of rhubarb-gardenia herb pair in cholestatic rats at pharmacodynamic and pharmacokinetic levels.
Dong, LC; Dong, X; Fan, YX; Li, HJ; Li, P; Ma, J; Yu, Q, 2015
)
0.42
" For pharmacodynamic study, biochemical and histopathological tests were performed to assess the hepatoprotective effects."( Synergistic effects of rhubarb-gardenia herb pair in cholestatic rats at pharmacodynamic and pharmacokinetic levels.
Dong, LC; Dong, X; Fan, YX; Li, HJ; Li, P; Ma, J; Yu, Q, 2015
)
0.42
" The pharmacokinetic study indicated RGHP could significantly elevate systemic exposure level and prolong retention time of five markers in comparison with rhubarb or gardenia alone."( Synergistic effects of rhubarb-gardenia herb pair in cholestatic rats at pharmacodynamic and pharmacokinetic levels.
Dong, LC; Dong, X; Fan, YX; Li, HJ; Li, P; Ma, J; Yu, Q, 2015
)
0.42
"The present study demonstrated the synergistic effects of RGHP in ANIT-induced cholestatic rats at pharmacodynamic and pharmacokinetic levels, and has significant enlightenments for the rational use of the related TCM formulas containing RGHP."( Synergistic effects of rhubarb-gardenia herb pair in cholestatic rats at pharmacodynamic and pharmacokinetic levels.
Dong, LC; Dong, X; Fan, YX; Li, HJ; Li, P; Ma, J; Yu, Q, 2015
)
0.42
" Their biodistribution and pharmacokinetic properties were determined in rat models of induced necrosis."( Effects of skeleton structure on necrosis targeting and clearance properties of radioiodinated dianthrones.
Feng, Y; Gao, M; Huang, D; Jiang, C; Ni, Y; Shao, H; Sun, Z; Wang, X; Yang, S; Yin, Z; Zhang, D; Zhang, J, 2016
)
0.43
" Pharmacokinetic studies have demonstrated that emodin has poor oral bioavailability in rats because of its extensive glucuronidation."( Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics.
Cao, S; Dong, X; Fu, J; Li, X; Lin, L; Ni, J; Yin, X, 2016
)
2.13
" It is well-known that some compounds could influence other compounds' pharmacokinetic parameters significantly."( Pharmacokinetic studies unveiled the drug-drug interaction between trans-2,3,5,4'-tetrahydroxystilbene-2-O-β-d-glucopyranoside and emodin that may contribute to the idiosyncratic hepatotoxicity of Polygoni Multiflori Radix.
Gao, X; Han, L; Hu, L; Wang, C; Wang, L; Xing, Y; Yang, W; Zhang, Y, 2019
)
0.72
" Pathological state is an important factor affecting the efficacy of drugs, the pharmacokinetic behavior of drugs could be significantly changed when people or animal were under different pathological state."( Nine components pharmacokinetic study of rat plasma after oral administration raw and prepared Semen Cassiae in normal and acute liver injury rats.
Cai, B; Jin, J; Peng, S; Qin, K; Sun, K; Xie, L; Yang, B; Zhen, Y, 2019
)
0.51
" (2) Methods: The three pharmacodynamic indicators are neurological function score, brain water content, and cerebral infarction area; UPLC-MS/MS was used in pharmacokinetic studies to detect plasma concentrations at different time points, and DAS software was used to calculate pharmacokinetic parameters in a noncompartmental model."( Pharmacodynamics of Five Anthraquinones (Aloe-emodin, Emodin, Rhein, Chysophanol, and Physcion) and Reciprocal Pharmacokinetic Interaction in Rats with Cerebral Ischemia.
Feng, SX; Li, JS; Li, RR; Liu, XF; Qu, LB; Shu, SN; Wang, PY; Zhang, N, 2019
)
0.77
" However, the determination and pharmacokinetic study of aloin-A in rat plasma need to be improved and systematically demonstrated."( UHPLC-MS/MS method for the quantification of aloin-A in rat plasma and its application to a pharmacokinetic study.
Bao, S; Chen, G; Chen, R; Cui, X; Niu, C; Sun, J; Xiao, S; Ye, W, 2020
)
0.56
" However, their pharmacodynamic differences and the structure-activity relationships associated with their anti-inflammatory properties have not been systematically explored."( Assessment of the anti-inflammatory effects of three rhubarb anthraquinones in LPS-Stimulated RAW264.7 macrophages using a pharmacodynamic model and evaluation of the structure-activity relationships.
Hu, Y; Huang, W; Luo, Y; Meng, X; Wang, P; Wu, J; Xiang, L; Xu, C; Zeng, Y; Zhang, Y, 2021
)
0.62
"7 cells and then calculated median effect equations and built a dynamic pharmacodynamic model to quantitatively evaluate the efficacy of these three anthraquinones."( Assessment of the anti-inflammatory effects of three rhubarb anthraquinones in LPS-Stimulated RAW264.7 macrophages using a pharmacodynamic model and evaluation of the structure-activity relationships.
Hu, Y; Huang, W; Luo, Y; Meng, X; Wang, P; Wu, J; Xiang, L; Xu, C; Zeng, Y; Zhang, Y, 2021
)
0.62
" However, the metabolic transformation and pharmacokinetic behavior of emodin dianthrones in vivo have still not been elucidated."( Pharmacokinetics and metabolism of trans-emodin dianthrones in rats.
Chen, J; Cheng, X; Gao, H; Ma, S; Si, D; Song, Y; Sun, M; Wang, X; Wei, F; Yang, J, 2022
)
1.22
"A rapid and sensitive UPLC-qqq-MS/MS method was developed for accurate quantification of TED in plasma and successfully applied to the pharmacokinetic evaluation of TED in rats after intravenous and oral administration."( Pharmacokinetics and metabolism of trans-emodin dianthrones in rats.
Chen, J; Cheng, X; Gao, H; Ma, S; Si, D; Song, Y; Sun, M; Wang, X; Wei, F; Yang, J, 2022
)
0.99
" This is the first study to investigate the pharmacokinetics of SWYST, and our findings elucidate the causes of their different pharmacokinetic behaviors in CRF rats."( Comparative pharmacokinetics of six bioactive components of Shen-Wu-Yi-Shen tablets in normal and chronic renal failure rats based on UPLC-TSQ-MS/MS.
Cao, L; Gao, X; Hu, Y; Li, X; Liu, W; Lv, K; Mei, Y; Tong, X; Wang, J; Wang, Z; Xiao, W, 2023
)
0.91
"The study aimed to explore the pharmacokinetic and pharmacodynamic alterations of the active components of Shenkang injection (i."( Pharmacokinetic-pharmacodynamic modeling of the active components of Shenkang injection in rats with chronic renal failure and its protective effect on damaged renal cells.
Fu, Z; Jia, Q; Sun, Z; Wang, X; Xia, J; Xue, L; Zhang, L; Zhou, L, 2023
)
0.91

Compound-Compound Interactions

Emodin and its combination with Ara-C may be considered a promising therapeutic approach in AML and worthy of further investigation.

ExcerptReferenceRelevance
" High-speed countercurrent chromatography (HSCCC) combined with silica gel column chromatography was developed for the preparative separation of the two individual aloins."( [Preparative separation of aloin diastereoisomers by high-speed countercurrent chromatography combined with silica gel column chromatography].
Cao, X; Dong, Y; Huang, D; Zhao, H, 2006
)
0.33
"In the present experiment, we aimed to determine the feasibility and curative effects of emodin combined with danshensu on experimental severe acute pancreatitis (SAP) and the mutual benefit of this synergistic strategy by a prospective animal study."( Protective effects of emodin combined with danshensu on experimental severe acute pancreatitis.
Gao, Y; Jiang, H; Li, X; Sun, B; Wang, G; Xue, D; Zhu, H, 2010
)
0.9
" SAP rats in each group received no further intervention, emodin alone, danshensu (DSS) alone, and emodin combined with DSS (EDSS), respectively."( Protective effects of emodin combined with danshensu on experimental severe acute pancreatitis.
Gao, Y; Jiang, H; Li, X; Sun, B; Wang, G; Xue, D; Zhu, H, 2010
)
0.92
" From those results we performed the checkerboard test to determine the synergism of EM in combination with ampicillin (AM) or oxacillin (OX) against all strains."( Synergistic effect of emodin in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus.
Choi, JG; Jeong, GS; Kang, OH; Keum, JH; Kim, SB; Kim, YC; Kwon, DY; Lee, YS; Oh, YC; Shin, DW, 2010
)
0.68
"Modulation of drug transporters via herbal medicines which have been widely used in combination with conventional prescription drugs may result in herb-drug interactions in clinical practice."( Inhibitory effects of herbal constituents on P-glycoprotein in vitro and in vivo: herb-drug interactions mediated via P-gp.
Hu, J; Li, X; Li, Y; Liu, Z; Sheng, L; Wang, B; Yang, S, 2014
)
0.4
"To investigate the effect of Emodin combined with 3'-azido-3'-deoxythymidine (AZT) on the proliferation and apoptosis of concentrated leukemia stem cells (CLSC)-human acute myeloid leukemia KG-la cells and expression of BCL-2, NF-κB and TGF-β."( [Effect of Emodin Combined with AZT on the Proliferation and the Expression of BCL-2, NF-κB, TGF-β in the Leukemia Stem Cells-KG-1a cells].
Chen, C; Jia, MF; Li, M; Li, ZJ; Liu, CX; Ma, T; Wang, LN; Xi, YM; Zhang, H; Zhao, L, 2015
)
1.1
"Heparin sodium (HS)-loaded polylactic-co-glycolic acid-D-α-tocopheryl polyethylene glycol 1000 succinate (PLGA-TPGS) nanoparticles (HPTNs) were prepared as a sustained and targeting delivery carrier and combined with emodin (EMO)-loaded PLGA-TPGS nanoparticles (EPTNs), which were investigated previously to form a combination therapy system for the treatment of liver cancer."( Emodin-Loaded PLGA-TPGS Nanoparticles Combined with Heparin Sodium-Loaded PLGA-TPGS Nanoparticles to Enhance Chemotherapeutic Efficacy Against Liver Cancer.
Deng, S; Gao, D; Gao, M; Gao, X; Liu, H; Lv, L; Ma, C; Tian, Y; Wang, C; Xu, H; Zhang, C, 2016
)
2.06
" The apoptosis of HepG2 cells induced by EPTNs in combination with HPTNs was determined by Annexin V-FITC staining and PI labelling."( Emodin-Loaded PLGA-TPGS Nanoparticles Combined with Heparin Sodium-Loaded PLGA-TPGS Nanoparticles to Enhance Chemotherapeutic Efficacy Against Liver Cancer.
Deng, S; Gao, D; Gao, M; Gao, X; Liu, H; Lv, L; Ma, C; Tian, Y; Wang, C; Xu, H; Zhang, C, 2016
)
1.88
" EPTNs combined with HPTNs induced HepG2 cell apoptosis with synergistic effects."( Emodin-Loaded PLGA-TPGS Nanoparticles Combined with Heparin Sodium-Loaded PLGA-TPGS Nanoparticles to Enhance Chemotherapeutic Efficacy Against Liver Cancer.
Deng, S; Gao, D; Gao, M; Gao, X; Liu, H; Lv, L; Ma, C; Tian, Y; Wang, C; Xu, H; Zhang, C, 2016
)
1.88
" In this study, we investigated the anti-leukemia effects of emodin alone or in combination with cytarabine (Ara-C) on multidrug-resistant AML HL-60/ADR cells and in a mouse xenograft model of human highly tumorigenic AML HL-60/H3 cells."( Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen, Y; Gan, D; Hu, J; Huang, Q; Lin, D; Luo, X, 2018
)
2.16
"Emodin and its combination with Ara-C may be considered a promising therapeutic approach in AML and worthy of further investigation."( Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen, Y; Gan, D; Hu, J; Huang, Q; Lin, D; Luo, X, 2018
)
3.37
"The aim of the present study was to explore the antileishmanial performance and wound healing effect of exosomes isolated from Wharton Jelly derived mesenchymal stem cells (WJ-MSCs) in combination with aloe-emodin."( Wharton Jelly Derived Mesenchymal Stem Cell's Exosomes Demonstrate Significant Antileishmanial and Wound Healing Effects in Combination with Aloe-Emodin: An in Vitro Study.
Abamor, ES; Allahverdiyev, A; Karaoz, E; Koken, GY, 2022
)
1.11
" Sonoantimicrobial chemotherapy (SACT) is a novel therapy of low-frequency and low-intensity ultrasound (LFLIU) combined with a sonosensitizer."( Emodin Combined with Multiple-Low-Frequency, Low-Intensity Ultrasound To Relieve Osteomyelitis through Sonoantimicrobial Chemotherapy.
Chen, G; He, Z; Hu, H; Jin, X; Lu, F; Song, X; Sun, J; Wu, X; Zhang, J, 2022
)
2.16
" This study proposed a rapid strategy for identifying neuraminidase inhibitors from different crude extracts (Polygonum cuspidatum, Cortex Fraxini, and Herba Siegesbeckiae) using ultrafiltration combined with mass spectrometry guided by molecular docking."( Discovery of the potential neuraminidase inhibitors from Polygonum cuspidatum by ultrafiltration combined with mass spectrometry guided by molecular docking.
Chen, M; Rong, R; Sun, Q; Wang, L; Yang, Y, 2023
)
0.91
" In this study, we examined the effects of emodin combined with cisplatin on the invasion and migration of HepG2 cells and analyzed the role of emodin."( Effect of emodin combined with cisplatin on the invasion and migration of HepG2 hepatoma cells.
Chen, X; Deng, H; Lai, Q; Leng, Y; Wang, H; Xiong, Z; Yang, M, 2023
)
1.58

Bioavailability

Emodin (1,3,8-trihydroxy-6-methylanthraquinone) has been widely used as a traditional medicine and was shown to possess a multitude of health-promoting properties. Its bioavailability was low due to the extensive glucuronidation in liver and intestine, hindering the development of emodin as a feasible chemopreventive agent.

ExcerptReferenceRelevance
" Phase II metabolic enzymes such as glucuronyl transferase or sulfate transferase may also play an important role in the first-pass metabolism of emodin in the small intestine, which may ultimately reduce the bioavailability (and thus the efficacy) of orally administered emodin."( Quantitation assay for absorption and first-pass metabolism of emodin in isolated rat small intestine using liquid chromatography-tandem mass spectrometry.
Cao, DY; Liu, RW; Liu, XY; Mei, QB; Teng, ZH; Yang, JY; Yang, RT; Yang, X; Zhang, BL; Zhou, SY, 2007
)
0.78
" Some ingredients in GKG may increase the dissolution and absorption, and improve bioavailability of icariin, emodin and psoralen in rats."( In vivo pharmacokinetics comparisons of icariin, emodin and psoralen from gan-kang granules and extracts of herba Epimedii, Nepal dock root, Ficus hirta yahl.
Chen, Y; Duan, J; Guo, T; Li, B; Li, Y; Xie, W; Yan, S; Zhou, Y, 2009
)
0.82
"The aim of the present study was to define the mechanisms responsible for poor bioavailability of emodin by determining its metabolism using in vitro and in situ disposition models of the intestine and liver."( Species and gender differences affect the metabolism of emodin via glucuronidation.
Cai, Z; Hu, M; Liu, W; Liu, Z; Tang, L; Xia, B; Ye, L; Zhang, J, 2010
)
0.82
"Herein we chronicle the discovery of CX-4945 (25n), a first-in-class, orally bioavailable ATP-competitive inhibitor of protein kinase CK2 in clinical trials for cancer."( Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.
Anderes, K; Bliesath, J; Bourbon, P; Chen, TK; Chua, PC; Darjania, L; Drygin, D; Haddach, M; Ho, C; Michaux, J; Nagasawa, J; O'Brien, SE; Omori, M; Pierre, F; Proffitt, C; Rice, WG; Ryckman, DM; Schwaebe, MK; Siddiqui-Jain, A; Stansfield, R; Stefan, E; Streiner, N; Trent, K; Vialettes, A; Whitten, JP, 2011
)
0.37
" The developed and validated analytical method was successfully applied to study the gender-dependent 10-fold higher oral bioavailability of total emodin in male than female rats."( Sensitive and robust UPLC-MS/MS method to determine the gender-dependent pharmacokinetics in rats of emodin and its glucuronide.
Gao, S; Hu, M; Liu, W; Liu, X; Liu, Z; Yang, Z; Ye, L; Zheng, Z, 2011
)
0.78
" The absolute bioavailability is about 54."( Development and validation of a highly rapid and sensitive LC-MS/MS method for determination of SZ-685C, an investigational marine anticancer agent, in rat plasma--application to a pharmacokinetic study in rats.
Chen, JY; Huang, M; Huang, ZY; Li, JL; Li, MF; Qin, XL; Wang, XD; Zhong, GP; Zhu, X, 2011
)
0.37
"Emodin is a poorly bioavailable but promising plant-derived anticancer drug candidate."( Coupling of UDP-glucuronosyltransferases and multidrug resistance-associated proteins is responsible for the intestinal disposition and poor bioavailability of emodin.
Feng, Q; Hu, M; Li, Y; Liu, W; Liu, Z; Ye, L, 2012
)
2.02
"These results indicate that influence of the processing could improve the bioavailability of gallic acid and reduce the absorption of PM-SG, polydatin and emodin in rats."( Influence of processing on pharmacokinetic of typical constituents in radix polygoni multiflori after oral administration by LC-ESI-MS/MS.
Chang, YX; Gao, XM; He, J; Li, J; Ma, WF; Zhang, BL; Zhang, L; Zhang, P; Zheng, F, 2013
)
0.59
"Emodin (1,3,8-trihydroxy-6-methylanthraquinone) has been widely used as a traditional medicine and was shown to possess a multitude of health-promoting properties in pre-clinical studies, but its bioavailability was low due to the extensive glucuronidation in liver and intestine, hindering the development of emodin as a feasible chemopreventive agent."( Effect of piperine on the bioavailability and pharmacokinetics of emodin in rats.
Di, X; Liu, Y; Wang, X, 2015
)
2.1
"Oral emodin, a natural anthraquinone and active component of many herbal medicines, is poorly bioavailable because of extensive first-pass glucuronidation."( Cremophor EL-based nanoemulsion enhances transcellular permeation of emodin through glucuronidation reduction in UGT1A1-overexpressing MDCKII cells.
Dong, D; Lu, D; Wang, S; Wu, B; Zhang, T, 2016
)
1.18
" Pharmacokinetic studies have demonstrated that emodin has poor oral bioavailability in rats because of its extensive glucuronidation."( Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics.
Cao, S; Dong, X; Fu, J; Li, X; Lin, L; Ni, J; Yin, X, 2016
)
2.13
" Nanoparticle encapsulation of drugs is beneficial for drug targeting and bioavailability as well as for lowering drug toxicity side effects."( Nanoparticle-encapsulated emodin decreases diabetic neuropathic pain probably via a mechanism involving P2X3 receptor in the dorsal root ganglia.
Gao, Y; Gong, Y; Guo, L; Han, X; Jia, T; Li, G; Li, L; Liang, S; Liu, H; Liu, S; Sheng, X; Shi, L; Wu, B; Xu, H; Yi, Z; Yuan, H; Zhang, C; Zhao, S; Zou, L, 2017
)
0.76
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Therefore, a metabolism inhibitor would be necessary to improve the oral bioavailability of emodin further."( Improved Solubility and Oral Absorption of Emodin-Nicotinamide Cocrystal Over Emodin with PVP as a Solubility Enhancer and Crystallization Inhibitor.
An, SH; Ban, E; Jung, BH; Kim, A; Park, B; Park, M; Yoon, NE, 2020
)
1.04
" This method has been used to quantitate these compounds in samples such as human intestinal epithelial cell lysates and mouse plasma or GI tissues in research aimed at examining the bioavailability of curcumin in the presence of piperine."( Analysis of curcumin and piperine in biological samples by reversed-phase liquid chromatography with multi-wavelength detection.
Bi, C; Hage, DS; Juritsch, AF; Kaur, H; Li, Z; Moreau, R; Rodriguez, EL; Woolfork, AG; Zhang, C, 2021
)
0.62
" The goals of this review are to (1) highlight emodin's anti-cancer properties within GI cancers, (2) discuss the known anti-cancer mechanisms of action of emodin, (3) address emodin's potential as a treatment complementary to standard chemotherapeutics, (4) assess the efficacy and bioavailability of emodin derivatives as they relate to cancer, and (5) evaluate the safety of emodin."( Therapeutic Potential of Emodin for Gastrointestinal Cancers.
Cardaci, TD; Enos, RT; Fairman, CM; Fan, D; McDonald, SJ; Murphy, EA; VanderVeen, BN; Velazquez, KT,
)
0.69
" The oral bioavailability of EMO and Tan IIA was significantly improved when they were loaded into the hierarchically structured microcapsules, ultimately contributing to superior therapeutic outcomes in rats with unilateral ureteral obstruction."( Hierarchically structured microcapsules for oral delivery of emodin and tanshinone IIA to treat renal fibrosis.
Fan, X; Hou, Y; Li, F; Piao, J; Sun, J; Wei, Y; Xu, Z; Yao, W; Zheng, H, 2022
)
0.96
"Taking trans-emodin dianthrones (TED) as an example, the present study was conducted to investigate the pharmacokinetics and bioavailability of TED in rats and characterized its metabolic transformation in the plasma, urine and feces of rats."( Pharmacokinetics and metabolism of trans-emodin dianthrones in rats.
Chen, J; Cheng, X; Gao, H; Ma, S; Si, D; Song, Y; Sun, M; Wang, X; Wei, F; Yang, J, 2022
)
1.36
" We observed Eu-CS-Man-Ps-P(HEMA-DMAM)/EMO-QDs to be an effective approach for the improvement of EMO solubility in an aqueous medium with an increased oral bioavailability (3."( Dual-targeted colon-based integrated micelle drug delivery system for treatment of ulcerative colitis.
Gu, M; Lu, L; Miao, Z; Ning, L; Xu, Y; Yan, J, 2022
)
0.72
" However, the poor oral bioavailability of EMO and the insufficient monotherapy therapy compromise its efficacy."( Deoxycholic acid-chitosan coated liposomes combined with in situ colonic gel enhances renal fibrosis therapy of emodin.
Fan, X; Hou, Y; Piao, JG; Sun, J; Wei, Y; Xu, Z; Yao, W; Zhang, K; Zhang, Q; Zhu, L, 2022
)
0.93
"Overall, the combination of DCS-Lips and EMO-IGE alleviated renal fibrosis effectively, resulting from the improved oral bioavailability of EMO by DCS-Lips and the restoration of gut microbiota by EMO-IGE, thus, presenting an innovative and promising potential for renal fibrosis treatment."( Deoxycholic acid-chitosan coated liposomes combined with in situ colonic gel enhances renal fibrosis therapy of emodin.
Fan, X; Hou, Y; Piao, JG; Sun, J; Wei, Y; Xu, Z; Yao, W; Zhang, K; Zhang, Q; Zhu, L, 2022
)
0.93
" In silico ADME studies prediction of AEBH-5a revealed a favorable bioavailability score and prominent drug-likeness profile."( Aloe emodin-conjugated sulfonyl hydrazones as novel type of antibacterial modulators against S. aureus 25923 through multifaceted synergistic effects.
Bheemanaboina, RRY; Deng, Z; Luo, Y; Zhou, CH, 2022
)
1.24
" The functionalization of bioactive natural products with selected peptide sequences to enhance their bioavailability and specificity of action is a powerful and promising strategy."( Peptide-Mediated Targeted Delivery of Aloe-Emodin as Anticancer Drug.
Calcabrini, A; Cecchetti, S; Colone, M; Dupuis, ML; Gori, A; Serra, S; Spadaro, F; Stringaro, A; Vitali, A, 2022
)
0.98
" Because its bioavailability is low, there are limitations in clinical therapeutic use."( Recent advances in the therapeutic potential of emodin for human health.
Aidarbekovna, DS; Calina, D; Cho, WC; Hano, C; Herrera-Bravo, J; Kamiloglu, S; Martorell, M; Mishra, AP; Monserrat-Mesquida, M; Petroni, K; Sharifi-Rad, J; Sureda, A; Ydyrys, A; Yessimsiitova, Z, 2022
)
0.98

Dosage Studied

Emodin is safe for use in both male and female mice when given at 20, 40, and 80 mg/kg doses for 12 weeks. Sex differences should be considered when establishing dosing intervals for emodin treatment.

ExcerptRelevanceReference
" In the same dosage it also showed antiulcer activity against 4 hr pylorus-ligated, aspirin and immobilization stress-induced gastric ulcers in rats."( Antiulcerogenic and anti-inflammatory effects of emodin, isolated from Rhamnus triquerta wall.
Das Gupta, G; Goel, RK; Pandey, VB; Ram, SN, 1991
)
0.54
" In culture, the addition of the sera obtained from the rat fed with RO inhibited significantly the proliferation of renal tubular cells, and the effect become even more strong with the increase of the dosage or the long time of administration of RO to the rat."( [Effect of Rheum officinal on the proliferation of renal tubular cells in vitro].
Zheng, F, 1993
)
0.29
" Different dosage of emodin (50 mg/L,100 mg/L) was added into MC stimulated by TNF-alpha."( [Role of cyclin kinase inhibitor p27 in inhibition of emodin on mesangial cell proliferation induced by tumor necrosis factor-alpha].
Cui, RL; Mei, XB; Wu, H; Yuan, WJ; Zhan, FL; Zhang, XY, 2004
)
0.89
" Depletion of endogenous ACh in the presence of HC-3 was achieved by construction of an ACh dose-response curve, using exogenous ACh, prior to re-testing the effects of emodin in the presence of HC-3."( The stimulant cathartic, emodin, contracts the rat isolated ileum by triggering release of endogenous acetylcholine.
Ali, S; Osborne, RH; Watson, MS, 2004
)
0.82
" The evaluating score of neural symptoms, brain water ratio and cerebral infarction area improved obviously in every emodin group, especially in emodin low dosage group."( [Preventive effects of emodin on cerebral ischemia injury and expression of the inflammatory factors in rats with cerebral ischemia].
Fang, J; Liang, SW; Liu, JX; Lu, JS; Wang, D; Zhang, WY, 2005
)
0.85
" The requirement for slow dosage increases of arsenic and the time required to achieve a pharmacologic active dose in patients is a major obstacle because median survival of patients with ATL is about 6 months."( Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1.
Bellon, M; Brown, M; Nicot, C, 2007
)
1.78
" In the correspondence analysis (CA) diagram of eight quantitative parameters taken from the HFP-time curves, it could be deduced that emodin had definite dose-effect relationship as the distance between different concentrations of it increased along with the dosage and the effect."( Effect of emodin on Candida albicans growth investigated by microcalorimetry combined with chemometric analysis.
Dai, CM; Jin, C; Kong, WJ; Li, ZL; Wang, JB; Xiao, XH; Zhao, YL, 2009
)
0.96
"Rat models of experimental hepatic fibrosis were established by injection with CCl(4); the treated rats received emodin via oral administration at a dosage of 20 mg/kg twice a week at the same time."( Emodin protects rat liver from CCl(4)-induced fibrogenesis via inhibition of hepatic stellate cells activation.
Dong, MX; Geng, YT; Jia, Y; Li, CC; Li, XY; Liu, JC; Niu, YC; Zhang, YB; Zhou, L, 2009
)
2.01
" However, the toxicity is caused by over dosage or by the herb itself remains unclear."( Toxicity of raw and processed roots of Polygonum multiflorum.
Chen, X; Fang, D; Huang, Q; Li, G; Wu, X; Zhang, G, 2012
)
0.38
" After being fed a high-fat diet for two weeks, rats were dosed orally with emodin (20, 40, 80 mg/kg/day) or pioglitazone (20 mg/kg/day), once daily for eight weeks."( Emodin protects against high-fat diet-induced obesity via regulation of AMP-activated protein kinase pathways in white adipose tissue.
Chang, CJ; Liou, SS; Liu, IM; Lu, HJ; Tzeng, TF, 2012
)
2.05
" The results revealed that the medium dosage group (10 mg/kg) of 5g and the high dosage group (25 mg/kg) of 5h showed significant antitumor activity compared to the control group."( Synthesis and antitumor activity of emodin quaternary ammonium salt derivatives.
Bai, Z; Shao, J; Wang, C; Wang, W; Yuan, Y; Zhang, F, 2012
)
0.65
" The blood samples were collected before dosing and subsequently at 10, 15, 20, 30, 45 min, 1, 2, 4, 8, and 12 h following gavage."( Effect of formula compatibility on the pharmacokinetics of components from Dachengqi Decoction [See Text] in rats.
Chen, GY; Gong, HL; Huang, X; Tang, WF; Wang, J, 2012
)
0.38
"We concluded that acute pancreatitis may significantly affect the pharmacokinetics of Liu-He-Dan while external applied on belly, which indicated the dosage modification in AP."( Effect of acute pancreatitis on the pharmacokinetics of Chinese herbal ointment Liu-He-Dan in anaesthetized rats.
Chen, GY; Chen, WW; Tang, WF; Wan, MH; Xiang, J; Yu, Q; Zhao, XL, 2013
)
0.39
" Dose-response studies showed that emodin at 100 µM was not cytotoxic to naive cells, and that the same dose caused proliferation to be significantly reduced in ConA-stimulated cells."( Emodin inhibits splenocyte proliferation and inflammation by modulating cytokine responses in a mouse model system.
Sharma, R; Tiku, AB, 2016
)
2.15
"In conclusion, EPTN could be used in the treatment of liver cancer acted as a kind of promising intravenous dosage forms."( A Promising Emodin-Loaded Poly (Lactic-Co-Glycolic Acid)-d-α-Tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles for Liver Cancer Therapy.
Deng, S; Gao, M; Guan, X; Liu, H; Lv, L; Tian, Y; Xu, H; Zhang, C, 2016
)
0.81
" Emodin transport and metabolism were evaluated in Transwell-cultured MDCK1A1 cells after apical dosing of EMO-NE or control solution."( Cremophor EL-based nanoemulsion enhances transcellular permeation of emodin through glucuronidation reduction in UGT1A1-overexpressing MDCKII cells.
Dong, D; Lu, D; Wang, S; Wu, B; Zhang, T, 2016
)
1.58
" Optimal dosing of iv emodin and especially BTB 14431 for maximal efficacy remains unclear and should be a subject of further research."( Anti-tumorigenic Effects of Emodin and Its' Homologue BTB14431 on Vascularized Colonic Cancer in a Rat Model.
Braumann, C; Dubiel, W; Freiburger, M; Höhn, P; Koplin, G; Luu, AM, 2020
)
1.17
" Both TDA and emodin caused various degrees of damage to the morphology and cytoskeleton of HK-2 cells with the degree of damage correlating positively with the dosage of the tested substances."( In vitro study of the nephrotoxicity of total Dahuang (Radix Et Rhizoma Rhei Palmati) anthraquinones and emodin in monolayer human proximal tubular epithelial cells cultured in a transwell chamber.
Cao, C; Hao, R; Hui, L; Li, C; Liu, T; Yang, Y; Zhang, J; Zhang, Y, 2019
)
1.09
"Dual dosage enhanced apoptosis through ROS generation, anti- migratory effect by targeting FAK &Integrins, displaying effective stemness control by assessing regulatory proteins- Oct4, Sox2, Nanog, ALDH1/2."( Combinatorial therapy of Thymoquinone and Emodin synergistically enhances apoptosis, attenuates cell migration and reduces stemness efficiently in breast cancer.
Adhikary, A; Basu, A; Bhattacharjee, M; Das, S; Ghosh, A; Ghosh, S; Sarker, S; Upadhyay, P, 2020
)
0.82
"Findings will provide timely information on the safety, efficacy, and optimal dosing of t-PA to treat moderate/severe COVID-19-induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634)."(
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y, 2022
)
0.72
" We sought to determine the effective concentration of emodin on chondrocytes and to identify the dosage of emodin that induces a comparable therapeutic effect with the COX-2 inhibitor drug, celecoxib that is currently used to treat OA."( Emodin protects knee joint cartilage in rats through anti-matrix degradation pathway: An in vitro and in vivo study.
Bai, H; Gao, L; Hu, H; Li, Y; Liu, L; Ma, T; Song, X; Wang, X; Zhao, M, 2021
)
2.31
") in order to begin to establish effective dosing intervals."( Safety of natural anthraquinone emodin: an assessment in mice.
Chatzistamou, I; Cotham, W; Enos, RT; Fan, D; Kelly, B; McDonald, S; Murphy, EA; Nagarkatti, M; Sougiannis, AT; VanderVeen, BN; Velazquez, KT, 2021
)
0.9
"In summary, our studies establish that 1) emodin is safe for use in both male and female mice when given at 20, 40, and 80 mg/kg doses for 12 weeks and 2) sex differences should be considered when establishing dosing intervals for emodin treatment."( Safety of natural anthraquinone emodin: an assessment in mice.
Chatzistamou, I; Cotham, W; Enos, RT; Fan, D; Kelly, B; McDonald, S; Murphy, EA; Nagarkatti, M; Sougiannis, AT; VanderVeen, BN; Velazquez, KT, 2021
)
1.17
" Emodin and rhein showed greater inhibition than the other compounds; dosage at 50 μM reduced intracellular triglyceride (TG) by about 30% in the differentiated adipocytes."( Rhubarb hydroxyanthraquinones act as antiobesity agents to inhibit adipogenesis and enhance lipolysis.
Aljuffali, IA; Chen, WJ; Fang, JY; Hsu, CY; Huang, TH, 2022
)
1.63
"The model of DIC was established via the intraperitoneal administration of Dox at a dosage of 5 mg/kg per week for a span of 4 weeks."( Emodin attenuates cardiomyocyte pyroptosis in doxorubicin-induced cardiotoxicity by directly binding to GSDMD.
Chen, Y; Dai, S; Fan, X; Han, J; Huang, W; Huang, Z; Lin, J; Liu, Q; Su, L; Ye, B; Zhang, Y; Zhong, L, 2023
)
2.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
tyrosine kinase inhibitorAny protein kinase inhibitor that interferes with the action of tyrosine kinase.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
laxativeAn agent that produces a soft formed stool, and relaxes and loosens the bowels, typically used over a protracted period, to relieve constipation. Compare with cathartic, which is a substance that accelerates defecation. A substances can be both a laxative and a cathartic.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
trihydroxyanthraquinoneA member of the class of hydroxyanthraquinones carrying three hydroxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (156)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency28.14640.003245.467312,589.2998AID1705; AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency26.83030.004023.8416100.0000AID485290
Chain A, HADH2 proteinHomo sapiens (human)Potency0.39810.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency0.39810.025120.237639.8107AID886
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency44.66840.631035.7641100.0000AID504339
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID2323
Chain A, CruzipainTrypanosoma cruziPotency3.16230.002014.677939.8107AID1476
LuciferasePhotinus pyralis (common eastern firefly)Potency33.24220.007215.758889.3584AID1224835
interleukin 8Homo sapiens (human)Potency66.82420.047349.480674.9780AID651758
acetylcholinesteraseHomo sapiens (human)Potency15.53510.002541.796015,848.9004AID1347398
thioredoxin reductaseRattus norvegicus (Norway rat)Potency9.46980.100020.879379.4328AID488773; AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency10.00000.012610.691788.5700AID887
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency10.71623.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency31.98890.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency23.91290.173734.304761.8120AID1346859; AID1346924
USP1 protein, partialHomo sapiens (human)Potency50.11870.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency2.81840.35487.935539.8107AID624146
SMAD family member 3Homo sapiens (human)Potency23.91290.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency14.47280.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency29.79570.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency9.45630.180013.557439.8107AID1460
ThrombopoietinHomo sapiens (human)Potency12.58930.02517.304831.6228AID917; AID918
AR proteinHomo sapiens (human)Potency23.08930.000221.22318,912.5098AID1259243; AID1259247; AID588515; AID588516; AID743035; AID743036; AID743053; AID743054
DNA polymerase III, partialBacillus subtilisPotency23.77811.062114.152826.6795AID485295
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency15.00570.013326.981070.7614AID1346978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency16.36730.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency10.00000.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency12.38110.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency13.34750.000657.913322,387.1992AID1259377; AID1259378; AID1259394
hypothetical protein, conservedTrypanosoma bruceiPotency9.52830.223911.245135.4813AID624147
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency32.78130.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency28.62320.000417.946075.1148AID1346795
regulator of G-protein signaling 4Homo sapiens (human)Potency10.62130.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency29.56590.001310.157742.8575AID1259252
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency12.58930.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency21.91120.000214.376460.0339AID588533; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency11.86340.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency16.61240.000817.505159.3239AID1159531; AID588544
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency33.22130.001530.607315,848.9004AID1224819; AID1224821; AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency30.90800.375827.485161.6524AID588526; AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency33.91630.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency22.90270.000229.305416,493.5996AID1259244; AID1259248; AID1259383; AID588513; AID588514; AID743069; AID743075; AID743077; AID743079; AID743080; AID743091
67.9K proteinVaccinia virusPotency10.00000.00018.4406100.0000AID720580
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency21.52330.001024.504861.6448AID588534; AID588535
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency24.80650.001019.414170.9645AID588537; AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency22.45120.023723.228263.5986AID588541; AID588543; AID743222; AID743223
arylsulfatase AHomo sapiens (human)Potency2.13311.069113.955137.9330AID720538
caspase-3Homo sapiens (human)Potency15.00570.013326.981070.7614AID1346978
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency5.29800.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency25.39100.000723.06741,258.9301AID651777; AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency39.13260.001723.839378.1014AID743083
Histone H2A.xCricetulus griseus (Chinese hamster)Potency49.94390.039147.5451146.8240AID1224845; AID1224896
Bloom syndrome protein isoform 1Homo sapiens (human)Potency3.54810.540617.639296.1227AID2364; AID2528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency22.10610.00207.533739.8107AID891
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency20.59620.01262.451825.0177AID485313
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency31.62280.316212.443531.6228AID902; AID924
cytochrome P450 2C19 precursorHomo sapiens (human)Potency16.53110.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency5.96220.00636.904339.8107AID883
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency23.93410.134610.395030.1313AID1347049
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency22.38720.006026.168889.1251AID488953; AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency112.20200.010039.53711,122.0200AID1479
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency19.95263.548119.542744.6684AID743266
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency39.81070.01789.637444.6684AID588834
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency28.18380.794321.275750.1187AID624246
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency15.81360.000323.4451159.6830AID743065; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency3.42110.037617.082361.1927AID1259364; AID1259388
heat shock protein beta-1Homo sapiens (human)Potency26.91780.042027.378961.6448AID743210
DNA polymerase betaHomo sapiens (human)Potency11.22020.022421.010289.1251AID485314
mitogen-activated protein kinase 1Homo sapiens (human)Potency11.90470.039816.784239.8107AID1454; AID995
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency26.12160.00669.809418.4927AID1347050
flap endonuclease 1Homo sapiens (human)Potency20.50510.133725.412989.1251AID488816; AID588795
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency26.67950.168316.404067.0158AID720504
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency9.28320.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency50.11870.425612.059128.1838AID504891
DNA polymerase eta isoform 1Homo sapiens (human)Potency15.84890.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency16.08240.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency13.45130.004611.374133.4983AID463097; AID624296; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency61.35630.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency10.00000.031610.279239.8107AID884; AID885
M-phase phosphoprotein 8Homo sapiens (human)Potency25.21600.177824.735279.4328AID488949
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency15.84890.00419.962528.1838AID2675
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency23.71500.058010.694926.6086AID588379
lethal factor (plasmid)Bacillus anthracis str. A2012Potency2.51190.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency0.00560.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency48.55770.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency16.58500.002319.595674.0614AID651631; AID651743; AID720552
Integrin beta-3Homo sapiens (human)Potency31.62280.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency31.62280.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency48.55770.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency5.96220.00638.235039.8107AID883
Nuclear receptor ROR-gammaHomo sapiens (human)Potency42.16320.026622.448266.8242AID651802
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency31.62281.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency10.00001.000012.224831.6228AID885
2,3-bisphosphoglycerate-independent phosphoglycerate mutaseLeishmania major strain FriedlinPotency37.93307.568615.230621.3313AID504548
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency23.93410.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, PROTEIN KINASE CK2, ALPHA SUBUNITZea maysIC50 (µMol)1.00001.00001.00001.0000AID977608
Chain A, Casein kinase II, alpha chainZea maysKi1.85001.85001.85001.8500AID977610
3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZYersinia pseudotuberculosis YPIIIIC50 (µMol)36.40005.30006.12507.7000AID1801643
Spike glycoproteinBetacoronavirus England 1IC50 (µMol)10.00000.03002.72839.5100AID1804127
Replicase polyprotein 1abBetacoronavirus England 1IC50 (µMol)10.00000.00403.43889.5100AID1804127
Transmembrane protease serine 2Homo sapiens (human)IC50 (µMol)10.00000.01802.61989.5100AID1804127
Protein tyrosine phosphatase type IVA 3Homo sapiens (human)IC50 (µMol)22.16670.30001.90003.5000AID637923; AID637924; AID637927
TransthyretinHomo sapiens (human)IC50 (µMol)100.00000.16004.292110.0000AID1755162
Estrogen receptorHomo sapiens (human)IC50 (µMol)2.70000.00000.723732.7000AID70335
Estrogen receptorHomo sapiens (human)Ki0.77000.00000.42297.9070AID70353
Cytochrome P450 1A1Homo sapiens (human)IC50 (µMol)12.25000.00791.24789.9000AID1453003
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)7.99000.00011.774010.0000AID1453003; AID1453004
Heme oxygenase 1 Rattus norvegicus (Norway rat)IC50 (µMol)1.22001.10004.320010.0000AID1633141
Procathepsin LHomo sapiens (human)IC50 (µMol)10.00000.00021.66619.5100AID1804127
Neutrophil elastaseHomo sapiens (human)IC50 (µMol)52.00000.00632.073422.3780AID66485
Accessory gene regulator protein AStaphylococcus aureusIC50 (µMol)17.10006.00007.05008.1000AID1155420
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusIC50 (µMol)10.00000.03002.29719.5100AID1804127
Replicase polyprotein 1abHuman coronavirus 229EIC50 (µMol)10.00000.03002.14419.5100AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusIC50 (µMol)10.00000.00402.92669.9600AID1804127
Spike glycoproteinSevere acute respiratory syndrome coronavirus 2IC50 (µMol)200.00000.03803.19957.0000AID1845465
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)10.00000.00022.45859.9600AID1804127
Serine/threonine-protein kinase pim-1Homo sapiens (human)IC50 (µMol)2.50000.00040.887110.0000AID1303472
Genome polyproteinDengue virus 2 Puerto Rico/PR159-S1/1969IC50 (µMol)48.33501.52005.50009.4600AID458603; AID458604
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)36.40000.00040.908610.0000AID1256631
Aldo-keto reductase family 1 member B1Homo sapiens (human)IC50 (µMol)2.69000.00101.191310.0000AID1315336
Aldo-keto reductase family 1 member B1Homo sapiens (human)Ki2.11300.01903.41939.3000AID1315338
Casein kinase II subunit alpha'Homo sapiens (human)IC50 (µMol)1.04000.00031.432010.0000AID1167185; AID1202638; AID1341988; AID757709
Casein kinase II subunit alpha'Homo sapiens (human)Ki1.90000.00020.90117.6700AID1750468
Proteasome subunit beta type-1Homo sapiens (human)IC50 (µMol)0.24000.00060.73766.3700AID1633140
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)4.32000.00002.37899.7700AID1888748
Amine oxidase [flavin-containing] BHomo sapiens (human)IC50 (µMol)3.24000.00001.89149.5700AID1888749
Proteasome subunit beta type-5Homo sapiens (human)IC50 (µMol)1.22000.00050.939410.0000AID1633141
Casein kinase II subunit alphaZea maysKi1.85001.85001.85001.8500AID1796663
Bifunctional epoxide hydrolase 2Homo sapiens (human)IC50 (µMol)36.40000.00000.54509.1000AID1256631
Proteasome subunit beta type-2Homo sapiens (human)IC50 (µMol)20.85000.00131.39067.9540AID1633139
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusIC50 (µMol)10.00000.03002.77319.5100AID1804127
Casein kinase II subunit betaHomo sapiens (human)IC50 (µMol)0.86670.00031.487510.0000AID1167185; AID1202638; AID1341988; AID1403186; AID650670; AID757709
Casein kinase II subunit betaHomo sapiens (human)Ki1.90000.00021.11247.6700AID1750468
Casein kinase II subunit alphaHomo sapiens (human)IC50 (µMol)1.01120.00051.333210.0000AID1167185; AID1202638; AID1341988; AID1403186; AID352795; AID435639; AID650670; AID757709
Casein kinase II subunit alphaHomo sapiens (human)Ki9.42000.00041.09847.6700AID1539764; AID1750468; AID1796664; AID435763; AID435887
Tissue alpha-L-fucosidaseBos taurus (cattle)IC50 (µMol)32.00000.00500.05750.1100AID1688689
Genome polyprotein Human rhinovirus sp.IC50 (µMol)150.00000.00052.98388.2000AID163631
Casein kinase II subunit alpha 3Homo sapiens (human)Ki1.90000.00041.86517.6700AID1750468
Estrogen receptor betaHomo sapiens (human)IC50 (µMol)5.20000.00010.529432.7000AID70654
Estrogen receptor betaHomo sapiens (human)Ki1.50000.00000.12512.8760AID70660
Angiotensin-converting enzyme 2 Homo sapiens (human)IC50 (µMol)10.00000.00042.207910.0000AID1804127
P2Y purinoceptor 12Homo sapiens (human)Ki10.00000.00202.82209.8300AID375433
Sialidase-2Homo sapiens (human)IC50 (µMol)760.00003.90006.73337.8000AID466938
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, (3R)-hydroxymyristoyl-acyl carrier protein dehydrataseHelicobacter pyloriKd0.45000.45000.45000.4500AID977611
Chain B, (3R)-hydroxymyristoyl-acyl carrier protein dehydrataseHelicobacter pyloriKd0.45000.45000.45000.4500AID977611
Spike glycoproteinBetacoronavirus England 1EC50 (µMol)200.00000.00304.57559.8200AID1804127
Replicase polyprotein 1abBetacoronavirus England 1EC50 (µMol)200.00000.00304.57559.8200AID1804127
Transmembrane protease serine 2Homo sapiens (human)EC50 (µMol)200.00000.00304.51689.8200AID1804127
Procathepsin LHomo sapiens (human)EC50 (µMol)200.00000.00304.48749.8200AID1804127
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusEC50 (µMol)200.00000.00304.61369.8200AID1804127
Replicase polyprotein 1abHuman coronavirus 229EEC50 (µMol)200.00000.00304.61369.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusEC50 (µMol)200.00000.00304.45549.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2EC50 (µMol)200.00000.00304.11059.8200AID1804127
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusEC50 (µMol)200.00000.00304.57559.8200AID1804127
Angiotensin-converting enzyme 2 Homo sapiens (human)EC50 (µMol)200.00000.00304.57559.8200AID1804127
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (472)

Processvia Protein(s)Taxonomy
viral translationTransmembrane protease serine 2Homo sapiens (human)
proteolysisTransmembrane protease serine 2Homo sapiens (human)
protein autoprocessingTransmembrane protease serine 2Homo sapiens (human)
positive regulation of viral entry into host cellTransmembrane protease serine 2Homo sapiens (human)
endothelial cell migrationProtein tyrosine phosphatase type IVA 3Homo sapiens (human)
regulation of DNA-templated transcriptionProtein tyrosine phosphatase type IVA 3Homo sapiens (human)
Notch signaling pathwayProtein tyrosine phosphatase type IVA 3Homo sapiens (human)
positive regulation of vascular permeabilityProtein tyrosine phosphatase type IVA 3Homo sapiens (human)
regulation of vascular endothelial growth factor signaling pathwayProtein tyrosine phosphatase type IVA 3Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionProtein tyrosine phosphatase type IVA 3Homo sapiens (human)
positive regulation of establishment of protein localizationProtein tyrosine phosphatase type IVA 3Homo sapiens (human)
cellular response to leukemia inhibitory factorProtein tyrosine phosphatase type IVA 3Homo sapiens (human)
endothelial cell migrationProtein tyrosine phosphatase type IVA 3Homo sapiens (human)
signal transductionTransthyretinHomo sapiens (human)
purine nucleobase metabolic processTransthyretinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
antral ovarian follicle growthEstrogen receptorHomo sapiens (human)
epithelial cell developmentEstrogen receptorHomo sapiens (human)
chromatin remodelingEstrogen receptorHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
signal transductionEstrogen receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayEstrogen receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationEstrogen receptorHomo sapiens (human)
androgen metabolic processEstrogen receptorHomo sapiens (human)
male gonad developmentEstrogen receptorHomo sapiens (human)
negative regulation of gene expressionEstrogen receptorHomo sapiens (human)
positive regulation of phospholipase C activityEstrogen receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayEstrogen receptorHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptorHomo sapiens (human)
response to estradiolEstrogen receptorHomo sapiens (human)
regulation of toll-like receptor signaling pathwayEstrogen receptorHomo sapiens (human)
negative regulation of smooth muscle cell apoptotic processEstrogen receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionEstrogen receptorHomo sapiens (human)
negative regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
response to estrogenEstrogen receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
fibroblast proliferationEstrogen receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEstrogen receptorHomo sapiens (human)
stem cell differentiationEstrogen receptorHomo sapiens (human)
regulation of inflammatory responseEstrogen receptorHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
RNA polymerase II preinitiation complex assemblyEstrogen receptorHomo sapiens (human)
uterus developmentEstrogen receptorHomo sapiens (human)
vagina developmentEstrogen receptorHomo sapiens (human)
prostate epithelial cord elongationEstrogen receptorHomo sapiens (human)
prostate epithelial cord arborization involved in prostate glandular acinus morphogenesisEstrogen receptorHomo sapiens (human)
regulation of branching involved in prostate gland morphogenesisEstrogen receptorHomo sapiens (human)
mammary gland branching involved in pregnancyEstrogen receptorHomo sapiens (human)
mammary gland alveolus developmentEstrogen receptorHomo sapiens (human)
epithelial cell proliferation involved in mammary gland duct elongationEstrogen receptorHomo sapiens (human)
protein localization to chromatinEstrogen receptorHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptorHomo sapiens (human)
negative regulation of miRNA transcriptionEstrogen receptorHomo sapiens (human)
regulation of epithelial cell apoptotic processEstrogen receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptorHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptorHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1A1Homo sapiens (human)
response to hypoxiaCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
lipid hydroxylationCytochrome P450 1A1Homo sapiens (human)
fatty acid metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A1Homo sapiens (human)
steroid metabolic processCytochrome P450 1A1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A1Homo sapiens (human)
amine metabolic processCytochrome P450 1A1Homo sapiens (human)
response to nematodeCytochrome P450 1A1Homo sapiens (human)
response to herbicideCytochrome P450 1A1Homo sapiens (human)
ethylene metabolic processCytochrome P450 1A1Homo sapiens (human)
coumarin metabolic processCytochrome P450 1A1Homo sapiens (human)
flavonoid metabolic processCytochrome P450 1A1Homo sapiens (human)
response to iron(III) ionCytochrome P450 1A1Homo sapiens (human)
insecticide metabolic processCytochrome P450 1A1Homo sapiens (human)
dibenzo-p-dioxin catabolic processCytochrome P450 1A1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
response to foodCytochrome P450 1A1Homo sapiens (human)
response to lipopolysaccharideCytochrome P450 1A1Homo sapiens (human)
response to vitamin ACytochrome P450 1A1Homo sapiens (human)
response to immobilization stressCytochrome P450 1A1Homo sapiens (human)
vitamin D metabolic processCytochrome P450 1A1Homo sapiens (human)
retinol metabolic processCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
9-cis-retinoic acid biosynthetic processCytochrome P450 1A1Homo sapiens (human)
camera-type eye developmentCytochrome P450 1A1Homo sapiens (human)
nitric oxide metabolic processCytochrome P450 1A1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1A1Homo sapiens (human)
digestive tract developmentCytochrome P450 1A1Homo sapiens (human)
tissue remodelingCytochrome P450 1A1Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A1Homo sapiens (human)
response to hyperoxiaCytochrome P450 1A1Homo sapiens (human)
maternal process involved in parturitionCytochrome P450 1A1Homo sapiens (human)
hepatocyte differentiationCytochrome P450 1A1Homo sapiens (human)
cellular response to copper ionCytochrome P450 1A1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A1Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleCytochrome P450 1A1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1A1Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
proteolysisNeutrophil elastaseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINeutrophil elastaseHomo sapiens (human)
response to yeastNeutrophil elastaseHomo sapiens (human)
leukocyte migration involved in inflammatory responseNeutrophil elastaseHomo sapiens (human)
biosynthetic process of antibacterial peptides active against Gram-negative bacteriaNeutrophil elastaseHomo sapiens (human)
proteolysisNeutrophil elastaseHomo sapiens (human)
intracellular calcium ion homeostasisNeutrophil elastaseHomo sapiens (human)
response to UVNeutrophil elastaseHomo sapiens (human)
extracellular matrix disassemblyNeutrophil elastaseHomo sapiens (human)
protein catabolic processNeutrophil elastaseHomo sapiens (human)
response to lipopolysaccharideNeutrophil elastaseHomo sapiens (human)
negative regulation of chemokine productionNeutrophil elastaseHomo sapiens (human)
negative regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
positive regulation of interleukin-8 productionNeutrophil elastaseHomo sapiens (human)
defense response to bacteriumNeutrophil elastaseHomo sapiens (human)
positive regulation of MAP kinase activityNeutrophil elastaseHomo sapiens (human)
positive regulation of smooth muscle cell proliferationNeutrophil elastaseHomo sapiens (human)
negative regulation of inflammatory responseNeutrophil elastaseHomo sapiens (human)
positive regulation of immune responseNeutrophil elastaseHomo sapiens (human)
negative regulation of chemotaxisNeutrophil elastaseHomo sapiens (human)
pyroptosisNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumNeutrophil elastaseHomo sapiens (human)
neutrophil-mediated killing of fungusNeutrophil elastaseHomo sapiens (human)
positive regulation of leukocyte tethering or rollingNeutrophil elastaseHomo sapiens (human)
phagocytosisNeutrophil elastaseHomo sapiens (human)
acute inflammatory response to antigenic stimulusNeutrophil elastaseHomo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
protein phosphorylationSerine/threonine-protein kinase pim-1Homo sapiens (human)
apoptotic processSerine/threonine-protein kinase pim-1Homo sapiens (human)
regulation of transmembrane transporter activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of apoptotic processSerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of DNA-binding transcription factor activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
negative regulation of innate immune responseSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of DNA-templated transcriptionSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein autophosphorylationSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein stabilizationSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
vitamin D receptor signaling pathwaySerine/threonine-protein kinase pim-1Homo sapiens (human)
cellular response to type II interferonSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of brown fat cell differentiationSerine/threonine-protein kinase pim-1Homo sapiens (human)
regulation of hematopoietic stem cell proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of TORC1 signalingSerine/threonine-protein kinase pim-1Homo sapiens (human)
positive regulation of cardioblast proliferationSerine/threonine-protein kinase pim-1Homo sapiens (human)
cellular detoxificationSerine/threonine-protein kinase pim-1Homo sapiens (human)
retinoid metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
epithelial cell maturationAldo-keto reductase family 1 member B1Homo sapiens (human)
renal water homeostasisAldo-keto reductase family 1 member B1Homo sapiens (human)
carbohydrate metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
C21-steroid hormone biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
L-ascorbic acid biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
regulation of urine volumeAldo-keto reductase family 1 member B1Homo sapiens (human)
retinol metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
negative regulation of apoptotic processAldo-keto reductase family 1 member B1Homo sapiens (human)
daunorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
doxorubicin metabolic processAldo-keto reductase family 1 member B1Homo sapiens (human)
fructose biosynthetic processAldo-keto reductase family 1 member B1Homo sapiens (human)
cellular hyperosmotic salinity responseAldo-keto reductase family 1 member B1Homo sapiens (human)
metanephric collecting duct developmentAldo-keto reductase family 1 member B1Homo sapiens (human)
double-strand break repairCasein kinase II subunit alpha'Homo sapiens (human)
apoptotic processCasein kinase II subunit alpha'Homo sapiens (human)
spermatogenesisCasein kinase II subunit alpha'Homo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit alpha'Homo sapiens (human)
cerebral cortex developmentCasein kinase II subunit alpha'Homo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit alpha'Homo sapiens (human)
liver regenerationCasein kinase II subunit alpha'Homo sapiens (human)
regulation of mitophagyCasein kinase II subunit alpha'Homo sapiens (human)
positive regulation of protein targeting to mitochondrionCasein kinase II subunit alpha'Homo sapiens (human)
regulation of chromosome separationCasein kinase II subunit alpha'Homo sapiens (human)
negative regulation of apoptotic signaling pathwayCasein kinase II subunit alpha'Homo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alpha'Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alpha'Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-1Homo sapiens (human)
proteolysis involved in protein catabolic processProteasome subunit beta type-1Homo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
proteolysisProteasome subunit beta type-5Homo sapiens (human)
response to oxidative stressProteasome subunit beta type-5Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-5Homo sapiens (human)
response to toxic substanceBifunctional epoxide hydrolase 2Homo sapiens (human)
positive regulation of gene expressionBifunctional epoxide hydrolase 2Homo sapiens (human)
dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
cholesterol homeostasisBifunctional epoxide hydrolase 2Homo sapiens (human)
stilbene catabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
phospholipid dephosphorylationBifunctional epoxide hydrolase 2Homo sapiens (human)
regulation of cholesterol metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide metabolic processBifunctional epoxide hydrolase 2Homo sapiens (human)
response to organonitrogen compoundProteasome subunit beta type-2Homo sapiens (human)
response to organic cyclic compoundProteasome subunit beta type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
signal transductionCasein kinase II subunit betaHomo sapiens (human)
negative regulation of cell population proliferationCasein kinase II subunit betaHomo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit betaHomo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit betaHomo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit betaHomo sapiens (human)
positive regulation of activin receptor signaling pathwayCasein kinase II subunit betaHomo sapiens (human)
adiponectin-activated signaling pathwayCasein kinase II subunit betaHomo sapiens (human)
negative regulation of blood vessel endothelial cell migrationCasein kinase II subunit betaHomo sapiens (human)
regulation of DNA bindingCasein kinase II subunit betaHomo sapiens (human)
positive regulation of SMAD protein signal transductionCasein kinase II subunit betaHomo sapiens (human)
endothelial tube morphogenesisCasein kinase II subunit betaHomo sapiens (human)
protein-containing complex assemblyCasein kinase II subunit betaHomo sapiens (human)
symbiont-mediated disruption of host cell PML bodyCasein kinase II subunit betaHomo sapiens (human)
negative regulation of viral life cycleCasein kinase II subunit betaHomo sapiens (human)
double-strand break repairCasein kinase II subunit alphaHomo sapiens (human)
protein phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
apoptotic processCasein kinase II subunit alphaHomo sapiens (human)
DNA damage responseCasein kinase II subunit alphaHomo sapiens (human)
signal transductionCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of cell population proliferationCasein kinase II subunit alphaHomo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of translationCasein kinase II subunit alphaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of Wnt signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of cell growthCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of protein catabolic processCasein kinase II subunit alphaHomo sapiens (human)
rhythmic processCasein kinase II subunit alphaHomo sapiens (human)
protein stabilizationCasein kinase II subunit alphaHomo sapiens (human)
chaperone-mediated protein foldingCasein kinase II subunit alphaHomo sapiens (human)
symbiont-mediated disruption of host cell PML bodyCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of aggrephagyCasein kinase II subunit alphaHomo sapiens (human)
regulation of chromosome separationCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of double-strand break repair via homologous recombinationCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of apoptotic signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
regulation of cell cycleCasein kinase II subunit alphaHomo sapiens (human)
glycolipid catabolic processTissue alpha-L-fucosidaseBos taurus (cattle)
protein phosphorylationCasein kinase II subunit alpha 3Homo sapiens (human)
positive regulation of cell population proliferationCasein kinase II subunit alpha 3Homo sapiens (human)
positive regulation of cell growthCasein kinase II subunit alpha 3Homo sapiens (human)
positive regulation of protein catabolic processCasein kinase II subunit alpha 3Homo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alpha 3Homo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alpha 3Homo sapiens (human)
regulation of cell cycleCasein kinase II subunit alpha 3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
signal transductionEstrogen receptor betaHomo sapiens (human)
cell-cell signalingEstrogen receptor betaHomo sapiens (human)
negative regulation of cell growthEstrogen receptor betaHomo sapiens (human)
intracellular estrogen receptor signaling pathwayEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-templated transcriptionEstrogen receptor betaHomo sapiens (human)
positive regulation of DNA-binding transcription factor activityEstrogen receptor betaHomo sapiens (human)
cellular response to estradiol stimulusEstrogen receptor betaHomo sapiens (human)
regulation of transcription by RNA polymerase IIEstrogen receptor betaHomo sapiens (human)
cellular response to estrogen stimulusEstrogen receptor betaHomo sapiens (human)
negative regulation of signaling receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cytokine productionAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin-mediated drinking behaviorAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme 2 Homo sapiens (human)
tryptophan transportAngiotensin-converting enzyme 2 Homo sapiens (human)
viral life cycleAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of transmembrane transporter activityAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cell population proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of smooth muscle cell proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of inflammatory responseAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of amino acid transportAngiotensin-converting enzyme 2 Homo sapiens (human)
maternal process involved in female pregnancyAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of cardiac muscle contractionAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane fusionAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeAngiotensin-converting enzyme 2 Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme 2 Homo sapiens (human)
entry receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of gap junction assemblyAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cardiac conductionAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of L-proline import across plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAngiotensin-converting enzyme 2 Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
monoatomic ion transportP2Y purinoceptor 12Homo sapiens (human)
substrate-dependent cell migration, cell extensionP2Y purinoceptor 12Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
hemostasisP2Y purinoceptor 12Homo sapiens (human)
calcium-mediated signalingP2Y purinoceptor 12Homo sapiens (human)
cerebral cortex radial glia-guided migrationP2Y purinoceptor 12Homo sapiens (human)
cell projection organizationP2Y purinoceptor 12Homo sapiens (human)
lamellipodium assemblyP2Y purinoceptor 12Homo sapiens (human)
platelet activationP2Y purinoceptor 12Homo sapiens (human)
positive regulation of integrin activation by cell surface receptor linked signal transductionP2Y purinoceptor 12Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinP2Y purinoceptor 12Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 12Homo sapiens (human)
positive regulation of monoatomic ion transportP2Y purinoceptor 12Homo sapiens (human)
response to axon injuryP2Y purinoceptor 12Homo sapiens (human)
regulation of chemotaxisP2Y purinoceptor 12Homo sapiens (human)
positive regulation of chemotaxisP2Y purinoceptor 12Homo sapiens (human)
establishment of localization in cellP2Y purinoceptor 12Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionP2Y purinoceptor 12Homo sapiens (human)
platelet aggregationP2Y purinoceptor 12Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 12Homo sapiens (human)
visual system developmentP2Y purinoceptor 12Homo sapiens (human)
positive regulation of ruffle assemblyP2Y purinoceptor 12Homo sapiens (human)
regulation of microglial cell migrationP2Y purinoceptor 12Homo sapiens (human)
positive regulation of microglial cell migrationP2Y purinoceptor 12Homo sapiens (human)
glycoprotein catabolic processSialidase-2Homo sapiens (human)
ganglioside catabolic processSialidase-2Homo sapiens (human)
oligosaccharide catabolic processSialidase-2Homo sapiens (human)
glycosphingolipid catabolic processSialidase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (166)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityTransmembrane protease serine 2Homo sapiens (human)
protein bindingTransmembrane protease serine 2Homo sapiens (human)
serine-type peptidase activityTransmembrane protease serine 2Homo sapiens (human)
prenylated protein tyrosine phosphatase activityProtein tyrosine phosphatase type IVA 3Homo sapiens (human)
protein bindingProtein tyrosine phosphatase type IVA 3Homo sapiens (human)
protein tyrosine phosphatase activityProtein tyrosine phosphatase type IVA 3Homo sapiens (human)
hormone activityTransthyretinHomo sapiens (human)
protein bindingTransthyretinHomo sapiens (human)
identical protein bindingTransthyretinHomo sapiens (human)
thyroid hormone bindingTransthyretinHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
TFIIB-class transcription factor bindingEstrogen receptorHomo sapiens (human)
transcription coregulator bindingEstrogen receptorHomo sapiens (human)
transcription corepressor bindingEstrogen receptorHomo sapiens (human)
transcription coactivator bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificEstrogen receptorHomo sapiens (human)
chromatin bindingEstrogen receptorHomo sapiens (human)
DNA-binding transcription factor activityEstrogen receptorHomo sapiens (human)
nuclear receptor activityEstrogen receptorHomo sapiens (human)
steroid bindingEstrogen receptorHomo sapiens (human)
protein bindingEstrogen receptorHomo sapiens (human)
calmodulin bindingEstrogen receptorHomo sapiens (human)
beta-catenin bindingEstrogen receptorHomo sapiens (human)
zinc ion bindingEstrogen receptorHomo sapiens (human)
TBP-class protein bindingEstrogen receptorHomo sapiens (human)
enzyme bindingEstrogen receptorHomo sapiens (human)
protein kinase bindingEstrogen receptorHomo sapiens (human)
nitric-oxide synthase regulator activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptorHomo sapiens (human)
nuclear estrogen receptor bindingEstrogen receptorHomo sapiens (human)
estrogen response element bindingEstrogen receptorHomo sapiens (human)
identical protein bindingEstrogen receptorHomo sapiens (human)
ATPase bindingEstrogen receptorHomo sapiens (human)
14-3-3 protein bindingEstrogen receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingEstrogen receptorHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
iron ion bindingCytochrome P450 1A1Homo sapiens (human)
protein bindingCytochrome P450 1A1Homo sapiens (human)
arachidonic acid monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A1Homo sapiens (human)
oxidoreductase activity, acting on diphenols and related substances as donorsCytochrome P450 1A1Homo sapiens (human)
flavonoid 3'-monooxygenase activityCytochrome P450 1A1Homo sapiens (human)
oxygen bindingCytochrome P450 1A1Homo sapiens (human)
enzyme bindingCytochrome P450 1A1Homo sapiens (human)
heme bindingCytochrome P450 1A1Homo sapiens (human)
Hsp70 protein bindingCytochrome P450 1A1Homo sapiens (human)
demethylase activityCytochrome P450 1A1Homo sapiens (human)
Hsp90 protein bindingCytochrome P450 1A1Homo sapiens (human)
aromatase activityCytochrome P450 1A1Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A1Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 1A1Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
protease bindingNeutrophil elastaseHomo sapiens (human)
transcription corepressor activityNeutrophil elastaseHomo sapiens (human)
endopeptidase activityNeutrophil elastaseHomo sapiens (human)
serine-type endopeptidase activityNeutrophil elastaseHomo sapiens (human)
protein bindingNeutrophil elastaseHomo sapiens (human)
heparin bindingNeutrophil elastaseHomo sapiens (human)
peptidase activityNeutrophil elastaseHomo sapiens (human)
cytokine bindingNeutrophil elastaseHomo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein serine/threonine kinase activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
protein bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
ATP bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
transcription factor bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
manganese ion bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
ribosomal small subunit bindingSerine/threonine-protein kinase pim-1Homo sapiens (human)
protein serine kinase activitySerine/threonine-protein kinase pim-1Homo sapiens (human)
retinal dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
aldose reductase (NADPH) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein bindingAldo-keto reductase family 1 member B1Homo sapiens (human)
electron transfer activityAldo-keto reductase family 1 member B1Homo sapiens (human)
prostaglandin H2 endoperoxidase reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glyceraldehyde oxidoreductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
allyl-alcohol dehydrogenase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
L-glucuronate reductase activityAldo-keto reductase family 1 member B1Homo sapiens (human)
glycerol dehydrogenase [NADP+] activityAldo-keto reductase family 1 member B1Homo sapiens (human)
all-trans-retinol dehydrogenase (NADP+) activityAldo-keto reductase family 1 member B1Homo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit alpha'Homo sapiens (human)
protein bindingCasein kinase II subunit alpha'Homo sapiens (human)
ATP bindingCasein kinase II subunit alpha'Homo sapiens (human)
protein serine kinase activityCasein kinase II subunit alpha'Homo sapiens (human)
protein bindingProteasome subunit beta type-1Homo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
protein bindingProteasome subunit beta type-5Homo sapiens (human)
peptidase activityProteasome subunit beta type-5Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
magnesium ion bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
epoxide hydrolase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
toxic substance bindingBifunctional epoxide hydrolase 2Homo sapiens (human)
phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
10-hydroxy-9-(phosphonooxy)octadecanoate phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lipid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
protein homodimerization activityBifunctional epoxide hydrolase 2Homo sapiens (human)
lysophosphatidic acid phosphatase activityBifunctional epoxide hydrolase 2Homo sapiens (human)
protein bindingProteasome subunit beta type-2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit betaHomo sapiens (human)
chromatin bindingCasein kinase II subunit betaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit betaHomo sapiens (human)
signaling receptor bindingCasein kinase II subunit betaHomo sapiens (human)
protein bindingCasein kinase II subunit betaHomo sapiens (human)
protein kinase regulator activityCasein kinase II subunit betaHomo sapiens (human)
protein domain specific bindingCasein kinase II subunit betaHomo sapiens (human)
protein-macromolecule adaptor activityCasein kinase II subunit betaHomo sapiens (human)
identical protein bindingCasein kinase II subunit betaHomo sapiens (human)
metal ion bindingCasein kinase II subunit betaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCasein kinase II subunit betaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit alphaHomo sapiens (human)
protein bindingCasein kinase II subunit alphaHomo sapiens (human)
ATP bindingCasein kinase II subunit alphaHomo sapiens (human)
kinase activityCasein kinase II subunit alphaHomo sapiens (human)
identical protein bindingCasein kinase II subunit alphaHomo sapiens (human)
Hsp90 protein bindingCasein kinase II subunit alphaHomo sapiens (human)
protein serine kinase activityCasein kinase II subunit alphaHomo sapiens (human)
alpha-L-fucosidase activityTissue alpha-L-fucosidaseBos taurus (cattle)
protein serine/threonine kinase activityCasein kinase II subunit alpha 3Homo sapiens (human)
protein bindingCasein kinase II subunit alpha 3Homo sapiens (human)
ATP bindingCasein kinase II subunit alpha 3Homo sapiens (human)
protein serine kinase activityCasein kinase II subunit alpha 3Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingEstrogen receptor betaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificEstrogen receptor betaHomo sapiens (human)
DNA bindingEstrogen receptor betaHomo sapiens (human)
nuclear steroid receptor activityEstrogen receptor betaHomo sapiens (human)
nuclear receptor activityEstrogen receptor betaHomo sapiens (human)
steroid bindingEstrogen receptor betaHomo sapiens (human)
protein bindingEstrogen receptor betaHomo sapiens (human)
zinc ion bindingEstrogen receptor betaHomo sapiens (human)
enzyme bindingEstrogen receptor betaHomo sapiens (human)
nuclear estrogen receptor activityEstrogen receptor betaHomo sapiens (human)
estrogen response element bindingEstrogen receptor betaHomo sapiens (human)
receptor antagonist activityEstrogen receptor betaHomo sapiens (human)
virus receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
metallocarboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
identical protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
G protein-coupled adenosine receptor activityP2Y purinoceptor 12Homo sapiens (human)
G protein-coupled ADP receptor activityP2Y purinoceptor 12Homo sapiens (human)
guanyl-nucleotide exchange factor activityP2Y purinoceptor 12Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 12Homo sapiens (human)
exo-alpha-sialidase activitySialidase-2Homo sapiens (human)
protein bindingSialidase-2Homo sapiens (human)
exo-alpha-(2->3)-sialidase activitySialidase-2Homo sapiens (human)
exo-alpha-(2->6)-sialidase activitySialidase-2Homo sapiens (human)
exo-alpha-(2->8)-sialidase activitySialidase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (91)

Processvia Protein(s)Taxonomy
extracellular regionTransmembrane protease serine 2Homo sapiens (human)
nucleoplasmTransmembrane protease serine 2Homo sapiens (human)
plasma membraneTransmembrane protease serine 2Homo sapiens (human)
extracellular exosomeTransmembrane protease serine 2Homo sapiens (human)
nucleusProtein tyrosine phosphatase type IVA 3Homo sapiens (human)
cytoplasmProtein tyrosine phosphatase type IVA 3Homo sapiens (human)
early endosomeProtein tyrosine phosphatase type IVA 3Homo sapiens (human)
plasma membraneProtein tyrosine phosphatase type IVA 3Homo sapiens (human)
nucleusProtein tyrosine phosphatase type IVA 3Homo sapiens (human)
cytoplasmProtein tyrosine phosphatase type IVA 3Homo sapiens (human)
extracellular regionTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
azurophil granule lumenTransthyretinHomo sapiens (human)
extracellular exosomeTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nucleoplasmEstrogen receptorHomo sapiens (human)
transcription regulator complexEstrogen receptorHomo sapiens (human)
cytoplasmEstrogen receptorHomo sapiens (human)
Golgi apparatusEstrogen receptorHomo sapiens (human)
cytosolEstrogen receptorHomo sapiens (human)
plasma membraneEstrogen receptorHomo sapiens (human)
membraneEstrogen receptorHomo sapiens (human)
chromatinEstrogen receptorHomo sapiens (human)
euchromatinEstrogen receptorHomo sapiens (human)
protein-containing complexEstrogen receptorHomo sapiens (human)
nucleusEstrogen receptorHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
mitochondrial inner membraneCytochrome P450 1A1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A1Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
extracellular regionNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
cytoplasmNeutrophil elastaseHomo sapiens (human)
cytosolNeutrophil elastaseHomo sapiens (human)
cell surfaceNeutrophil elastaseHomo sapiens (human)
secretory granuleNeutrophil elastaseHomo sapiens (human)
azurophil granule lumenNeutrophil elastaseHomo sapiens (human)
specific granule lumenNeutrophil elastaseHomo sapiens (human)
phagocytic vesicleNeutrophil elastaseHomo sapiens (human)
collagen-containing extracellular matrixNeutrophil elastaseHomo sapiens (human)
extracellular exosomeNeutrophil elastaseHomo sapiens (human)
transcription repressor complexNeutrophil elastaseHomo sapiens (human)
extracellular spaceNeutrophil elastaseHomo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
plasma membraneSpike glycoproteinSevere acute respiratory syndrome coronavirus 2
virion membraneSpike glycoproteinSevere acute respiratory syndrome coronavirus 2
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
nucleusSerine/threonine-protein kinase pim-1Homo sapiens (human)
nucleoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
nucleolusSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytosolSerine/threonine-protein kinase pim-1Homo sapiens (human)
plasma membraneSerine/threonine-protein kinase pim-1Homo sapiens (human)
cytoplasmSerine/threonine-protein kinase pim-1Homo sapiens (human)
extracellular spaceAldo-keto reductase family 1 member B1Homo sapiens (human)
nucleoplasmAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
extracellular exosomeAldo-keto reductase family 1 member B1Homo sapiens (human)
cytosolAldo-keto reductase family 1 member B1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
PcG protein complexCasein kinase II subunit alpha'Homo sapiens (human)
acrosomal vesicleCasein kinase II subunit alpha'Homo sapiens (human)
nucleusCasein kinase II subunit alpha'Homo sapiens (human)
nucleoplasmCasein kinase II subunit alpha'Homo sapiens (human)
cytosolCasein kinase II subunit alpha'Homo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alpha'Homo sapiens (human)
chromatinCasein kinase II subunit alpha'Homo sapiens (human)
cytosolCasein kinase II subunit alpha'Homo sapiens (human)
nucleusCasein kinase II subunit alpha'Homo sapiens (human)
nucleusProteasome subunit beta type-1Homo sapiens (human)
cytoplasmProteasome subunit beta type-1Homo sapiens (human)
proteasome complexProteasome subunit beta type-1Homo sapiens (human)
extracellular regionProteasome subunit beta type-1Homo sapiens (human)
nucleusProteasome subunit beta type-1Homo sapiens (human)
nucleoplasmProteasome subunit beta type-1Homo sapiens (human)
cytosolProteasome subunit beta type-1Homo sapiens (human)
secretory granule lumenProteasome subunit beta type-1Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-1Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit beta type-1Homo sapiens (human)
proteasome core complexProteasome subunit beta type-1Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-1Homo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
cytoplasmProteasome subunit beta type-5Homo sapiens (human)
proteasome complexProteasome subunit beta type-5Homo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
nucleoplasmProteasome subunit beta type-5Homo sapiens (human)
centrosomeProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-5Homo sapiens (human)
proteasome core complexProteasome subunit beta type-5Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomal matrixBifunctional epoxide hydrolase 2Homo sapiens (human)
cytosolBifunctional epoxide hydrolase 2Homo sapiens (human)
extracellular exosomeBifunctional epoxide hydrolase 2Homo sapiens (human)
peroxisomeBifunctional epoxide hydrolase 2Homo sapiens (human)
nucleusProteasome subunit beta type-2Homo sapiens (human)
cytoplasmProteasome subunit beta type-2Homo sapiens (human)
proteasome complexProteasome subunit beta type-2Homo sapiens (human)
nucleusProteasome subunit beta type-2Homo sapiens (human)
nucleoplasmProteasome subunit beta type-2Homo sapiens (human)
cytosolProteasome subunit beta type-2Homo sapiens (human)
membraneProteasome subunit beta type-2Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-2Homo sapiens (human)
proteasome core complexProteasome subunit beta type-2Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-2Homo sapiens (human)
cytosolProteasome subunit beta type-2Homo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneCasein kinase II subunit betaHomo sapiens (human)
PcG protein complexCasein kinase II subunit betaHomo sapiens (human)
PML bodyCasein kinase II subunit betaHomo sapiens (human)
extracellular regionCasein kinase II subunit betaHomo sapiens (human)
nucleusCasein kinase II subunit betaHomo sapiens (human)
nucleoplasmCasein kinase II subunit betaHomo sapiens (human)
cytoplasmCasein kinase II subunit betaHomo sapiens (human)
cytosolCasein kinase II subunit betaHomo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit betaHomo sapiens (human)
secretory granule lumenCasein kinase II subunit betaHomo sapiens (human)
extracellular exosomeCasein kinase II subunit betaHomo sapiens (human)
ficolin-1-rich granule lumenCasein kinase II subunit betaHomo sapiens (human)
chromatinCasein kinase II subunit betaHomo sapiens (human)
cytoplasmCasein kinase II subunit betaHomo sapiens (human)
PcG protein complexCasein kinase II subunit alphaHomo sapiens (human)
PML bodyCasein kinase II subunit alphaHomo sapiens (human)
nucleusCasein kinase II subunit alphaHomo sapiens (human)
nucleoplasmCasein kinase II subunit alphaHomo sapiens (human)
cytosolCasein kinase II subunit alphaHomo sapiens (human)
plasma membraneCasein kinase II subunit alphaHomo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alphaHomo sapiens (human)
Sin3-type complexCasein kinase II subunit alphaHomo sapiens (human)
cytosolCasein kinase II subunit alphaHomo sapiens (human)
nucleusCasein kinase II subunit alphaHomo sapiens (human)
nucleoplasmCasein kinase II subunit alpha 3Homo sapiens (human)
nucleusCasein kinase II subunit alpha 3Homo sapiens (human)
cytosolCasein kinase II subunit alpha 3Homo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alpha 3Homo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
nucleoplasmEstrogen receptor betaHomo sapiens (human)
mitochondrionEstrogen receptor betaHomo sapiens (human)
intracellular membrane-bounded organelleEstrogen receptor betaHomo sapiens (human)
chromatinEstrogen receptor betaHomo sapiens (human)
nucleusEstrogen receptor betaHomo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
endoplasmic reticulum lumenAngiotensin-converting enzyme 2 Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
ciliumAngiotensin-converting enzyme 2 Homo sapiens (human)
cell surfaceAngiotensin-converting enzyme 2 Homo sapiens (human)
membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
apical plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
endocytic vesicle membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane raftAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
plasma membraneP2Y purinoceptor 12Homo sapiens (human)
cell surfaceP2Y purinoceptor 12Homo sapiens (human)
membraneP2Y purinoceptor 12Homo sapiens (human)
cell projection membraneP2Y purinoceptor 12Homo sapiens (human)
cell body membraneP2Y purinoceptor 12Homo sapiens (human)
cytosolSialidase-2Homo sapiens (human)
catalytic complexSialidase-2Homo sapiens (human)
lysosomeSialidase-2Homo sapiens (human)
membraneSialidase-2Homo sapiens (human)
cytoplasmSialidase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (501)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID435142Percent residual p38delta activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID1080767Antibacterial activity against Escherichia coli using 50 uL of compound solution from 500 ug/mL stock solution after 24 hr by agar disk diffusion method2009Journal of agricultural and food chemistry, Aug-26, Volume: 57, Issue:16
Study on the anthraquinones separated from the cultivation of Trichoderma harzianum strain Th-R16 and their biological activity.
AID637923Inhibition of PRL3 after 1 hr by DiFMUP assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Emodin inhibits migration and invasion of DLD-1 (PRL-3) cells via inhibition of PRL-3 phosphatase activity.
AID358215Cytotoxicity against human SNB75 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1633141Inhibition of chymotrypsin-like activity of human 26S proteasome assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method2019European journal of medicinal chemistry, Apr-01, Volume: 167Another look at phenolic compounds in cancer therapy the effect of polyphenols on ubiquitin-proteasome system.
AID1601209Cytotoxicity against mouse L5178Y cells at 100 uM2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Xanthone, benzophenone and bianthrone derivatives from the hypersaline lake-derived fungus Aspergillus wentii.
AID356320Antioxidant activity assessed as DPPH radical scavenging activity2003Journal of natural products, Aug, Volume: 66, Issue:8
Sulfemodin 8-O-beta-D-glucoside, a new sulfated anthraquinone glycoside, and antioxidant phenolic compounds from Rheum emodi.
AID1315350In vivo inhibition of aldose reductase in transgenic PAR37 mouse expressing human aldose reductase assessed as vacuolization at 35 mg/kg, po administered 3 days prior to birth followed by compound treatment till day 16 by hematoxylin/eosin staining (Rvb =2016Journal of natural products, 05-27, Volume: 79, Issue:5
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
AID360624Growth inhibition of human HeLa cells assessed as [3H]thymidine incorporation at 6.25 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID733838Induction of helD promoter in Bacillus subtilis IS34 at 64 ug/mL after 3 hrs by luciferase reporter gene assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID1102425Antifungal activity against Sclerotinia sclerotiorum assessed as mycelial growth inhibition after 4 to 8 days2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID687695Cytotoxicity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay2012European journal of medicinal chemistry, Oct, Volume: 56Synthesis and antitumor activity of emodin quaternary ammonium salt derivatives.
AID435768Percent residual G-CK activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID358188Cytotoxicity against human MOLT4 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID70335Inhibition of binding of 17 beta-estradiol to human Estrogen receptor alpha2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID641165Induction of apoptosis in human HCT116 cells overexpressing PI3Kalpha assessed DNA fragmentation at 25 uM after 48 hrs by ELISA relative to control2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases.
AID435391Percent residual PDK1 activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID358189Cytotoxicity against human RPMI8226 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1435966Cytotoxicity against human HepG2 cells assessed as growth inhibition at 10 uM measured after 72 hrs by CCK-8 assay relative to control
AID1435971Selectivity index, ratio of CC50 for human Caco2 cells to IC50 for human alpha-glucosidase expressed in Saccharomyces cerevisiae
AID360616Growth inhibition of human Calu1 cells assessed as [3H]thymidine incorporation at 12.5 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID607594Cytotoxicity against human OE21 cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Growth inhibitory activities of oxyprenylated and non-prenylated naturally occurring phenylpropanoids in cancer cell lines.
AID1601212Cytotoxicity against human A2780S cells at 100 uM2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Xanthone, benzophenone and bianthrone derivatives from the hypersaline lake-derived fungus Aspergillus wentii.
AID358483Cytotoxicity against human SKOV3 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID634902Cytotoxicity against human HepG2 cells after 2 days by alamar blue assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Synthesis and antitumor activity of conjugates of 5-Fluorouracil and emodin.
AID358482Cytotoxicity against human OVCAR5 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID358475Cytotoxicity against human MALME-3M cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1102426Antifungal activity against Sclerotinia minor assessed as mycelial growth inhibition after 4 to 8 days2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID733845Antibacterial activity against Escherichia coli ATCC 25922 assessed as growth inhibition by CLSI broth microdilution method2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID472353Cytotoxicity against human THP1 cells after 48 hrs assessed morphological changes compound exposed to light for 20 mins before treatment2009Journal of natural products, Oct, Volume: 72, Issue:10
Light-independent metabolomics of endophytic Thielavia subthermophila provides insight into microbial hypericin biosynthesis.
AID1633140Inhibition of caspase-like activity of human 26S proteasome assessed as decrease in fluorescence using Z-Nle-Pro-Nle-Asp-aminoluciferin as substrate incubated for 2 hrs by fluorescence based method2019European journal of medicinal chemistry, Apr-01, Volume: 167Another look at phenolic compounds in cancer therapy the effect of polyphenols on ubiquitin-proteasome system.
AID1601217Antibacterial activity against Pseudomonas aeruginosa2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Xanthone, benzophenone and bianthrone derivatives from the hypersaline lake-derived fungus Aspergillus wentii.
AID37426Inhibitory activity against yeast alpha-glucosidase; mild activity observed2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Yeast and mammalian alpha-glucosidase inhibitory constituents from Himalayan rhubarb Rheum emodi Wall.ex Meisson.
AID336953Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 1000 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID1688692Inhibition of jack bean alpha-mannosidase at 1 mM using PNPG as substrate incubated for 10 mins by spectrophotometric method2020European journal of medicinal chemistry, Feb-15, Volume: 188Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
AID733850Antibacterial activity against Streptococcus pneumoniae ATCC 49619 assessed as growth inhibition by CLSI broth microdilution method2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID358491Cytotoxicity against human TK10 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1808019Inhibition of SARS CoV2 C-terminal His6-tagged 3CL protease (3264 to 3569 residues) expressed in Escherichia coli BL21 DE3 using rr-K(MCA)-ATLQAIAS-K(DNP)-COOH preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 0.02021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1167184Inhibition of human recombinant CK2a1/CK2b holoenzyme expressed in Escherichia coli BL21(DE3) at 10 uM pre-incubated for 10 mins before substrate addition by capillary electrophoresis based assay2015Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1
Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
AID641164Induction of apoptosis in human HCT116 cells assessed DNA fragmentation at 25 uM after 48 hrs by ELISA relative to control2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases.
AID435268Percent residual p38alpha activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID358205Cytotoxicity against human HCC2998 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID335387Inhibition of bovine thymus p56 LCK activity by competitive inhibition assay1992Journal of natural products, May, Volume: 55, Issue:5
Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum.
AID358195Cytotoxicity against human NCI-H226 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID48230Inhibitory activity against Cathepsin G (CatG) at 53 uM concentration1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Novel anthraquinone inhibitors of human leukocyte elastase and cathepsin G.
AID492246Displacement of ethidium bromide form calf thymus DNA by fluorometric assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Synthesis and biological evaluation of cytotoxic activity of novel anthracene L-rhamnopyranosides.
AID435765Percent residual p38beta activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID637924Inhibition of PRL-3-mediated cell migration in human DLD1 cells after 15 hrs by crystal violet staining based microscopic assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Emodin inhibits migration and invasion of DLD-1 (PRL-3) cells via inhibition of PRL-3 phosphatase activity.
AID335922Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of arachidonic acid-stimulated platelet aggregation pretreated 2 mins before arachidonic acid challenge
AID398696Inhibition of lipid peroxidation in Sprague-Dawley rat heart mitochondria assessed as inhibition of FeSO4-induced oxygen consumption1995Journal of natural products, Sep, Volume: 58, Issue:9
Effect of anthraquinone derivatives on lipid peroxidation in rat heart mitochondria: structure-activity relationship.
AID360623Growth inhibition of human HeLa cells assessed as [3H]thymidine incorporation at 12.5 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID1601220Antibacterial activity against Enterobacter aerogenes2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Xanthone, benzophenone and bianthrone derivatives from the hypersaline lake-derived fungus Aspergillus wentii.
AID1845465Inhibition of SARS-CoV 2 spike glycoprotein2021Journal of natural products, 01-22, Volume: 84, Issue:1
Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.
AID492245Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Synthesis and biological evaluation of cytotoxic activity of novel anthracene L-rhamnopyranosides.
AID1808029Inhibition of SARS-COV2 main protease2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID733844Antibacterial activity against ciprofloxacin-resistant Escherichia coli WT-3-1 MB2 assessed as growth inhibition by CLSI broth microdilution method2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID358207Cytotoxicity against human HCT15 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID358199Cytotoxicity against human NCI-H522 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID358186Cytotoxicity against human HL-60(TB) cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID634900Cytotoxicity against human HO8910 cells after 2 days by alamar blue assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Synthesis and antitumor activity of conjugates of 5-Fluorouracil and emodin.
AID360615Growth inhibition of human Calu1 cells assessed as [3H]thymidine incorporation at 25 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID358202Cytotoxicity against human DMS273 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1080759Antibacterial activity against Staphylococcus aureus after 24 hr by agar disk diffusion method2009Journal of agricultural and food chemistry, Aug-26, Volume: 57, Issue:16
Study on the anthraquinones separated from the cultivation of Trichoderma harzianum strain Th-R16 and their biological activity.
AID358192Cytotoxicity against human HOP18 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID338266Inhibition of Ca2+ ATPase activity in human red blood cells at 1600 uM by spectrophotometry1994Journal of natural products, Dec, Volume: 57, Issue:12
Novel Ca(2+)-ATPase inhibitors from the dried root tubers of Polygonum Multiflorum.
AID360647Inhibition of african green monkey Vero cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID358201Cytotoxicity against human DMS114 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID360652Growth inhibition of human WISH cells assessed as [3H]thymidine incorporation at 6.25 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID285173Effect on Streptococcus mutans LMG 14558 assessed as inhibition of biofilm formation in modified Robbin's device at 2 ug/ml relative to BHIS control2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID1601211Cytotoxicity against human A2780S cells at 10 ug/ml2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Xanthone, benzophenone and bianthrone derivatives from the hypersaline lake-derived fungus Aspergillus wentii.
AID355621Toxicity in brine shrimp
AID435888Relative inhibition of V66A-mutated CK2 holoenzyme compared to wild-type2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID670257Inhibition of CK22012Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
Discovery and structure-activity relationship of 2,6-disubstituted pyrazines, potent and selective inhibitors of protein kinase CK2.
AID358485Cytotoxicity against human A498 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID360614Growth inhibition of human Calu1 cells assessed as [3H]thymidine incorporation at 50 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID295726Cytotoxicity against mouse B16 cells2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Spectroscopic studies of DNA binding modes of cation-substituted anthrapyrazoles derived from emodin.
AID360643Growth inhibition of african green monkey Vero cells assessed as [3H]thymidine incorporation at 25 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID435390Percent residual PKA activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID1403186Inhibition of human CK2-alpha/beta expressed in Escherichia coli BL21(DE3) using RRRDDDSDDD peptide as substrate after 15 mins by capillary electrophoresis method2018European journal of medicinal chemistry, Jan-20, Volume: 144A new family of densely functionalized fused-benzoquinones as potent human protein kinase CK2 inhibitors.
AID363328Cytotoxicity against MDR1 Pgp under-expressing human HCT116 cells after 24 hrs by MTT assay2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Comparison of the cytotoxic activities of naturally occurring hydroxyanthraquinones and hydroxynaphthoquinones.
AID358206Cytotoxicity against human HCT116 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID687698Cytotoxicity against human HELF cells assessed as cell viability after 24 hrs by MTT assay2012European journal of medicinal chemistry, Oct, Volume: 56Synthesis and antitumor activity of emodin quaternary ammonium salt derivatives.
AID466938Inhibition of human Neu2 assessed as MuNANA substrate hydrolysis in presence of 0.1% Triton X-100 by discontinuous fluorimetric assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Potent inhibitor scaffold against Trypanosoma cruzi trans-sialidase.
AID360628Growth inhibition of human K562 cells assessed as [3H]thymidine incorporation at 50 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID1539764Inhibition of CK2alpha (unknown origin)2019European journal of medicinal chemistry, Nov-01, Volume: 181Small molecule modulators targeting protein kinase CK1 and CK2.
AID1601213Cytotoxicity against human A2780S cells at 10 uM2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Xanthone, benzophenone and bianthrone derivatives from the hypersaline lake-derived fungus Aspergillus wentii.
AID360654Inhibition of human WISH cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID1688684Inhibition of Saccharomyces cerevisiae alpha-glucosidase using maltose as substrate preincubated for 5 mins followed by substrate addition and measured after 15 mins by LC-TQ-MS/MS analysis2020European journal of medicinal chemistry, Feb-15, Volume: 188Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
AID566116Inhibition of CK2 assessed as inhibition of [gamma32P]GTP incorporation into substrate by liquid scintillation counting2011Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2
Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.
AID435271Percent residual PiD261 activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID1808020Inhibition of porcine heart malate dehydrogenase preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID360613Growth inhibition of human Calu1 cells assessed as [3H]thymidine incorporation at 100 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID1330889Induction of C57/BL6 mouse primary BMDM proliferation assessed at 5 uM after 2 days by MTT assay relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and biological evaluation of rhein amides as inhibitors of osteoclast differentiation and bone resorption.
AID1303472Inhibition of recombinant human Pim12016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Identification of quinones as novel PIM1 kinase inhibitors.
AID748704Induction of tau K19 (unknown origin) disaggregation assessed as decrease in paired helical filament formation measured disassembly-inducing half maxima after 10 days by thioflavin S fluorescence assay in presence of heparin2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Progress and developments in tau aggregation inhibitors for Alzheimer disease.
AID733837Induction of bmrC promoter in Bacillus subtilis IS34 promoter at 64 ug/mL after 3 hrs by luciferase reporter gene assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID360651Growth inhibition of human WISH cells assessed as [3H]thymidine incorporation at 12.5 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID1601214Antitubercular activity against Mycobacterium tuberculosis H37Rv2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Xanthone, benzophenone and bianthrone derivatives from the hypersaline lake-derived fungus Aspergillus wentii.
AID733839Induction of liaI promoter in Bacillus subtilis IS34 promoter at 64 ug/mL after 3 hrs by luciferase reporter gene assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID358191Cytotoxicity against human A549 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1601218Antibacterial activity against Enterococcus faecium2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Xanthone, benzophenone and bianthrone derivatives from the hypersaline lake-derived fungus Aspergillus wentii.
AID358194Cytotoxicity against human HOP92 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID358478Cytotoxicity against human SK-MEL-28 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID19840Partition coefficient of compound in octanol and water by Fragmental method of Leo/Hansch2003Bioorganic & medicinal chemistry letters, Feb-24, Volume: 13, Issue:4
Determination of active components in rhubarb and study of their hydrophobicity by micellar electrokinetic chromatography.
AID687696Cytotoxicity against human BGC cells assessed as cell viability after 24 hrs by MTT assay2012European journal of medicinal chemistry, Oct, Volume: 56Synthesis and antitumor activity of emodin quaternary ammonium salt derivatives.
AID375433Displacement of [3H]PSB0413 from human platelet P2Y12 receptor2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID435144Percent residual S6K1 activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID734250Cytotoxicity against human THP1 cells assessed as growth inhibition after 48 hrs by Alamar blue assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID295725Binding affinity to calf thymus DNA2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Spectroscopic studies of DNA binding modes of cation-substituted anthrapyrazoles derived from emodin.
AID1256631Inhibition of sEH (unknown origin) assessed as 6-methoxy-2-naphthaldehyde formation by fluorometry assay using 40 uM cyano-(6-methoxy-naphthalen-2-yl)-methyl ester as substrate2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Constituents of the seeds of Cassia tora with inhibitory activity on soluble expoxide hydrolease.
AID435549Percent residual MAPKAPK2 activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID1888750Selectivity index, ratio IC50 for recombinant human MAO-B to IC50 for recombinant human MAO-A2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID1403185Inhibition of human CK2-alpha/beta expressed in Escherichia coli BL21(DE3) at 10 uM using RRRDDDSDDD peptide as substrate after 15 mins by capillary electrophoresis method relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144A new family of densely functionalized fused-benzoquinones as potent human protein kinase CK2 inhibitors.
AID358200Cytotoxicity against human LXFL 529L cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID358486Cytotoxicity against human ACHN cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1755162Inhibition of acid-mediated aggregation of TTR V30M mutant (unknown origin) expressed in Escherichia coli pretreated for 30 mins at pH 7 followed by protein dilution in acetate buffer and further incubated for 96 hrs at pH 4.6 by thioflavin-T fluorescence2021Bioorganic & medicinal chemistry, 08-15, Volume: 44Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID360644Growth inhibition of african green monkey Vero cells assessed as [3H]thymidine incorporation at 12.5 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID380384Phytotoxicity against Amaranthus hypochondriacus assessed as inhibition of radicle elongation2000Journal of natural products, Jun, Volume: 63, Issue:6
Phytotoxic compounds from the new coprophilous fungus guanomyces polythrix.
AID260055Antifungal activity against Phytopthora infestans at 0.5 mg/ml2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Isolation and inhibitory activity against ERK phosphorylation of hydroxyanthraquinones from rhubarb.
AID435764Inhibition of V66A-mutated CK2 holoenzyme2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID733842Antibacterial activity against Bacillus subtilis subsp. subtilis str. 168 trpC2 assessed as concentration required for partial growth inhibition by CLSI broth microdilution method2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID339133Inhibition of collagen-induced platelet aggregation in rabbit platelet-rich plasma at 50 ug/mL after 3 mins by turbidimetric method1993Journal of natural products, Jun, Volume: 56, Issue:6
Antiplatelet effects and vasorelaxing action of some constituents of Formosan plants.
AID380387Binding affinity to bovine brain calmodulin at 0.033 ug/mL after 1.5 hrs by electrophoretic mobility assay in presence of EGTA2000Journal of natural products, Jun, Volume: 63, Issue:6
Phytotoxic compounds from the new coprophilous fungus guanomyces polythrix.
AID70654Inhibition of binding of 17 beta-estradiol to human Estrogen receptor beta2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID435140Relative inhibition of I174A-mutated CK2 holoenzyme compared to wild-type2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID1315339Inhibition of human recombinant AKR1B10 expressed in Escherichia coli using DL-glyceraldehyde as substrate at 5 uM in presence of NADPH by spectrophotometric analysis2016Journal of natural products, 05-27, Volume: 79, Issue:5
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
AID358474Cytotoxicity against human LOXIMVI cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1601219Antibacterial activity against Klebsiella pneumoniae2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Xanthone, benzophenone and bianthrone derivatives from the hypersaline lake-derived fungus Aspergillus wentii.
AID1315338Uncompetitive inhibition of human recombinant aldose reductase expressed in Escherichia coli using DL-glyceraldehyde as substrate by double reciprocal plot analysis2016Journal of natural products, 05-27, Volume: 79, Issue:5
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
AID360629Growth inhibition of human K562 cells assessed as [3H]thymidine incorporation at 25 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID328648Antimicrobial activity against Pseudomonas aeruginosa DSM 1128 by disk diffusion method2008Journal of natural products, Feb, Volume: 71, Issue:2
An endophytic fungus from Hypericum perforatum that produces hypericin.
AID1167185Inhibition of human recombinant CK2a1/CK2b holoenzyme expressed in Escherichia coli BL21(DE3) pre-incubated for 10 mins before substrate addition by capillary electrophoresis based assay2015Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1
Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
AID358212Cytotoxicity against human SF268 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID358193Cytotoxicity against human HOP62 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID755276Antidiabetic nephropathic activity in rat HBZY-1 cells assessed as inhibition of high concentration glucose-induced IL-6 production at 10 uM treated 1 hr before glucose challenge measured after 24 hrs by ELISA2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Anthraquinone derivatives from Rumex plants and endophytic Aspergillus fumigatus and their effects on diabetic nephropathy.
AID358197Cytotoxicity against human NCI-H322M cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID650670Inhibition of human CSNK2A1/2B expressed in Escherichia coli BL21(DE3) using RRRDDDSDDD as substrate after 15 mins by scintillation counting2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors.
AID343963Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Correlation between reduction potentials and inhibitions of Epstein-Barr virus activation by anthraquinone derivatives.
AID358487Cytotoxicity against human Caki1 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID358210Cytotoxicity against human KM20L2 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1256630Inhibition of sEH (unknown origin) assessed as 6-methoxy-2-naphthaldehyde formation at 50 uM by fluorometry assay using 40 uM cyano-(6-methoxy-naphthalen-2-yl)-methyl ester as substrate2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Constituents of the seeds of Cassia tora with inhibitory activity on soluble expoxide hydrolease.
AID358477Cytotoxicity against human SK-MEL-2 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID343961Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells at 10 molar ratio relative to control2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Correlation between reduction potentials and inhibitions of Epstein-Barr virus activation by anthraquinone derivatives.
AID1688687Inhibition of Saccharomyces cerevisiae alpha-glucosidase using PNPG as substrate incubated for 10 mins by spectrophotometric method2020European journal of medicinal chemistry, Feb-15, Volume: 188Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
AID641155Inhibition of PI3Kalpha in human HCT116 cells using [32P]ATP at 10 uM after 10 mins2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases.
AID1155420Inhibition of AGR quorum sensing system in methicillin-resistant Staphylococcus aureus AH2759 incubated for 15 hrs by P3-LUX reporter gene assay2014Journal of natural products, Jun-27, Volume: 77, Issue:6
Polyhydroxyanthraquinones as quorum sensing inhibitors from the guttates of Penicillium restrictum and their analysis by desorption electrospray ionization mass spectrometry.
AID472354Cytotoxicity against human THP1 cells after 48 hrs assessed as morphological changes in the dark condition2009Journal of natural products, Oct, Volume: 72, Issue:10
Light-independent metabolomics of endophytic Thielavia subthermophila provides insight into microbial hypericin biosynthesis.
AID358198Cytotoxicity against human NCI-H460 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID336960Cytotoxicity against human Raji cells assessed as cell viability at 10 molar ratio
AID435511Percent residual CK2 activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID339128Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich plasma at 100 ug/mL after 3 mins by turbidimetric method1993Journal of natural products, Jun, Volume: 56, Issue:6
Antiplatelet effects and vasorelaxing action of some constituents of Formosan plants.
AID1315346In vivo inhibition of aldose reductase in wild type mouse assessed as reduction in vacuolization at 35 mg/kg, po for 16 days by hematoxylin/eosin staining2016Journal of natural products, 05-27, Volume: 79, Issue:5
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID328647Antimicrobial activity against Klebsiella pneumoniae ssp. ozaenae DSM 681 by disk diffusion method2008Journal of natural products, Feb, Volume: 71, Issue:2
An endophytic fungus from Hypericum perforatum that produces hypericin.
AID285174Effect on Streptococcus mutans LMG 14558 assessed as inhibition of biofilm formation in modified Robbin's device at 1 ug/ml relative to BHIS control2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID641153Growth inhibition of human HCT116 cells overexpressing PI3Kalpha H1047R mutant after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases.
AID1453003Inhibition of recombinant human CYP1A1 expressed in supersomes using 7-ethoxyresorufin O-deethylation as substrate after 5 mins in presence of NADP+ by spectrofluorimetric analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Inhibitors of cytochrome P450 (CYP) 1B1.
AID641154Growth inhibition of human HCT116 cells after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases.
AID358216Cytotoxicity against human U251 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID423618Cytotoxicity against mouse L5178Y cells at 10 ug/mL by MTT assay2009Journal of natural products, Apr, Volume: 72, Issue:4
Bioactive metabolites from the endophytic fungus Stemphylium globuliferum isolated from Mentha pulegium.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID435770Percent residual CSK activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID435893Percent residual CK1 activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID358481Cytotoxicity against human OVCAR4 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1354708Cytotoxicity against human 786-O cells after 72 hrs by CCK8 assay
AID641163Inhibition of Akt expression in human HCT116 cells at 10 uM by immunoblot analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases.
AID260052Antiproliferative activity against prostate cancer PC3 cell line at 20 uM by MTT method2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Isolation and inhibitory activity against ERK phosphorylation of hydroxyanthraquinones from rhubarb.
AID637928Inhibition of PRL-3-mediated cell invasion in human DLD1 cells at 40 uM after 20 hrs using crystal violet staining by Matrigel invasion assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Emodin inhibits migration and invasion of DLD-1 (PRL-3) cells via inhibition of PRL-3 phosphatase activity.
AID358489Cytotoxicity against human RXF631 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1888749Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by fluorescence spectrophotometric assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID757712Inhibition of human recombinant CK2 expressed in Escherichia coli BL21(DE3) using RRRDDDSDDD as substrate at 10 uM after 15 mins by capillary electrophoretic analysis relative to control2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2.
AID734249Cytotoxicity against mouse BALB/3T3 cells assessed as growth inhibition after 48 hrs by Alamar blue assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID1459613Cytotoxicity against human HepG2 cells measured after 24 hrs by MTT assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis, SAR and pharmacological characterization of novel anthraquinone cation compounds as potential anticancer agents.
AID360618Inhibition of human Calu1 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID1435972Non-competitive inhibition of human alpha-glucosidase expressed in Saccharomyces cerevisiae using varying levels of p-nitophenyl-alpha-glucopyranoside as substrate pretreated with substrate for 15 mins followed by enzyme addition measured after 15 mins by
AID357642Cytotoxicity against human KB cells2001Journal of natural products, Sep, Volume: 64, Issue:9
Cytotoxicity of Rhamnosylanthraquinones and Rhamnosylanthrones from Rhamnus nepalensis.
AID360649Growth inhibition of human WISH cells assessed as [3H]thymidine incorporation at 50 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID224313Inhibition of human purified recombinant pp60c-src tyrosine kinase at 100 uM2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
The design, synthesis and activity of non-ATP competitive inhibitors of pp60(c-src) tyrosine kinase. Part 1: hydroxynaphthalene derivatives.
AID358214Cytotoxicity against human SNB19 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID358211Cytotoxicity against human SW620 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID360642Growth inhibition of african green monkey Vero cells assessed as [3H]thymidine incorporation at 50 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID360648Growth inhibition of human WISH cells assessed as [3H]thymidine incorporation at 100 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID1435964Cytotoxicity against human Caco2 cells measured after 72 hrs by MTT assay
AID339150Inhibition of bovine thymus p56-LCK protein tyrosine kinase activity1993Journal of natural products, Jun, Volume: 56, Issue:6
Flavonoids from Koelreuteria henryi and other sources as protein-tyrosine kinase inhibitors.
AID734244Antibacterial activity against ceftazidime, clarithromycin, ciprofloxacin, clindamycin, doxycycline, erythromycin, methicillin, moxifloxacin, kanamycin, telithromycin, rifampicin, methicillin-resistant, vancomycin-intermediate Staphylococcus aureus subsp.2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID295727Cytotoxicity against human HepG2 cells2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Spectroscopic studies of DNA binding modes of cation-substituted anthrapyrazoles derived from emodin.
AID358480Cytotoxicity against human UACC257 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID70660Inhibition of binding of 17 beta-estradiol to human Estrogen receptor beta2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID435890Percent residual MSK1 activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID1080766Antibacterial activity against Staphylococcus aureus using 50 uL of compound solution from 500 ug/mL stock solution after 24 hr by agar disk diffusion method2009Journal of agricultural and food chemistry, Aug-26, Volume: 57, Issue:16
Study on the anthraquinones separated from the cultivation of Trichoderma harzianum strain Th-R16 and their biological activity.
AID1557217Antibiofilm activity against Streptococcus mutans assessed as inhibition of biofilm formation on hydroxyapatite surface at 5 ug/ml relative to control2019MedChemComm, Jul-01, Volume: 10, Issue:7
Targeting
AID67314Inhibitory activity against Human Leukocyte Elastase (HLE) at 53 uM concentration1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Novel anthraquinone inhibitors of human leukocyte elastase and cathepsin G.
AID358476Cytotoxicity against human M14 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1315344In vivo inhibition of aldose reductase in transgenic PAR37 mouse expressing human aldose reductase assessed as reduction in vacuolization at 35 mg/kg, po for 16 days by hematoxylin/eosin staining2016Journal of natural products, 05-27, Volume: 79, Issue:5
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
AID1083211Bactericidal activity against Erwinia amylovora 295/93 assessed as growth inhibition in King's B full medium measured at pH 7.2 after overnight incubation by suspension culture assay2012Journal of agricultural and food chemistry, Dec-12, Volume: 60, Issue:49
Potent and specific bactericidal effect of juglone (5-hydroxy-1,4-naphthoquinone) on the fire blight pathogen Erwinia amylovora.
AID634901Cytotoxicity against human SGC7901 cells after 2 days by alamar blue assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Synthesis and antitumor activity of conjugates of 5-Fluorouracil and emodin.
AID1315349In vivo inhibition of aldose reductase in transgenic PAR37 mouse expressing human aldose reductase assessed as vacuolization at 35 mg/kg, po for 16 days by hematoxylin/eosin staining (Rvb = 18%)2016Journal of natural products, 05-27, Volume: 79, Issue:5
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
AID260049Inhibitory activity on PDGF-induced ERK phosphorylation in NIH3T3 cells at 20 uM2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Isolation and inhibitory activity against ERK phosphorylation of hydroxyanthraquinones from rhubarb.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1435969Cytotoxicity against human K562 cells assessed as growth inhibition at 10 uM measured after 72 hrs by CCK-8 assay relative to control
AID458599Antiviral activity against Dengue virus type 2 infected in human A549 cells assessed as decrease in viral E protein production by cell-based flavivirus immunodetection assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Novel inhibitors of dengue virus methyltransferase: discovery by in vitro-driven virtual screening on a desktop computer grid.
AID328649Antimicrobial activity against Salmonella enterica ssp. enterica DSM 9898 by disk diffusion method2008Journal of natural products, Feb, Volume: 71, Issue:2
An endophytic fungus from Hypericum perforatum that produces hypericin.
AID435639Inhibition of Zea mays CK2alpha2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID733843Antibacterial activity against doxycycline, kanamycin-resistant Klebsiella pneumoniae ATCC 27799 assessed as growth inhibition by CLSI broth microdilution method2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1315343Inhibition of human recombinant aldose reductase expressed in Escherichia coli at 1 uM using DL-glyceraldehyde as substrate in presence of NADPH measured up to 7 days at 37 degC by spectrophotometric analysis2016Journal of natural products, 05-27, Volume: 79, Issue:5
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
AID650668Inhibition of rat liver casein kinase-2 preincubated for 5 mins prior ATP addition measured after 40 mins2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors.
AID733848Antibacterial activity against clarithromycin, erythromycin, moxifloxacin, telithromycin, vancomycin-resistant Enterococcus faecalis UW 2689 assessed as growth inhibition by CLSI broth microdilution method2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID358217Cytotoxicity against human XF498 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1354714Antimicrobial activity against Erysipelothrix rhusiopathiae ATCC 19414 after 24 hrs by serial dilution method
AID1354713Antimicrobial activity against Staphylococcus aureus subsp. aureus Rosenbach ATCC 25923 after 24 hrs by serial dilution method
AID1808021Inhibition of porcine heart malate dehydrogenase assessed as reduction in enzyme inhibition at 3 times IC50 preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec in presence of 0.01% Triton-X100 by spectrop2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID755272Antidiabetic nephropathic activity in rat HBZY-1 cells assessed as inhibition of high concentration glucose-induced fibronectin production at 10 uM treated 1 hr before glucose challenge measured after 24 hrs by ELISA2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Anthraquinone derivatives from Rumex plants and endophytic Aspergillus fumigatus and their effects on diabetic nephropathy.
AID360650Growth inhibition of human WISH cells assessed as [3H]thymidine incorporation at 25 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID435272Percent residual Syk activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID435763Inhibitory constant against Zea mays CK2alpha2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID70353Inhibition of binding of 17 beta-estradiol to human Estrogen receptor alpha2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID358185Cytotoxicity against human CCRF-CEM cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1601208Cytotoxicity against mouse L5178Y cells at 10 ug/ml2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Xanthone, benzophenone and bianthrone derivatives from the hypersaline lake-derived fungus Aspergillus wentii.
AID336954Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 500 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID358203Cytotoxicity against human COLO205 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1102427Antifungal activity against Botryotinia fuckeliana assessed as mycelial growth inhibition after 4 to 8 days2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID336958Cytotoxicity against human Raji cells assessed as cell viability at 500 molar ratio
AID458596Cytotoxicity against human A549 cells after 48 hrs2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Novel inhibitors of dengue virus methyltransferase: discovery by in vitro-driven virtual screening on a desktop computer grid.
AID435141Percent residual p38-gamma activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID436039Inhibition of I174A-mutated CK2 holoenzyme2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID435640Inhibition of wild-type CK2 holoenzyme2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID1164704Cytotoxicity against human MCF7 cells after 48 hrs by PrestoBlue cell viability assay2014Journal of natural products, Sep-26, Volume: 77, Issue:9
Flemingins G-O, cytotoxic and antioxidant constituents of the leaves of Flemingia grahamiana.
AID607601Cytotoxicity against human U373 cells assessed as growth inhibition at MTT assay-related IC50 by quantitative video microscopy relative to control2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Growth inhibitory activities of oxyprenylated and non-prenylated naturally occurring phenylpropanoids in cancer cell lines.
AID733835Induction of recA promoter in Bacillus subtilis YB3001 using 4-methylumbelliferyl beta D-galactopyranoside as substrate incubated for 3 hrs prior to substrate addition measured after 1 hr by beta galactosidase reporter gene assay relative to control2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID360630Growth inhibition of human K562 cells assessed as [3H]thymidine incorporation at 12.5 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID358488Cytotoxicity against human RXF393 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID358204Cytotoxicity against human DLD1 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1354715Antimicrobial activity against Pasteurella multocida subsp. multocida ATCC 43137 after 24 hrs by serial dilution method
AID339132Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich plasma at 50 ug/mL after 3 mins by turbidimetric method1993Journal of natural products, Jun, Volume: 56, Issue:6
Antiplatelet effects and vasorelaxing action of some constituents of Formosan plants.
AID335388Inhibition of bovine thymus p56 LCK activity by noncompetitive inhibition assay1992Journal of natural products, May, Volume: 55, Issue:5
Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum.
AID343962Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Correlation between reduction potentials and inhibitions of Epstein-Barr virus activation by anthraquinone derivatives.
AID375434Displacement of [3H]PSB0413 from human platelet P2Y12 receptor at 10 uM2009Journal of medicinal chemistry, Jun-25, Volume: 52, Issue:12
High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors.
AID247402Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
CHMIS-C: a comprehensive herbal medicine information system for cancer.
AID355623Cytotoxicity against human A549 cells
AID435892Percent residual CHK1 activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID37282Inhibitory activity against rat alpha-glucosidase; mild activity observed2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Yeast and mammalian alpha-glucosidase inhibitory constituents from Himalayan rhubarb Rheum emodi Wall.ex Meisson.
AID641159Inhibition of PI3Kalpha in human HCT116 cells assessed as inhibition of Akt Ser473 phosphorylation at 10 uM by immunoblot analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases.
AID398701Antioxidant activity in Sprague-Dawley rat heart mitochondria assessed as inhibition of conjugated diene formation at 1 to 300 uM1995Journal of natural products, Sep, Volume: 58, Issue:9
Effect of anthraquinone derivatives on lipid peroxidation in rat heart mitochondria: structure-activity relationship.
AID398697Inhibition of lipid peroxidation in Sprague-Dawley rat heart mitochondria assessed as inhibition of FeSO4-induced malondialdehyde formation1995Journal of natural products, Sep, Volume: 58, Issue:9
Effect of anthraquinone derivatives on lipid peroxidation in rat heart mitochondria: structure-activity relationship.
AID398700Antioxidant activity assessed as DPPH radical scavenging activity after 90 mins1995Journal of natural products, Sep, Volume: 58, Issue:9
Effect of anthraquinone derivatives on lipid peroxidation in rat heart mitochondria: structure-activity relationship.
AID360637Growth inhibition of human Raji cells assessed as [3H]thymidine incorporation at 12.5 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID358213Cytotoxicity against human SF295 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID380385Phytotoxicity against Echinochloa crusgalli assessed as inhibition of radicle elongation2000Journal of natural products, Jun, Volume: 63, Issue:6
Phytotoxic compounds from the new coprophilous fungus guanomyces polythrix.
AID355622Antitumor activity against Agrobacterium tumefaciens-induced crown gall tumors in potato tubers by potato disk test
AID102409Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 1 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID360640Inhibition of human Raji cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID1315342Inhibition of aldose reductase in human FHL124 cells assessed as reduction in high glucose-induced elevation of sorbitol accumulation at 5 uM after 24 hrs by colorimetric assay2016Journal of natural products, 05-27, Volume: 79, Issue:5
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
AID339129Inhibition of collagen-induced platelet aggregation in rabbit platelet-rich plasma at 100 ug/mL after 3 mins by turbidimetric method1993Journal of natural products, Jun, Volume: 56, Issue:6
Antiplatelet effects and vasorelaxing action of some constituents of Formosan plants.
AID733847Antibacterial activity against clarithromycin, erythromycin, telithromycin, vancomycin-resistant Enterococcus faecium 6011 assessed as growth inhibition by CLSI broth microdilution method2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID336959Cytotoxicity against human Raji cells assessed as cell viability at 100 molar ratio
AID755271Cytotoxicity against rat HBZY-1 cells assessed as cell viability at 10 uM after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Anthraquinone derivatives from Rumex plants and endophytic Aspergillus fumigatus and their effects on diabetic nephropathy.
AID328652Antimicrobial activity against Candida albicans DSM 1386 by disk diffusion method2008Journal of natural products, Feb, Volume: 71, Issue:2
An endophytic fungus from Hypericum perforatum that produces hypericin.
AID358484Cytotoxicity against human 786-O cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID260054Antifungal activity against Gibberella zeae at 0.5 mg/ml2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Isolation and inhibitory activity against ERK phosphorylation of hydroxyanthraquinones from rhubarb.
AID637926Cytotoxicity against human DLD1 cells expressing PRL-3 assessed as inhibition of cell proliferation up to 50 uM after 24 hrs by WST-1 assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Emodin inhibits migration and invasion of DLD-1 (PRL-3) cells via inhibition of PRL-3 phosphatase activity.
AID1330880Inhibition of RANKL/M-CSF-induced osteoclastogenesis in C57/BL6 mouse primary BMDM assessed as reduction in TRAP activity using pNPP as substrate after 2 days by colorimetric assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and biological evaluation of rhein amides as inhibitors of osteoclast differentiation and bone resorption.
AID328650Antimicrobial activity against Escherichia coli DSM 682 by disk diffusion method2008Journal of natural products, Feb, Volume: 71, Issue:2
An endophytic fungus from Hypericum perforatum that produces hypericin.
AID358495Cytotoxicity against human SNB78 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID360634Growth inhibition of human Raji cells assessed as [3H]thymidine incorporation at 100 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID102411Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 3 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID435766Percent residual MAPKAPK1 activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID360631Growth inhibition of human K562 cells assessed as [3H]thymidine incorporation at 6.25 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID360620Growth inhibition of human HeLa cells assessed as [3H]thymidine incorporation at 100 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID641166Induction of apoptosis in human HCT116 cells overexpressing PI3Kalpha H1047R mutant assessed DNA fragmentation at 25 uM after 48 hrs by ELISA relative to control2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases.
AID224308Inhibition of human purified recombinant pp60c-src tyrosine kinase2000Bioorganic & medicinal chemistry letters, Mar-06, Volume: 10, Issue:5
The design, synthesis and activity of non-ATP competitive inhibitors of pp60(c-src) tyrosine kinase. Part 1: hydroxynaphthalene derivatives.
AID435143Percent residual SGK activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID1354707Cytotoxicity against human ACHN cells after 72 hrs by CCK8 assay
AID358174Inhibition of p56 lck1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1315348In vivo inhibition of aldose reductase in wild type mouse assessed as reduction in vacuolization at 35 mg/kg, po administered 3 days prior to birth followed by compound treatment till day 16 by hematoxylin/eosin staining2016Journal of natural products, 05-27, Volume: 79, Issue:5
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
AID67645Inhibitory activity against Porcine Pancreatic Elastase (PPE) at 53 uM concentration; NI = no inhibition1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Novel anthraquinone inhibitors of human leukocyte elastase and cathepsin G.
AID733849Antibacterial activity against doxycycline-intermediate Streptococcus agalactiae 013761 assessed as growth inhibition by CLSI broth microdilution method2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID637927Inhibition of PRL-3-mediated cell invasion in human DLD1 cells after 20 hrs using crystal violet staining by Matrigel invasion assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Emodin inhibits migration and invasion of DLD-1 (PRL-3) cells via inhibition of PRL-3 phosphatase activity.
AID360622Growth inhibition of human HeLa cells assessed as [3H]thymidine incorporation at 25 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID755273Antidiabetic nephropathic activity in rat HBZY-1 cells assessed as inhibition of high concentration glucose-induced collagen-4 production at 10 uM treated 1 hr before glucose challenge measured after 24 hrs by ELISA2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
Anthraquinone derivatives from Rumex plants and endophytic Aspergillus fumigatus and their effects on diabetic nephropathy.
AID1080768Antibacterial activity against Pseudomonas aeruginosa using 50 uL of compound solution from 500 ug/mL stock solution after 24 hr by agar disk diffusion method2009Journal of agricultural and food chemistry, Aug-26, Volume: 57, Issue:16
Study on the anthraquinones separated from the cultivation of Trichoderma harzianum strain Th-R16 and their biological activity.
AID1102423Antifungal activity against Botryotinia fuckeliana assessed as inhibition of conidia germination at 1 to 10 ug/mL after 5 hr by light adverse phase microscopic analysis2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID360626Inhibition of human HeLa cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID733834Induction of yorB promoter in Bacillus subtilis IS34 after 3 hrs at 0.01 to 100 ug/ml by luciferase reporter gene assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID435889Percent residual MKK1 activity in presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID435510Percent residual ROCK-II activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID1434015Inhibition of ATP citrate lyase (unknown origin) at 10 uM using sodium citrate as substrate after 60 mins by ADP-Glo luminescence assay relative to control2017European journal of medicinal chemistry, Jan-27, Volume: 126Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyase.
AID360641Growth inhibition of african green monkey Vero cells assessed as [3H]thymidine incorporation at 100 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID1435965Cytotoxicity against human MCF7 cells assessed as growth inhibition at 10 uM measured after 72 hrs by CCK-8 assay relative to control
AID1102424Antifungal activity against Verticillium dahliae assessed as mycelial growth inhibition after 4 to 8 days2003Journal of agricultural and food chemistry, Aug-13, Volume: 51, Issue:17
Cynodontin: a fungal metabolite with antifungal properties.
AID285172Effect on Streptococcus mutans LMG 14558 assessed as inhibition of biofilm formation in modified Robbin's device at 5 ug/ml relative to BHIS control2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID360627Growth inhibition of human K562 cells assessed as [3H]thymidine incorporation at 100 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID1601221Antibacterial activity against Acinetobacter baumannii2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Xanthone, benzophenone and bianthrone derivatives from the hypersaline lake-derived fungus Aspergillus wentii.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID336034Inhibition of bovine thymus p56LCK1993Journal of natural products, Oct, Volume: 56, Issue:10
Kinase inhibitors from Polygonum cuspidatum.
AID260051Antiproliferative activity against human epidermal carcinoma A431 cell line at 20 uM by MTT method2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Isolation and inhibitory activity against ERK phosphorylation of hydroxyanthraquinones from rhubarb.
AID163631Inhibitory activity against HRV 3Cpro using HPLC assay2001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
Discovery, total synthesis, HRV 3C-protease inhibitory activity, and structure-activity relationships of 2-methoxystypandrone and its analogues.
AID641160Inhibition of PI3Kalpha H1047R mutant in human HCT116 cells assessed as inhibition of Akt Ser473 phosphorylation at 10 uM by immunoblot analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases.
AID734245Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as concentration required for partial growth inhibition by CLSI broth microdilution method2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID641152Growth inhibition of human HCT116 cells overexpressing PI3Kalpha after 48 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases.
AID1330879Cytotoxicity against C57/BL6 mouse primary BMDM assessed as cell viability at 5 uM after 2 days in presence of M-CSF by MTT assay relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and biological evaluation of rhein amides as inhibitors of osteoclast differentiation and bone resorption.
AID748708Inhibition of tau K19 (unknown origin) aggregation assessed as inhibition of paired helical filament formation after 10 days by thioflavin S fluorescence assay in presence of heparin2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Progress and developments in tau aggregation inhibitors for Alzheimer disease.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID435894Percent residual Lyn activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID102410Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 10 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID363329Cytotoxicity against MDR1 Pgp overexpressing human HepG2 cells after 24 hrs by MTT assay2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Comparison of the cytotoxic activities of naturally occurring hydroxyanthraquinones and hydroxynaphthoquinones.
AID1888748Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by fluorescence spectrophotometric assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID358490Cytotoxicity against human SN12C cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID335924Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of collagen-stimulated platelet aggregation pretreated 2 mins before collagen challenge
AID641157Inhibition of PI3Kalpha H1047R mutant in human HCT116 cells using [32P]ATP at 10 uM after 10 mins2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases.
AID358196Cytotoxicity against human NCI-H23 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID285182Effect on membrane fluidity of DPH-labeled Streptococcus mutans LMG 14558 in BHI medium assessed as fluorescence anisotropy at 5 ug/ml relative to BHI control2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID358479Cytotoxicity against human SK-MEL-5 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID360635Growth inhibition of human Raji cells assessed as [3H]thymidine incorporation at 50 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1453004Inhibition of recombinant human CYP1A2 expressed in supersomes using 7-ethoxyresorufin O-deethylation as substrate after 5 mins in presence of NADP+ by spectrofluorimetric analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Inhibitors of cytochrome P450 (CYP) 1B1.
AID380386Binding affinity to bovine brain calmodulin at 0.033 ug/mL after 1.5 hrs by electrophoretic mobility assay in presence of calcium chloride2000Journal of natural products, Jun, Volume: 63, Issue:6
Phytotoxic compounds from the new coprophilous fungus guanomyces polythrix.
AID380388Binding affinity to spinach calmodulin at 0.033 ug/mL after 1.5 hrs by electrophoretic mobility assay in presence of calcium chloride2000Journal of natural products, Jun, Volume: 63, Issue:6
Phytotoxic compounds from the new coprophilous fungus guanomyces polythrix.
AID285176Effect on Streptococcus mutans LMG 14558 assessed as inhibition of biofilm formation in modified Robbin's device at 0.1 ug/ml relative to BHIS control relative to BHIS control2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID98690In vitro inhibition of L1210 mouse leukemia cell proliferation.1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Novel type of potential anticancer agents derived from chrysophanol and emodin. Some structure-activity relationship studies.
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID285171Activity against planktonic Streptococcus mutans LMG 145582007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID1080756Antifungal activity against Botryotinia fuckeliana as inhibition of mycelium growth after 4 days2009Journal of agricultural and food chemistry, Aug-26, Volume: 57, Issue:16
Study on the anthraquinones separated from the cultivation of Trichoderma harzianum strain Th-R16 and their biological activity.
AID607600Induction of human U373 cell death assessed as morphological changes at MTT assay-related IC50 after 72 hrs by quantitative video microscopy2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Growth inhibitory activities of oxyprenylated and non-prenylated naturally occurring phenylpropanoids in cancer cell lines.
AID1435970Inhibition of human alpha-glucosidase expressed in Saccharomyces cerevisiae using p-nitophenyl-alpha-glucopyranoside as substrate pretreated with substrate for 15 mins followed by enzyme addition measured after 15 mins
AID435769Percent residual Lck activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID336957Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio
AID343959Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells at 500 molar ratio relative to control2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Correlation between reduction potentials and inhibitions of Epstein-Barr virus activation by anthraquinone derivatives.
AID607593Cytotoxicity against human U373 cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Growth inhibitory activities of oxyprenylated and non-prenylated naturally occurring phenylpropanoids in cancer cell lines.
AID1354712Antimicrobial activity against Escherichia coli ATCC 25922 after 24 hrs by serial dilution method
AID607597Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Growth inhibitory activities of oxyprenylated and non-prenylated naturally occurring phenylpropanoids in cancer cell lines.
AID1459614Cytotoxicity against HELF cells measured after 24 hrs by MTT assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis, SAR and pharmacological characterization of novel anthraquinone cation compounds as potential anticancer agents.
AID285181Decrease in membrane fluidity of Streptococcus mutans LMG 14558 using pyrene in BHI medium at 5 ug/ml relative to BHI control2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID285180Susceptibility of Streptococcus mutans LMG 14558 in BHIS medium assessed as increase in biofilm formation at 5 ug/ml in presence of 0.025% cysteine2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID358190Cytotoxicity against human SR cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID1631834Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 bloodstream forms after 72 hrs by resazurin-based assay2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID435685Percent residual c-Fgr activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID1354711Cytotoxicity against human SGC7901 cells after 6 days by MTT assay
AID260053Antifungal activity against Fusarium oxysporum at 0.5 mg/ml2006Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
Isolation and inhibitory activity against ERK phosphorylation of hydroxyanthraquinones from rhubarb.
AID339130Inhibition of platelet activity factor-induced platelet aggregation in rabbit platelet-rich plasma at 100 ug/mL after 3 mins by turbidimetric method1993Journal of natural products, Jun, Volume: 56, Issue:6
Antiplatelet effects and vasorelaxing action of some constituents of Formosan plants.
AID358208Cytotoxicity against human HT-29 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID757709Inhibition of human recombinant CK2 expressed in Escherichia coli BL21(DE3) using RRRDDDSDDD as substrate after 15 mins by capillary electrophoretic analysis2013European journal of medicinal chemistry, Jul, Volume: 65Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2.
AID339136Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet-rich plasma at 25 ug/mL after 3 mins by turbidimetric method1993Journal of natural products, Jun, Volume: 56, Issue:6
Antiplatelet effects and vasorelaxing action of some constituents of Formosan plants.
AID343958Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells at 1000 molar ratio relative to control2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Correlation between reduction potentials and inhibitions of Epstein-Barr virus activation by anthraquinone derivatives.
AID1315341Cytotoxicity against human FHL124 cells assessed as reduction in cell viability at 10 uM after 24 hrs by MTT assay2016Journal of natural products, 05-27, Volume: 79, Issue:5
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
AID435887Inhibitory constant against maize casein kinase 2 2003The Journal of biological chemistry, Jan-17, Volume: 278, Issue:3
Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight.
AID328646Antimicrobial activity against Staphylococcus aureus ssp. Aureus DSM 799 by disk diffusion method2008Journal of natural products, Feb, Volume: 71, Issue:2
An endophytic fungus from Hypericum perforatum that produces hypericin.
AID1558358Cytotoxicity against African green monkey Vero E6 cells measured up to 24 to 72 hrs by MTT assay2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID1808022Inhibition of porcine heart malate dehydrogenase assessed as critical aggregation concentration preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1601216Antibacterial activity against Escherichia coli2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Xanthone, benzophenone and bianthrone derivatives from the hypersaline lake-derived fungus Aspergillus wentii.
AID1080758Antifungal activity against Botryotinia fuckeliana assessed as growth inhibition at 500 ug/mL after 4 days2009Journal of agricultural and food chemistry, Aug-26, Volume: 57, Issue:16
Study on the anthraquinones separated from the cultivation of Trichoderma harzianum strain Th-R16 and their biological activity.
AID1459615Cytotoxicity against human BGC823 cells measured after 24 hrs by MTT assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis, SAR and pharmacological characterization of novel anthraquinone cation compounds as potential anticancer agents.
AID435891Percent residual PKCalpha activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID1080760Antifungal activity against Rhizoctonia solani assessed as growth inhibition at 500 ug/mL after 2 days2009Journal of agricultural and food chemistry, Aug-26, Volume: 57, Issue:16
Study on the anthraquinones separated from the cultivation of Trichoderma harzianum strain Th-R16 and their biological activity.
AID466939Selectivity for Trypanosoma cruzi trans-sialidase mutant over human Neu22010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Potent inhibitor scaffold against Trypanosoma cruzi trans-sialidase.
AID1601210Cytotoxicity against mouse L5178Y cells at 10 uM2019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Xanthone, benzophenone and bianthrone derivatives from the hypersaline lake-derived fungus Aspergillus wentii.
AID466937Inhibition of Trypanosoma cruzi trans-sialidase containing catalytic domain (N58F, R200K) and lectin-like domain (S495 K, V496G, E520K, D593G, I597D, H599R) mutation expressed in Escherichia coli JM109 assessed as MuNANA substrate hydrolysis in presence o2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Potent inhibitor scaffold against Trypanosoma cruzi trans-sialidase.
AID1354709Cytotoxicity against human OS-RC2 cells after 72 hrs by CCK8 assay
AID360621Growth inhibition of human HeLa cells assessed as [3H]thymidine incorporation at 50 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID734253Antibacterial activity against ceftazidime, clarithromycin, ciprofloxacin, clindamycin, doxycycline, erythromycin, methicillin, moxifloxacin, kanamycin, telithromycin, rifampicin, methicillin-resistant, vancomycin-intermediate Staphylococcus aureus subsp.2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID436040Percent residual JNK activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID1330882Inhibition of RANKL/M-CSF-induced osteoclastogenesis in C57/BL6 mouse primary BMDM assessed reduction in TRAP-positive multinucleated cells at 5 uM after 5 days2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and biological evaluation of rhein amides as inhibitors of osteoclast differentiation and bone resorption.
AID355620In vivo cytotoxicity against mouse P388 cells relative to control
AID360617Growth inhibition of human Calu1 cells assessed as [3H]thymidine incorporation at 6.25 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID335386Inhibition of bovine thymus p56 LCK activity1992Journal of natural products, May, Volume: 55, Issue:5
Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum.
AID436001Percent residual DYRK1a activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID637930Inhibition of ezrin phosphorylation in human DLD1 cells assessed as increase in alpha-ERM-Thr567 phosphorylation at 10 to 40 uM after 15 hrs by chemiluminescence method2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Emodin inhibits migration and invasion of DLD-1 (PRL-3) cells via inhibition of PRL-3 phosphatase activity.
AID436041Percent residual PKBalpha activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID335923Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of ADP-stimulated platelet aggregation pretreated 2 mins before ADP challenge
AID155387Inhibitory activity against papain using HPLC assay; Not tested2001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
Discovery, total synthesis, HRV 3C-protease inhibitory activity, and structure-activity relationships of 2-methoxystypandrone and its analogues.
AID607596Cytotoxicity against human PC3 cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Growth inhibitory activities of oxyprenylated and non-prenylated naturally occurring phenylpropanoids in cancer cell lines.
AID360633Inhibition of human K562 cell proliferation assessed as [3H]thymidine incorporation after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID1354710Cytotoxicity against human HepG2 cells after 6 days by MTT assay
AID360645Growth inhibition of african green monkey Vero cells assessed as [3H]thymidine incorporation at 6.25 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID1558357Antiviral activity against Zika virus infected in African green monkey Vero E6 cells assessed as reduction in virus infectivity preincubated with virus for 1 hr followed by cell infection and measured after 96 hrs by crystal violet staining based assay2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID380389Binding affinity to spinach calmodulin at 0.033 ug/mL after 1.5 hrs by electrophoretic mobility assay presence of EGTA2000Journal of natural products, Jun, Volume: 63, Issue:6
Phytotoxic compounds from the new coprophilous fungus guanomyces polythrix.
AID1633139Inhibition of trypsin-like activity of human 26S proteasome assessed as decrease in AMC hydrolysis using Ac-Arg-Leu-Arg-AMC as substrate incubated for 2 hrs by fluorescence based method2019European journal of medicinal chemistry, Apr-01, Volume: 167Another look at phenolic compounds in cancer therapy the effect of polyphenols on ubiquitin-proteasome system.
AID1601215Antibacterial activity against Staphylococcus aureus ATCC 292132019Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
Xanthone, benzophenone and bianthrone derivatives from the hypersaline lake-derived fungus Aspergillus wentii.
AID295728Cytotoxicity against mouse LLC cells2007European journal of medicinal chemistry, Sep, Volume: 42, Issue:9
Spectroscopic studies of DNA binding modes of cation-substituted anthrapyrazoles derived from emodin.
AID358209Cytotoxicity against human KM12 cells1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
AID435684Percent residual Phosphorylase kinase activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID734252Antibacterial activity against doxycycline-intermediate Streptococcus pyogenes 014327 assessed as growth inhibition by CLSI broth microdilution method2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID637925Inhibition of PRL-3-mediated cell migration in human DLD1 cells at 40 uM after 15 hrs by crystal violet staining based microscopic assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Emodin inhibits migration and invasion of DLD-1 (PRL-3) cells via inhibition of PRL-3 phosphatase activity.
AID355625Cytotoxicity against human KBMRI cells
AID360638Growth inhibition of human Raji cells assessed as [3H]thymidine incorporation at 6.25 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID52618Inhibitory activity against Chymotrypsinogen at 53 uM concentration1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Novel anthraquinone inhibitors of human leukocyte elastase and cathepsin G.
AID1080765Antibacterial activity against Bacillus cereus using 50 uL of compound solution from 500 ug/mL stock solution after 24 hr by agar disk diffusion method2009Journal of agricultural and food chemistry, Aug-26, Volume: 57, Issue:16
Study on the anthraquinones separated from the cultivation of Trichoderma harzianum strain Th-R16 and their biological activity.
AID435269Percent residual AMPK activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID66485Compound was tested for the enzyme inhibitory activity against Human Leukocyte Elastase (HLE) at 53 uM concentration1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Novel anthraquinone inhibitors of human leukocyte elastase and cathepsin G.
AID734251Antibacterial activity against ceftazidime, ciprofloxacin, cefepime, gentamycin, imipenem, meropenem, piperacillin/tazobactam-resistant Pseudomonas aeruginosa 63230 assessed as growth inhibition by CLSI broth microdilution method2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID733846Antibacterial activity against Bacillus subtilis subsp. subtilis str. 168 trpC2 assessed as growth inhibition by CLSI broth microdilution method2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID1435968Cytotoxicity against human A549 cells assessed as growth inhibition at 10 uM measured after 72 hrs by CCK-8 assay relative to control
AID343960Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells at 100 molar ratio relative to control2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Correlation between reduction potentials and inhibitions of Epstein-Barr virus activation by anthraquinone derivatives.
AID352795Inhibition of GST-fused human recombinant CK2alpha expressed in Escherichia coli HMS174 (DE3)2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid.
AID637929Inhibition of PRL3-mediated ezrin phosphorylation in human DLD1 cells assessed as increase in alpha-ERM-Thr567 phosphorylation at 10 to 40 uM after 15 hrs by chemiluminescence method relative to control2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Emodin inhibits migration and invasion of DLD-1 (PRL-3) cells via inhibition of PRL-3 phosphatase activity.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID336956Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 10 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID1202638Inhibition of CK2 (unknown origin)2015European journal of medicinal chemistry, , Volume: 96Identification of protein kinase CK2 inhibitors using solvent dipole ordering virtual screening.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID435767Percent residual PRAK activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID1750468Inhibition of CK2 (unknown origin)
AID458604Inhibition of Dengue virus type 2 NS5 RNA methyltransferase SAM site2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Novel inhibitors of dengue virus methyltransferase: discovery by in vitro-driven virtual screening on a desktop computer grid.
AID607598Cytotoxicity against human LoVo cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Growth inhibitory activities of oxyprenylated and non-prenylated naturally occurring phenylpropanoids in cancer cell lines.
AID1315340Inhibition of human recombinant AKR1A1 expressed in Escherichia coli using DL-glyceraldehyde as substrate at 5 uM in presence of NADPH by spectrophotometric analysis2016Journal of natural products, 05-27, Volume: 79, Issue:5
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
AID687697Cytotoxicity against human AGS cells assessed as cell viability after 24 hrs by MTT assay2012European journal of medicinal chemistry, Oct, Volume: 56Synthesis and antitumor activity of emodin quaternary ammonium salt derivatives.
AID328651Antimicrobial activity against Aspergillus niger DSM 1988 by disk diffusion method2008Journal of natural products, Feb, Volume: 71, Issue:2
An endophytic fungus from Hypericum perforatum that produces hypericin.
AID634904Cytotoxicity against human HEK293 cells after 2 days by alamar blue assay2012European journal of medicinal chemistry, Jan, Volume: 47, Issue:1
Synthesis and antitumor activity of conjugates of 5-Fluorouracil and emodin.
AID1303473Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 72 hrs by Alamar blue assay2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Identification of quinones as novel PIM1 kinase inhibitors.
AID607595Cytotoxicity against human A549 cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14
Growth inhibitory activities of oxyprenylated and non-prenylated naturally occurring phenylpropanoids in cancer cell lines.
AID435641Percent residual GSK3-beta activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID1558356Antiviral activity against Zika virus infected in African green monkey Vero E6 cells assessed as reduction in virus infectivity at 40 uM preincubated with virus for 1 hr followed by cell infection and measured after 96 hrs by crystal violet staining based2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Drugs for the Treatment of Zika Virus Infection.
AID435389Percent residual ERK2 activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID492243Cytotoxicity against human KB cells after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Synthesis and biological evaluation of cytotoxic activity of novel anthracene L-rhamnopyranosides.
AID435270Percent residual CDK2-cyclinA activity in the presence of 10uM inhibitor2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID734246Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as growth inhibition by CLSI broth microdilution method2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID355624Cytotoxicity against human HT-29 cells
AID492244Cytotoxicity against human HL60 cells after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Synthesis and biological evaluation of cytotoxic activity of novel anthracene L-rhamnopyranosides.
AID285175Effect on Streptococcus mutans LMG 14558 assessed as inhibition of biofilm formation in modified Robbin's device at 0.5 ug/ml relative to BHIS control2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID1315336Inhibition of human recombinant aldose reductase expressed in Escherichia coli using DL-glyceraldehyde as substrate in presence of NADPH by spectrophotometric analysis2016Journal of natural products, 05-27, Volume: 79, Issue:5
Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.
AID458603Inhibition of Dengue virus type 2 NS5 RNA methyltransferase SAM site with 0.1 % TX1002010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Novel inhibitors of dengue virus methyltransferase: discovery by in vitro-driven virtual screening on a desktop computer grid.
AID1688689Inhibition of bovine kidney alpha-fucosidase using PNPG as substrate incubated for 10 mins by spectrophotometric method2020European journal of medicinal chemistry, Feb-15, Volume: 188Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
AID339127Inhibition of ADP-induced platelet aggregation in rabbit platelet-rich plasma at 100 ug/mL after 3 mins by turbidimetric method1993Journal of natural products, Jun, Volume: 56, Issue:6
Antiplatelet effects and vasorelaxing action of some constituents of Formosan plants.
AID1435967Cytotoxicity against human Jurkat cells assessed as growth inhibition at 10 uM measured after 72 hrs by CCK-8 assay relative to control
AID360636Growth inhibition of human Raji cells assessed as [3H]thymidine incorporation at 25 uM after 3 days by scintillation counting2001Journal of natural products, May, Volume: 64, Issue:5
Cytotoxic principles from Ventilago leiocarpa.
AID734243Antibacterial activity against amoxicillin, chloramphenicol, ciprofloxacin, clindamycin, erythromycin, fosmidomycin, gentamycin, kanamycin, nitrofurantoin, telithromycin, methicillin-resistant Staphylococcus aureus 25697 assessed as growth inhibition by C2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Atropisomeric dihydroanthracenones as inhibitors of multiresistant Staphylococcus aureus.
AID1459616Cytotoxicity against human A375 cells measured after 24 hrs by MTT assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Synthesis, SAR and pharmacological characterization of novel anthraquinone cation compounds as potential anticancer agents.
AID336955Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 100 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1796663Kinase Inhibition Assay from Article 10.1074/jbc.M209367200: \\Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight.\\2003The Journal of biological chemistry, Jan-17, Volume: 278, Issue:3
Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight.
AID1801643FabZ Inhibition Assay from Article 10.1021/acs.biochem.5b00832: \\u00DF-Hydroxyacyl-acyl Carrier Protein Dehydratase (FabZ) from Francisella tularensis and Yersinia pestis: Structure Determination, Enzymatic Characterization, and Cross-Inhibition Studies.\\2016Biochemistry, Feb-23, Volume: 55, Issue:7
β-Hydroxyacyl-acyl Carrier Protein Dehydratase (FabZ) from Francisella tularensis and Yersinia pestis: Structure Determination, Enzymatic Characterization, and Cross-Inhibition Studies.
AID1796664Kinase Inhibition Assay from Article 10.1042/BJ20030674: \\Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).\\2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID1804127No assay is provided from Article 10.1002/med.21724: \\The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.\\2021Medicinal research reviews, 01, Volume: 41, Issue:1
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2000The Journal of biological chemistry, Sep-22, Volume: 275, Issue:38
The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2003The Biochemical journal, Sep-15, Volume: 374, Issue:Pt 3
Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2009BMC microbiology, May-12, Volume: 9Emodin targets the beta-hydroxyacyl-acyl carrier protein dehydratase from Helicobacter pylori: enzymatic inhibition assay with crystal structural and thermodynamic characterization.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,735)

TimeframeStudies, This Drug (%)All Drugs %
pre-199063 (3.63)18.7374
1990's94 (5.42)18.2507
2000's403 (23.23)29.6817
2010's770 (44.38)24.3611
2020's405 (23.34)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.26 (24.57)
Research Supply Index7.49 (2.92)
Research Growth Index5.18 (4.65)
Search Engine Demand Index127.84 (26.88)
Search Engine Supply Index2.70 (0.95)

This Compound (56.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (0.17%)5.53%
Reviews72 (4.02%)6.00%
Case Studies4 (0.22%)4.05%
Observational1 (0.06%)0.25%
Other1,712 (95.54%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy and Safety of Transcutaneous Tibial Neuro-stimulation to Improve Voiding Dysfunction in Multiple Sclerosis Patients. [NCT04573673]68 participants (Anticipated)Interventional2021-12-01Recruiting
Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease (ADPKD) [NCT00801268]300 participants (Actual)Interventional2008-11-30Terminated(stopped due to high rate of drop-out)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]